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Synthetic xenoestrogens have differential estrogenic properties. Research has shown that 
exposures to xenoestrogens could promote breast cancer by disrupting normal function of 
the human epidermal growth factor receptor 2 (Her2) gene. Although animal models 
demonstrated a connection between xenoestrogen exposure and Her2 activity, no study 
using human cells has systematically examined their carcinogenic potential influencing 
the Her2 gene expression. Furthermore, breast cancer cells are phenotypically disparate 
(ER+, Her2+), with some phenotypes (Her2+), leading to more aggressive disease. This 
study aimed to dosimetrically assess the carcinogenic potential of commonly used 
xenoestrogens influencing Her2 gene expression, and delineate cellular phenotypes at 
greater risk of more aggressive disease. The study assessed whether the composition, 
concentrations, and exposure duration of BPA, EE, NPH, and DDT significantly altered 
Her2 copy numbers in estrogen and Her2 receptor positive or negative breast cancer 
lines. Each line was randomly assigned to cases (exposed) and control (unexposed) 
groups using a randomized block design. Fluorescent in-situ hybridization measured 
Her2 gene copies. Mann Whitney, Kruskal Wallis, and Incidence Rate Ratios revealed 
Her2 copy gains in all 4 xenoestrogens and receptor types with persistent exposures. A 
44% increase in Her2 was observed in the normal ER and Her2 line, marking a shift in its 
Her2 status, and a 30-times greater risk was noted in the Her2+ lines. These findings 
promote positive social change by revealing all 4 xenoestrogens as risk factors for breast 
cancer. This information can be used by breast cancer advocacy groups, health educators, 
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Chapter 1: Introduction to the Study 
Introduction and Epidemiology 
In 2011, the incidence and mortality for breast cancer in the United States were 
220,097 and 40,931 women respectively (Centers for Disease Control and Prevention 
[CDC], 2014). For 2015, is the American Cancer Society [ACS], (2015) estimated that 
231,840 cases of invasive and 60,290 cases of in situ breast cancer would be diagnosed. 
Regardless of race and ethnicity, breast cancer is the most common type of cancer found 
in American women (CDC, 2014). In the United States, breast cancer is the leading cause 
of death in Hispanic women and the second leading cause of death in women of all other 
ethnicities. Currently, almost 2.9 million women are living with a history of breast cancer 
in the United States (ACS, 2015; Surveillance, Epidemiology, and End Results Program 
[SEER], n.d.). Breast cancer cases are further estimated to increase by 50% in the next 15 
years in America (American Association for Cancer Research [AACR], 2015). 
The global incidence rate of breast cancer was 1.7 million cases in 2012 (Ferlay, 
Soerjometram, Dikshit, Eser, Mathers, ... Bray, 2014). Breast cancer is also the main 
cause of death for women globally, with its worldwide mortality rates reaching 522,000 
women in 2012 (Ferlay et al., 2014; International Agency for Research on Cancer 
[IARC], 2013). In 2012, the global incidence and mortality for breast cancer rose 
dramatically by more than 20% and 14% respectively compared to 2008 (IARC, 2013). 
Additionally, 6.3 million women worldwide were found to be living with a history of 
breast cancer diagnosed in the past five years (Ferlay et al., 2014; IARC, 2013). A 
woman’s lifetime risk of breast cancer today has increased, from 1 out of every 11 found 
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in the 1970s to 1 in every 8 women (ACS, 2013; Valeron, Pestano, Luzardo, Zumbado, & 
Boada, 2009). 
Financially, breast cancer accounted for $18.1 billion of annual health care 
expenditures in the United States alone, ranking highest amongst all cancer care 
expenditure for 2014 (National Cancer Institute [NCI], 2015a). Projections on the overall 
cost of breast cancer care using current statistics, have suggested that they will rise from 
$16.5 billion in 2010 to $23.24 billion in 2020, with the largest increments (40.9%) found 
to be in breast cancer (NCI, 2015b). Furthermore, a trend analysis of indirect costs of 
breast cancer, such as loss in time and economic productivity due to illness and mortality 
are projected to rise from $52.4 billion in 2010 to $102.26 billion by 2023, a 95.2% 
increase (Milken Institute, n.d.). Together, these statistics indicated that the breast cancer 
incidence, mortality, risk, and financial burden worldwide are on the rise, making breast 
cancer a public health concern. 
Major risk factors known for breast cancer (e.g., genetic predisposition of BRCA1 
and 2, parity, reproductive history, lactation, age at menarche) and the increased usage of 
screening mammography only account for a third of all breast cancer cases (Aube, 
Larochelle, & Ayotte, 2011; Buteau-Lozano, Velasco, Cristofari, Balaguer, & Perrot-
Applanat, 2008; Davis & Sieber, 1997). Lifestyle factors account for remainder (Aube, 
Larochelle, & Ayotte, 2011). Current researchers have considered exposure to 
environmental toxins as a lifestyle factor, and they have studied it as a potential risk 
factor for breast cancer (Aube, Larochelle, & Ayotte, 2011; Rudel, Attfield, Schifano, & 
Brody, 2007). Environmental toxins, such as xenoestrogens, have been partially blamed 
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for the increase in breast cancer incidence (Aube, Larochelle, & Ayotte, 2011; Buteau-
Lozano, Velasco, Cristofari, Balaguer, & Perrot-Applanat, 2008; Davis et al., 1997). 
Estrogen and progesterone are two hormones that are required for normal breast 
development and function, but their unregulated stimulation by extrinsic estrogen such as 
xenoestrogens can de-regulate the cell-cycle and result in breast cell proliferation, 
inducing carcinogenicity (Brown & Lamartinere, 1995; Murray, Maffini, Ucci, 
Sonnenschein, & Soto, 2007; Recchia et al., 2004). Estrogen receptors (ERs) are 
activated by ligands (e.g., estrogen, xenoestrogens), and with the help of many cofactors 
and growth factors can regulate estrogen responsive genes (Arpino, Wiechmann, 
Osborne, & Schiff, 2008; McKenna & O’Malley, 2002). Also, required for normal breast 
development is human epidermal growth factor receptor 2 (Her2), a proto-oncogene, 
which can mutate into its oncogenic state causing breast carcinogenesis. The Her2 proto-
oncogene is found in two copies in the normal breast tissue, but in its mutated form there 
is an increase in the gene copy numbers, also known as Her2 gene amplification or over-
activation. In its mutated (amplified/overactive) form, it becomes into an oncogene (i.e., 
cancer-causing gene) inducing carcinogenicity of the breast tissue. These tumors present 
an aggressive phenotype encompassing high tumor proliferation rates, metastasis, and 
mortality (Gutierrez & Schiff, 2011; Slamon, Eiermann, Robert, Pienkowski, Martin,  
Press, … Crown, 2011). Importantly, the estrogen receptor (ER) cross communicates 
with the Her2 receptors at the cellular surface for normal function of the cell, these 
signaling processes further activate Her2 gene within the nucleus of the cell (Her2 gene 
expression) and the phosphorylation of the nuclear ER (Jung, Park, Jun, Kong, Kim, 
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Kim, … Im, 2010; Stoica, Franke, Wellstein, Czubayko, List, Reiter, ...Stoica, 2003; 
Yang, Barnes, & Kumar, 2004). 
Biologically, estrogen signaling can occur by distinct pathways: genomic or 
nongenomic. In the genomic pathway, the ligand activated ER binds to the DNA, which 
further activates protein kinase (i.e., mitogen activated protein kinase [MAPK]) and 
modulates genes that regulate cellular functions. On the other hand, the nongenomic 
activity occurs within minutes after the formation of ligand (i.e., estrogen and 
xenoestrogens) receptor complex. In the nongenomic pathway, ligand-activated ER with 
the help of coactivators activates Her2, which then increases the phosphorylation of 
MAPK and modulates the nuclear ER. This Her2-dependant kinase activity of the nuclear 
ER is an important and essential component of normal regulation and function of nuclear 
ER. However, unregulated stimulation of ER causes an increase in Her2 expression, 
which then increases expression of coactivators, the MAPK kinase activity, and 
phosphorylation of nuclear ER (Jung et al., 2010; Montemurro, Cosimo, & Arpino, 
2013). 
How the xenoestrogens act in biological systems was a conundrum for many 
years. Only in the past decade or so has the research on their mechanistic properties 
gained some momentum. It has been observed that upon xenoestrogenic exposures, 
cellular ER gets activated within minutes, suggesting that xenoestrogens activate the 
nongenomic response of the ER (Bulaveya & Watson, 2004). Research done on their 
cellular membrane activity indicated that some xenoestrogens are slow-activators while 
others react quickly and are fast-activators (Bulaveya & Watson, 2004; Payne, Rajapakse, 
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Wilkins, & Kortenkamp, 2000). Similarly, nuclear transcriptional assays performed to 
assess their potency showed that some xenoestrogens are very weak (e.g., DDE), while 
others are somewhat weak (e.g., Bisphenol-A [BPA]), yet others are quite strong (e.g., 
Diethylstilbestrol [DES]) in their estrogenic activity (Silva et al., 2007). A couple of 
studies indicated that exposures with two xenoestrogens or multiple derivatives of a 
single xenoestrogen for a short time period (24 hours to 1 week) produce an additive 
effect on cellular membrane activity (Aube, Larochelle, & Ayotte, 2008; Rajapakse, Ong, 
& Kortenkamp, 2001). Together, these studies provided the insights that although 
xenoestrogens are categorically grouped under one umbrella, their biochemical properties 
are disparate and that react and interact differentially in biological systems.  
Reporter gene assays conducted to study carcinogenicity of organochlorines 
(OCs) indicated that 1-day exposure of normal mammary cells using nanomolar (nM) 
concentrations increases the expression of a number of protein kinase genes, including 
the Her3/ERRB3 kinase (Valeron, Pestano, Luzardo, Zumbado, & Boada, 2009). 
Interestingly, the structure of Her3 shows that Her3 itself does not have a protein kinase 
domain and it has to bond with other Her family members, especially Her2 for its kinase 
activity (Ross et al., 2009). A recent study showed that for a breast cancer cell line 
(MCF7) that had only ERs, the proliferative effect of xenoestrogens (OC mixture) was 
purely because of the estrogenic potential of the cells; whereas in another cell line 
(CAMA-1) with equal numbers of estrogen and androgen receptors (ARs), the cellular 
proliferation occurred due to the inhibition of androgenic receptors (Aube, Larochelle, & 
Ayotte, 2011). This suggested that xenoestrogens respond and interact differentially to 
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estrogen and androgen receptors. Studies conducted on xenoestrogens to assess their 
carcinogenicity have been performed using short-term exposures (up to 1 week) mainly 
with OCs and their derivatives (Aube, Larochelle, & Ayotte, 2011; Boada et al., 2009). 
However, because the biochemical nature of xenoestrogens is disparate, it follows that 
the carcinogenicity of xenoestrogens other than OCs, such as those commonly found in 
household products (e.g., BPA, NPH, and EE), used individually as well as in 
combination may be quite different from that of OCs. Additionally, breast cancer has 
been observed to have a long latency period (Marsden, Wright, Carrier, Moroz, & 
Rowan, 2012; Nadler & Zurbenko, 2013; Olsson, Baldetorp, Ferno, & Perfekt, 2003; 
Paez, Labonte, Bohanes, Zhang, Benhanim, Ning, … Lenz, 2011), whereas the 
aforementioned studies have only studied short-term exposures (24 hours to 8 days). 
Furthermore, breast cancer cells have been found to be phenotypically different 
(e.g., ER+, ER-, Her2+, and Her2-) making breast cancer a heterogeneous disease 
(Montemurro, Di Cosimo, & Arpino, 2013). It has also been observed that for ER-
positive breast cancers, specifically those with increased Her2 gene copies, the ERs 
activate Her2 signaling and vice-versa (Montemurro, Di Cosimo, & Arpino, 2013; 
Osborne, Zhao, & Fuqua, 2005). In Her2 and ER-positive (i.e., Her2+/ER+) breast 
cancer cells; either Her2 or ER can function as the promoter of cellular proliferation and 
survival (Wang, Morrison, Gillihan, Guo, Ward, Fu, ... Schiff,  2011). In this case, it is 
biologically plausible that some breast cancer cell-types (e.g., ER+/Her2+) may have a 
greater risk of breast carcinogenesis than others (e.g., ER-/Her2- or normal expression of 
ER and Her2) when exposed to xenoestrogens. 
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Some epidemiologic studies conducted on xenoestrogenic exposures suggested 
that the risk of having a more aggressive type of breast cancer is to those women that are 
ER negative, indicating that xenoestrogens are not only a risk factor for women that have 
an ER-positive status, but also to those with an ER-negative status. In fact, women with 
an ER-negative status had worse survival outcomes, and were resistant to therapy 
(Gammon, Wolff, Neugut, Eng, Teitelbaum, Brinton, ... Santella, 1999; Rosenberg, 
Zhang, Coogan, Strom, & Palmer, 2008). Importantly, Gammon et al. (1999) assessed the 
Her2 status in women that were using over-the-counter contraceptive pills and the 
researchers found that breast cancer aggressiveness and prognosis in these women were 
positively associated with the overexpression of Her2 oncogene. These findings were 
further supported by animal studies connecting an increase in Her2 and 3 expression 
levels with exposure to OCs (Jenkins, Raghuraman, Eltoum, Carpenter, Russo, & 
Lamartiniere, 2009). Another study found that increased Her2 gene expression causes  
shorter breast cancer latency period and faster progression rates when the mice were 
exposed with derivatives of DDT (o’ p’ Dichlorodiphenyltrichloroethane [DDT], and p’ 
p’ DDT) (Johnson, Ho, Cline, Hughe, Foster, & Davis, 2012). Collectively, these data 
suggested that the mechanism underlying breast carcinogenesis with xenoestrogen 
exposure observed in animal models may also correspond to that found in humans and 
the critical assessment of Her2 is warranted.  
Because breast cancer is a heterogeneous disease with a long latency period, 
assessing the carcinogenic potential of the commonly used synthetic xenoestrogens in 
relation to the Her2 gene, with multiple and prolonged exposures using different breast 
8 
 
cancer cellular phenotypes, is important. In this exploratory research project, I aimed to 
do exactly that. This study was intended to provide a model for gene-environment 
interaction (GEI) that will aid in predicting the carcinogenic potential of four 
xenoestrogens (BPA, Nonylphenol [NP or NPH], ethinyl estradiol [EE], and DDT) 
commonly used in household products (e.g., plastics, oral contraceptives, pesticides) in 
relation to the Her2 gene, as well as discern cellular phenotypes (i.e., ER+/- and Her2+/-) 
that may be more susceptible to aggressive disease upon prolonged exposures (7 to 8 
weeks), individually and in combination. The results from this research may impact 
breast cancer risk factor assessment with xenoestrogen exposure/s, useful in decision-
making for policy-level changes as well as advocacy purposes for its primary prevention 
and discerning cellular phenotypes that may be at a greater risk of breast cancer 
progression, which could be monitored for early intervention using biologically targeted 
therapies for its secondary prevention.  
Background 
Historically, cancer has been known primarily as a genetic disease with a long 
latency period (Barrett, 1993, Knudson, 2001; Pitot & Dragon, 1991). Both nonhereditary 
(i.e., somatic cell) and hereditary (i.e., germ cell) cancers are caused by genetic accidents 
(e.g., mutations) that disturb the cellular proliferation systems. However, a vast majority 
of cancers (>70%) occur due to somatic cell mutations and are not inherited (Cornelisse 
& Devilee, 1997; Knudson, 2001, Lee & Muller, 2010). Models of breast carcinogenesis 
provide evidence that carcinogenesis is a multistage process, accompanied either by the 
mutation/amplification of a proto-oncogene into its oncogenic form, or inactivation of a 
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tumor suppressor gene [TSG] (Barrett, 1993; Lee & Muller, 2010; Leedham & 
Tomilinson, 2012; Pitot et al., 1993). Her2 is a proto-oncogene that has been implicated 
in breast carcinogenesis (Dressman, Baras, Malinowski, Alvis, Kwon, Walz, & 
Polymeropoulas, 2003; Hynes & Stern, 1994; Jung et al., 2010; Slamon et al., 1989).  
As a proto-oncogene, Her2 plays a pivotal role in cell-signaling processes for the 
normal growth and development of the mammary epithelia (Akiyama, Ogawara, 
Toyoshima, & Yamamoto, 1986; Slamon et al., 2011; Yardin & Sliwkowski, 2001). 
When the Her2 proto-oncogene mutates (i.e., oncogenic form), it deregulates the cell-
cycle; which then initiates uncontrolled cellular proliferation of the mammary cells 
(Gutierrez & Schiff, 2011; Slamon et al., 1989; Slamon et al., 2011). Her2 gene is a 
member of the epidermal growth factor receptor (EGFR), encoding for a transmembrane 
tyrosine kinase (TK), which is an enzyme that is important for cellular signal 
transduction. This enzyme is a key regulator of normal mammary cell growth, but also 
plays a critical role in the development and progression of cancer (Gutierrez & Schiff, 
2011; Hynes et al., 1994). Mutation of the Her2 gene increases its gene copy numbers 
with in the nucleus, also known as Her2 gene amplification. The gene amplification (i.e., 
increase in gene copy numbers) results in an increased production of Her2 receptors on 
the cellular surface for which the gene encodes. Because amplification of the Her2 gene 
(nucleus) directly results in the overexpression of the Her2 receptors (cell surface), the 
gene amplification observed at the genomic level can thus be used as a proxy for the 
overexpression of its protein product (Her2 receptors) at the cellular surface (Gutierrez & 
Schiff, 2011; Slamon et al., 1989; Slamon et al., 2011). Additionally, the terms gene 
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amplification, or the increase in gene copy numbers, and gene overexpression can be 
used interchangeably in the case of breast carcinogenesis (Dressman et al., 2003; 
Gutierrez & Schiff, 2011; McCormick, Lillemoe, Beneke, Schrauth, & Reinartz, 2002; 
Meng, Tripathy, Shete, Ashfaq, Haley, Perkins, …Uhr, 2004; Slamon et al., 1989). 
Empirical data revealed that Her2 is overexpressed in up to a third (30%) of 
incident breast cancer patients (Bertucci, Borie, Ginestier, Groulet, Charafe-Jauffret, 
Adelaide, …Birnbaum, 2004; Korkaya, Paulson, Iovino, & Wicha, 2008 Slamon et al., 
1989;; Slamon et al., 2011). The percentage of patients with Her2 overexpression has 
been found to increase (by 40%) with higher disease stage and progression (Meng et al., 
2004). It has been widely demonstrated that when there is amplification or 
overexpression of the Her2 oncogene, then the patient prognosis relates to a more 
aggressive type of breast cancer with disease progression, tumor invasion, fewer disease-
free days, and worse survival outcomes lending to its poor prognostic value (Baselga & 
Swain, 2009; Gutierrez & Schiff, 2011; Johnson et al., 2012; Lindemann, Resau, Nahrig, 
Kort, Leeser, Annecke, …Harbeck. 2007; Slamon et al., 2011). 
In vitro and vivo studies clearly showed that these exposures to xenoestrogens 
promote (a) mitosis and changes in breast tissue morphology (Brown & Lamartinere, 
1995), (b) nuclear activity (Murray, Maffini, Ucci, Sonnenschein, & Soto,  2007; Recchia 
et al., 2004), and (c) cellular proliferation (Bulaveya et al., 2004; Mercado-Feliciano & 
Bigsby, 2008; Recchia et al., 2004). Additionally, the kinases used in bringing about 
these changes are estrogen receptor kinases 1 and 2 [ERK1/2] (Bulaveya & Watson, 
2004). Interestingly, these cellular end-points and kinases overlap those when Her2 is 
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amplified, inducing breast carcinogenicity (Ellsworth, Ellsworth, Patney, Deyarmin, 
Love, Hooke, ... Shriver, 2008; Zhang, Wolf-Yadlin, Ross, Pappin, Rush, Laufenburger, 
& White, 2005; Yang et al., 2004). Cross-talk between ER and Her2 receptors exists, 
especially during breast carcinogenesis, and the cellular end-points with xenoestrogenic 
exposures overlap those when Her2 is amplified. Hence, it is plausible that perturbing the 
normal levels of estrogens with xenoestrogenic exposures further heightens this chemical 
cross-communication between ER and Her2 thereby leading to Her2 mutation and its 
oncogenic activation, inducing breast carcinogenicity. 
Population-based studies assessing the risk of breast cancer with xenoestrogenic 
exposures have employed methods susceptible to recall and other systemic biases. The 
exposure assessment was conducted using interviews or self-reports and women may not 
be able to identify these xenoestrogens correctly, thus leading to misclassification (Van 
Hoften, Burger, Peeters, Grobbee, Van Noord, & Leufkens, 2000). Some studies have 
used controlled that were suffering from benign breast disease or mammomegaly 
(Stellman, Djordevic, Britton, Muscat, Citron, Kemney, …Gong, 2000; Zheng, Holford, 
Mayne, Ward, Carter, Owens, … Tessari, 1999; Zheng, Holford, Mayne, Tessari, Ward, 
Carter, … Hoarzham, 2000). Whereas some other studies used small (≤20) sample sizes 
(Djorveck, Hoffmann, Fan, Prokopczyk, Citron, & Stellman, 1994; Falck, Ricci, Wolff, 
Godbold, & Deckers, 1992). Furthermore, the unknown and the variables cannot be 
controlled in epidemiological studies, thus making it hard to establish direct correlation 
or causality between various xenoestrogenic exposures and mammary tumor outcomes. 
Keeping these in mind, a more sensitive approach to assessing the carcinogenic potential 
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of the xenoestrogens is necessary. Molecular genetics technologies, such as fluorescent 
in-situ hybridization (FISH), provide a sensitive tool to observe and assess gene level 
changes after xenoestrogenic exposures (Johnson et al., 2012; Press, Slamon, Flom, Park, 
Zhou, & Bernstein, 2002). 
Statement of the Problem 
Synthetic xenoestrogens and their repeated exposure could chemically modulate 
the promotion and progression of breast cancer (Aube, Larochelle, & Ayotte, 2013; 
Brody & Rudel, 2003; Valeron, Pestano, Luzardo, Zumbado, & Boada, 2009). Breast 
carcinogenesis is known to occur by the activation of oncogenes, or inactivation of TSGs 
(Barrett, 1993; Lee & Muller, 2010; Pitot & Dragon, 1993). Patient data showed that the 
Her2 oncogene is amplified (increased gene copy numbers) and overexpressed in almost 
a third (20% to 30%) of incident breast cancer patients (Korkaya, Paulson, Iovino, & 
Wicha,, 2008, Lee & Muller, 2010; Slamon et al., 1989; Slamon et al., 2011).  
Additionally, a few population-based studies indicated that some xenoestrogenic 
exposures leading to aggressive breast cancer were found in women with ER-negative 
and Her2-positive status (Gammon et al., 1999; Rosenberg, Zhang, Coogan, Strom, & 
Palmer, 2008). Because breast cancer cells possess differential cellular receptor 
phenotypes, such as ER and Her2 (positive or negative) (Gutierrez & Schiff, 2011; 
Slamon et al., 2011), it is possible that the carcinogenic potential influencing the Her2 
oncogene may differ for various xenoestrogens within these receptor types, rendering 
some phenotypes more susceptible to aggressive disease over others, and this also has not 
yet been assessed. 
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Furthermore, studies showed that xenoestrogens had an additive effect, but these 
studies only used binary exposures at a single time-point for a few hours (48 hours) or 
exposures to mixtures of OCs for a short time period (9 days) (Aube, Larochelle, & 
Ayotte, 2008; Rajapakse, Ong, & Kortenkamp, 2001). However, cancer is a disease that 
has a long latency period (Barrett et al., 1993; Marlow, Honeth, Lombardt, Cariatti, 
Hessey, Piplli, … Dontu,  2013; Nadler & Zurbenko, 2013; Pitot & Dragon, 1993). Also, 
most women are exposed daily to various xenoestrogens commonly used in household 
products. However, no study to date has critically examined how the concentration, 
duration, and type of xenoestrogen exposure influence the Her2 gene and, in turn, cancer 
cell growth and proliferation in human cells. Additionally, prolonged, continuous (7 to 8 
weeks) and multiple (3 to 4 xenoestrogens) exposures of commonly used household 
xenoestrogens, such as BPA, NPH, estrogen and DDT, have not yet been studied using 
human cells or cell lines. 
Purpose and Objectives of the Study 
Using an experimental case-control study design nested with in a randomized 
block design (RBD), this research study quantitatively assessed Her2 copy numbers with 
FISH technology on four phenotypically disparate human breast cancer cell-lines (ER 
and Her2 positive or negative lines) after exposing them to differential exposures with 
four commonly used xenoestrogens (i.e., BPA, NPH, DDT, and EE). Controls remained 
unexposed to any xenoestrogen. Her2 gene copy numbers for the cases and controls were 
counted and differences evaluated for statistical significance. The study determined the 
relationship between Her2 copy numbers with increasing exposure concentrations and 
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durations to various xenoestrogens applied individually or in combination to the cell-
lines. This research produced molecular data that provide mechanistic insights on the 
workings of this oncogene with differential xenoestrogenic exposures further assisting in 
the evaluation of their carcinogenic potential and breast cancer risk assessment with the 
various breast cell phenotypes.  
The main objectives of this case-control study were to 
 assess the carcinogenic potential of commonly used xenoestrogens influencing 
the Her2 oncogene and 
 to discern cellular phenotypes that maybe more susceptible to more aggressive 
disease with xenoestrogenic exposures. 
Theoretical Construct 
Breast carcinogenesis occurs with the activation of oncogenes or the inactivation 
of TSGs (Lee & Muller, 2010; Pitot & Dragon, 1993). Exposures to chemicals and 
hormones, including xenoestrogens, can trigger the activation of oncogenes (Brody, 
Tickner, & Rudel, 2005; Davis, Bradlow, Wolf, Woodruff, Hoet, & Anton-Culver, 1997; 
Montemurro, DiCasimo, & Arpino, 2013). Her2 is a proto-oncogene, needed for normal 
mammary cell development and function, but it can mutate and become oncogenic. Her2 
oncogenic overexpression is noted in up to 30% of incident breast cancer patients 
(Korkaya, Paulson, Iovino, & Wicha, 2008; Slamon et al., 1989; Slamon et al., 2011), 
with the number of patients increasing by 40% with disease progression (Meng et al., 
2004). Mammary carcinogenesis is controlled by cross-talk that occurs between ERs and 
Her2, forming a positive feedback loop for cellular proliferation, survival tactics used by 
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tumor cells, and their invasion and migratory activities (Montemurro, DiCasimo, & 
Arpino 2013; Osborne & Schiff, 2005; Wang, Morrison, Gillihan, Guo, Ward, Fu, 
…Schiff,  2011). Her2 can interact with ER once the estrogen receptor ligand complex is 
formed activating the Phosphoinositide 3-kinase (PI-3K) pathways (Jung et al., 2010; 
Montemurro, DiCosimo, & Arpino, 2013; Stoica et al., 2003). Its increased expression 
initializes the mitogen activated protein kinase (MAPK) pathway, which then relocalizes 
more ER from the nucleus to the cellular cytoplasm, thus forming a positive feedback 
loop for the Her2 amplification (Jung et al., 2010; Montemurro, DiCosimo, & Arpino, 
2013; Yang, Barnes, & Kumar, 2004). Once activated, Her2 can take over this pathway 
by homo-dimers or hetero-dimers with its other family members thereby activating an 
autocrine loop, in which case Her2 becomes self-sufficient for its renewal (Fiszman & 
Jasnis, 2011; Pinkas-Kramarski et al., 1998; Witsch, 2010). 
The MAPK, also known as estrogen receptor kinase (ERK), is a protein found in a 
cell that communicates a signal from the cell surface receptor to the DNA found within 
the cell’s nucleus. The cell’s signaling is initiated when a ligand (e.g., growth factor, 
hormone, or xenoestrogen) binds to the receptor and ends when the DNA in the nucleus 
initiates transcription of a protein and produces a change in the cell, such as cellular 
growth. Thus, it is a signaling pathway governing some of the key cellular processes, 
such as proliferation, differentiation, and cell-survival (Duronio & Xiong, 2013; Fiszman 
& Jasnis, 2011; Witsch & Yarden, 2010). The MAPK/ERK pathway includes many 
proteins that communicate. When the proteins involved in the pathway have a mutation, 
the signals sent to the nucleus go awry, which is a necessary step for carcinogenesis. 
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MAPK/ERK pathway is found to be de-regulated in various diseases, including breast 
cancer (Duronio & Xiong, 2013; Orton, Sturm, Vyshemirsky, Calder, Gilbert, & Kolch, 
2005).  
Several pathways leading to breast cancer (e.g., radiation, estrogens, alcohol, and 
diet) were initially hypothesized by Davis, Bradlow, Wolf, Woodruff, Hoe, Anton-Culver 
(1993), one of these pathways also showed that xenoestrogens increase the estrogenicity 
of a cell above normal levels and this leads to the mutation of genes found in the 17q loci. 
Interestingly, the Her2 gene maps to this area (17q11.2-17q12) of the human genome, 
and this pathway provided the theoretical construct for this exploratory research project. 
The nongenomic and genomic action of ER and its cross-talk with Her2 buttress this 
construct (Jung et al., 2010; Montemurro et al., 2013). 
Xenoestrogens for the Study 
Xenoestrogen selection criteria were geared towards products found in almost 
every household across the globe or those that bio-accumulate. 
Using the aforementioned criteria, the following xenoestrogens were selected: 
• DDT is an insecticide that was produced in large quantities (approx. 22 
million pounds) in the United States in the mid-1900s. One of its important 
properties is that it bio-accumulates. Due to this, even though DDT was 
banned in the United States in 1972, it still persists in the environment. More 
so, DDT is still being used as malarial vector control by many countries (e.g., 
India, Africa), and it can transported to other parts of the world from these 
countries (Agency for Toxic Substances & Disease Registry [ATSDR], n.d.). 
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• EE is an estrogen used in almost all formulations of present-day combined 
contraceptive pills. In the past few decades, the EE part of the pill has been 
reduced from 100ug to 20ug. Small amounts (6ug) of EE are also converted 
from 1 mg of norethindron acetate (NETA), which is a formulation used in 
hormone therapy (Chu, Zhang, Gentzschein, Stanczyk, & Lobo, 2007). 
• BPA is a chemical used in making plastics and resins. Some of its mainstream 
products that are used every day are plastic containers for storage, baby 
formula bottles, soda bottles, plastic tubing used for various purposes, and 
dental sealants. The chemical bonds that form BPA are highly unstable and 
can degrade with normal use. Factors such as increase in temperature, pH, and 
even time can break these bonds. When these bonds break, BPA can easily 
enter the human body (Jenkins et al., 2009).  
• NPH or NP is a subset of alkyl phenols. It is widely used in industrial 
detergents and surfactants, and is added to many consumer products like 
pesticides, paper manufacturing, dry-cleaning, paints, household cleaners, and 
cosmetics (Calafat, Kuklenyik, Reidy, Caudill, Ekong, & Needham, 2005). 
Research Questions, Variables, and Hypotheses 
Research Question 1: Do increasing concentrations of synthetic xenoestrogens 
significantly increase the Her2 copy numbers? 
Outcome/dependent variable: Her2 gene copy numbers  
Predictor/independent variable: Concentrations of xenoestrogens (0.000nM or 




Null (H01): There will be no significant increase in Her2 copy numbers with 
application with increasing concentrations of xenoestrogens. 
Alternate (H11): There will be a significant increase in Her2 copy observed with 
the application of xenoestrogens with increasing concentrations. 
Hypothesis 1: It is hypothesized that increasing the concentrations of the 
xenoestrogens will increase Her2 copy numbers. It will also do so for each cell line or 
receptor type. 
Research Question 2: Do the concentration at which the increments in Her2 copy 
numbers become significant vary between the four xenoestrogens? 
Outcome/dependent variable: Her2 gene copy numbers  
Predictor/independent variable: Xenoestrogenic exposures of BPA, NPH, DDT, 
and EE using .1nM, .01nM, .001nM concentrations. 
Null (H02): A significant increase in Her2 copy numbers occurred at similar 
concentration levels for all four xenoestrogens (BPA, NPH, DDT, and Estrogen). 
Alternate (H12): A significant increase in Her2 copy numbers occurred at 
different concentration levels for all xenoestrogens. 
Hypothesis 2: It is hypothesized that Her2 expressions will significantly increase 
for the four different xenoestrogens at different concentrations.  
Research Question 3: Overall, is there a significant increase in the Her2 gene 




Outcome/dependent variable: Her2 gene copy numbers 
Predictor/independent variable: Exposure duration (short-term: single, short-term 
vs. multiple, persistent), and Xenoestrogen (BPA, DDT, EE, NPH). 
Null (H03): No significant increase will be found in Her2 copy numbers between 
the short and long term applications of xenoestrogens. 
Alternate (H13): A significant difference in Her2 copy numbers will be found 
between short and long term xenoestrogenic exposures. 
Hypothesis 3: It is hypothesized that increasing the duration of xenoestrogenic 
exposures will significantly increase Her2 copy numbers overall and for each categorical 
xenoestrogen. 
Research Question 4: Overall, does Her2 expression vary significantly with each 
specific receptor type (i.e., cell line) upon exposure to xenoestrogens? 
Outcome/dependent variable: Her2 gene copy numbers 
Predictor/independent variable: Receptor types/Cell lines (ER+/Her2+, ER-
/Her2-, ER+/Her2-, and ER-/Her2+) and Exposure durations (single, short-term vs. 
multiple, long-term). 
Null (H04): Her2 copy numbers will not vary significantly between the different 
receptor types/cell lines upon exposure to xenoestrogens. 
Alternate (H14): A significant difference will be found in the Her2 copy numbers 
between the different receptor types/cell lines upon exposure to xenoestrogens. 
Hypothesis 4: It is hypothesized that differential Her2 copy number increase will 
be noted between the different receptor types/cell lines when they are exposed to 
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xenoestrogens. However, each cell line would show significant Her2 copy number gains 
with multiple, persistent exposures compared to single, short-term exposures. 
Operational Definition 
Measuring the Dependent Variable  
The dependent variable in this study was Her2 gene copy numbers. They were 
measured after conducting FISH experiments by counting the number of orange signals 
of the Her2 gene probe because each orange signal denotes a copy of the Her2 gene. The 
Her2 gene copy number was quantified in its absolute value, that is, total Her2 copies 
observed per nuclei (McCormick, Lillemoe, Beneke, Schrauth, & Reinartz, 2002). As 
humans are diploid (i.e., have two homologous chromosomes in normal individuals; 
Bilous, Morey, Armes, Cummings, & Francis, 2006), the increase of Her2 in its absolute 
value will be greater than 2 copies of the gene. 
Measuring the Independent Variables 
• Concentrations of the xenoestrogen/s were measured by their molar 
concentration, diluted to nanomolar (nM) concentrations. The specific 
concentrations used were .001nM, .01nM, and .1nM (Payne, Rajapakse, 
Wilkins, & Kortenkamp, 2000; Rajapakse, Ong, & Kortenkamp, 2001). 
• Duration of application (one time application cultured for 5 days vs. daily 
application for 50 days (Jenkins et al., 2009). 
• Number of xenoestrogens that were applied (exposed to1 xenoestrogen vs. 
exposed to all 4 xenoestrogens) (Payne, Rajapakse, Wilkins, & Kortenkamp, 




FISH technology was used to assess Her2 gene copy numbers, which provided 
high-test sensitivity (95% to 97%) and specificity (97% to 100%) (Press et al., 2002), 
thereby yielding a high predictive value (Mass et al., 2005; Olsson, Jansson, Holmund, & 
Gunnarson, 2013; Sauter, Lee, Bartlett, Slamon, & Press, 2007). Specifically, in the case 
of breast cancer, researchers have observed that the Her2 gene amplification or increased 
copy numbers found at the level of the gene directly corresponded to its transcribed 
mRNA and its protein overexpression (Dressman et al., 2003; Slamon et al., 1989; 
Slamon et al., 2011). Thus, these study data cut across two biologic processes (i.e., Her2 
oncogenic amplification and hence its protein overexpression). Because Her2 
measurements are not hindered by the number of xenoestrogens used, it did not 
overestimate or underestimate true values of xenoestrogenic exposures (Rajapakse, Ong, 
& Kortenkamp, 2001). 
This work was conducted in a laboratory, where the exposure types, amounts, and 
durations were measured precisely, controlled, and monitored. In the realm of the 
laboratory, this study was performed ethically using human cell-lines, whereas it would 
be unethical to do so in human populations (Brody, Tickner, & Rudel, 2005). 
Additionally, the Her2 probe-set is FDA-approved, which helped in the IRB approval. 
Furthermore, the experimental design (Trochim & Donnelly, 2007, p. 158) increased the 
validity of this study, because random assignment of the flasks was performed for the test 
and control groups for each line. 
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Lastly, this exploratory research was conducted in a laboratory using breast 
cancer cell-lines. However, FISH experiments can be performed with fresh or archived 
tissue samples (Garimberti & Tosi, 2010; Schruter, LeBrun, & Harrison, 2002) and FISH 
reproducibility is high (Garimberti & Tosi, 2010; Press et al., 2002), making further 
research possible using either prospective or retrospective study design to gather data at 
the population level. 
Limitations 
Conducting experiments with cell-lines required extreme caution with respect to 
how long the cell-lines had already been cultured and passaged in the bio-repository 
before their receipt in the laboratory, as cell-lines with high passage numbers (> 40) can 
easily change their genetic conformation in response to stress produced by the culturing 
environment (American Type Culture Collection [ATCC], 2007). Due to this reason, 
extra precaution was used when ordering the cell lines to make sure that the ordered lines 
had a low passage number (< 40). 
The cell repository had limited data on the lines, thus matching of data was not an 
option for other breast cancer risk factors (e.g., age, parity, breast-feeding, diet, smoking, 
and alcohol history). Another potential weakness could have been low yield of cells to 
work with after treatment with various xenoestrogens, which would be technically 
challenging. To combat this challenge FISH experiments were conducted using 
interphase nuclei. Interphase FISH is performed without a high yield of actively dividing 
cells (Ohlschlegel, Zahel, Kradolfer, Hell, & Jochum, 2012; Ohlschlegel, Zahel, 
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Kradolfer, Hell, & Jochum, 2013; Olsson, Jansson, Holmund, & Gunnarson, 2013; Press 
et al., 2002; Schruter, LeBrun, & Harrison, 2002). 
Generalizability 
Each normal healthy breast cell does have two copies of the Her2 proto-oncogene 
(Akiyama et al., 1986; Slamon et al., 2011). However, because this research was 
conducted using breast cancer cell-lines, the data were limited to cell-lines. Even so, the 
lines themselves were derived from humans. Breast cancer cell lines selected were ER- 
and Her2-positive or -negative because of the following reasons: (a) ER and Her2 are the 
main drivers of breast carcinogenesis (Gutierrez & Stoica, 2011), (b) xenoestrogens 
mediate their effects via ERs (Mercado-Feliciano & Bigsby, 2008; Stoica et al., 2003), 
and (c) ER cross-communicates with Her2 receptors in breast carcinogenesis (Jung et al., 
2010; Stoica et al., 2003). Different combinations of these two receptor types (e.g., 
Her2+/ER- and Her2-/ER+) were taken into consideration in the selection of these breast 
cancer cell-lines.  
The four cell-lines used were MCF7, BT474, MDA-MB-231, and SKBR3, and 
they had already been categorized as ER and Her2 positive or negative. The specific 
classification for each line was as follows: MCF7 (ER+/Her2-) BT474 (ER+/Her2+), 
SKBR3 (ER-/Her2+), and MDA-MB-231 (ER-/Her2-) (Chang, Chiu, Tseng, Chang, 
Chien, Wu, & Lui, 2006; Johnson et al., 2010; Wang, LiU, Wu, Hong, Yang, Liu, ... Gu, 
2010). The generalizability was limited beyond those receptors (e.g., insulin-growth 
factor receptors, progesterone receptors, androgenic receptors) that are also found on the 
cellular surface of a mammary cell. 
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Significance and Social Change 
Breast cancer still remains a public health concern (Aube, Larochelle, & Ayotte, 
2011; Valeron, Pestano, Luzardo, Zumbado, & Boada, 2009). Synthetic xenoestrogens 
are found in varying quantities in commercial products that are available quite easily 
(e.g., herbicides, plastics, pesticides, contraceptives) to which women in all societies and 
all over the world are constantly exposed (Cohn, 2011; Darbre & Charles, 2010; Inifo-
Nunez, Herreros, Eucinas, & Gonzalez-Bulnes, 2010; Kuch, Metzer, & von der Trenck, 
2010; Qui, Suri, Bi, Sheng, & Fu, 2010; Vogel, 2009). If commonly available synthetic 
xenoestrogens do increase the risk of breast cancer, their ease of availability needs to be 
curtailed. Studying the risk associated with these compounds in relation to breast cancer 
can provide clues that could lead to its primary prevention (Aube, Larochelle, & Ayotte, 
2011; Boada, Zumbado, Henriquez-Hernandez, Almeida-Gonzalez, Alvarez-Leon, Serra-
Majem, & Luzardo 2012; Buteau-Lozano, Velasco, Cristofari, Balaguer, & Perrot-
Applanat, 2008; Davis et al., 1997). Thus, reducing the risk factors of breast cancer 
would not only affect women, but also many families whose support structures they are. 
This would not only translate in financial terms, but also emotional terms for many 
children and husbands, who will not lose their mothers or spouses to breast cancer 
mortality. Furthermore, as synthetic xenoestrogens are found all over the world, this 
research would be far reaching, helping not only the immediate community in the fight 
against breast cancer, but also the global community. 
As cancer is primarily a multistage genetic disease (Croce, 2008; Hanahan & 
Weinberg, 2011; Knudson, 2001; Vogelstein & Kinzler, 2004), integrating molecular 
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technologies into risk assessment methodologies can provide a powerful tool for gaining 
insights into oncogenic alterations that occur in response to xenoestrogenic exposures 
(Bishop, 2010). Such oncogenic alterations offer the potential to understand the nature of 
the deregulated oncogene leading to carcinogenesis, thereby improving understanding of 
the molecular mechanisms underlying breast cancer pathogenesis and progression. 
This research provides a model for GEI that will aid in predicting the 
carcinogenic potential of four commonly used synthetic xenoestrogens influencing the 
Her2 oncogene, a biomarker of breast carcinogenesis. Additionally, the study discerned 
cellular phenotypes that are more susceptible to aggressive disease with these exposures. 
Taken together, these results impact breast cancer risk assessment with xenoestrogenic 
exposures and provide mechanistic insights useful in decision-making for policy-level 
changes for its primary prevention and advocacy against the usage of xenoestrogens, 
especially for those women that are at an increased risk of disease progression. 
Definitions of Terms Used 
Allele is one member of a pair of genes. It is located on a specific position of a 
specific chromosome (Ellsworth et al., 2008). 
Androgen receptors are responsible for the male phenotype. This nuclear receptor 
is activated by the binding of testosterone and Dihydrotestoterone (i.e., androgenic 
hormones) (Walters, Simanainen, & Handelsmann, 2010).  
Bioaccumulate is defined as the increase in concentration of contaminated air, 
water, or food in living things due to their slow metabolism or excretion (Environmental 
Protection Agency [EPA], 2012). 
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Carcinogenesis is the process of malignant transformation leading to the creation 
of cancer (Barrett, 1993). 
Catenin is a class of proteins that play an important role in cellular adhesion 
(Zhang et al., 2005). 
Chromosome carries hereditary information, is formed of condensed chromatin, 
and is located in the nucleus of a cell (Akiyama, Sudo, Ogawara, Toyoshima,  & 
Yamamoto,1986). 
Dimerization is the process when two molecules link via covalent bonding 
(Tzahar & Yarden, 1997). 
Endocytosis is the dissociation of dimers within the cell (Lenferink, Pinkas-
Kramarski, Van de Poll, Van Vugt, Klapper, Tzahar, …Yarden, 1998). 
Estrogen (E2) is a female sex-steroid hormone (Tora, White, Brou, Tasset, 
Webster, Scheer, & Chambon 1989). 
Estrogen receptor (ER) is the receptor found in the cell through which estrogen 
(ligand) mediates its effect (Tora et al., 1989). 
Enzyme-linked immunosorbent assay (ELISA) is a colorimetric assay that uses 
antibodies to identify the presence or absence of a protein (Engvall & Pearlmann, 1971; 
Konecny, Meng, Untch, Wang, Bauerfeind, Epstein, …Pegram, 2004) 
Fluorochromes are specific DNA sequences that are labeled with fluorescent 
probe (Nitta, Hauss-Wegrzyniak, Lehrkamp, Murillo, Gaire, Farrell, …Grogen,  2008). 
Immunohistochemistry is an assay that localizes antigens in cells of tissue-sections 
using antibodies that specifically bind to the antigens (Press et al., 2002). 
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Fluorochromes are specific DNA sequences that are labeled with fluorescent 
probe (Nitta et al., 2008). 
Immunohistochemistry is an assay that localizes antigens in cells of tissue-sections 
using antibodies that specifically bind to the antigens (Press et al., 2002). 
Isoform is when a protein exists in different configurations. They can be quite 
similar to each other, but are not exactly alike, and can perform different functions 
(Stoica et al., 2003). 
Ligand is a molecule (e.g., hormone or growth factor) that binds to a specific 
receptor forming a ligand-receptor complex? These ligand-receptor complexes are 
important as they can modulate signal transduction and gene transcriptional activities of a 
cell (Akiyama, Sudo, Ogawara, Toyoshima, & Yamamoto, 1986). 
Homodimer is when the dimerization occurs with like molecules (Her2-Her2) 
(Tzahar & Yarden, 1997). 
Homologs are DNA sequences that have similarity, and share a common ancestry 
(Vennstrom & Bishop, 1982). 
Heterodimer is when the dimerization occurs with two disparate molecules (Her2-
Her3) (Tzahar & Yarden, 1997). 
Molarity (M) is defined as the concentration of a solution expressed as moles of 
solute per liter of solution (Brown, Le May, & Burstein, 2002, p. G-9). 




p-arm is the short arm of the chromosome (Akiyama, Sudo, Ogawara, 
Toyoshima, & Yamamoto, 1986). 
Phosphorylation activates an effector molecule from its inactive state in order to 
convert one form of signal (i.e., stimulus) into another (e.g., cellular growth) (Tzahar & 
Yarden, 1989). 
Proto-oncogenes are genes that are required for the normal growth and 
development of cells and tissues (Barett, 1993). 
Sensitivity measures the proportion of true positives that are correctly identified 
by a test (Press et al., 2002).  
q-arm is the long arm of the chromosome (Akiyama et al., 1986). 
Specificity measures the proportion of true negatives correctly identified by a test 
(Press et al., 2002). 
Southern blot is an electrophoretic technique used in genetic testing. It is used to 
separate sequences of DNA that have been digested with enzymes which breaks the DNA 
into fragments. These fragments are then blotted onto a membrane and hybridized with 
labeled probe to detect the fragment containing the gene of interest (NCBI, 04).  
Tumor Suppressor Genes (TSGs) are required for the cell-death (apoptotic) 
processes of a normal cell (Barrett, 1993). 





Research data from in vivo, in vitro and some population-based studies have 
established that xenoestrogens are a risk factor for breast cancer (Bulaveya & Watson, 
2004; Charlier, Albert, Herman, Hamoir, Gaspard, Mevrisse, & Plomterix, 2003; 
Gammon et al., 1999; Johnson et al., 2012; Maras et al. 2005; Recchia, Vivacqua, 
Gabriele, Carpino, Fasanella, Rago, ...Maggiolini,  2004; Warner, Eskenazi, Mocarelli, 
Gerthoux, Samuels, Needham, ...Brambila, 2002).  
The designs of population-based studies pose technical challenges for exposure 
measurements as they are riddled with recall bias and misclassification, the variables 
cannot be controlled to establish causality or direct correlation between exposure and 
tumorigenesis, and conducting randomized trials to gather population-level information 
with xenoestrogen exposures is not an ethical option, but a costly one to detect low-level 
risk (i.e., less than twice) incurred by xenoestrogens. However, because most women 
around the globe are exposed to xenoestrogens, studying the risk that they pose and 
modifying these risk factors will have a great public health impact even though they only 
account for low levels of relative risk (Aube, Larochelle, & Ayotte, 2011; Brody, 
Tickner, & Rudel, 2005; Johnson et al., 2012). 
The carcinogenic process occurs primarily due to activation of an oncogene or 
turning off a tumor suppressor gene. In the case of breast cancer, empirical patient data 
provide evidence that the Her2 oncogene is activated in up to 30% of breast cancer 
patients (Gutierrez & Schiff, 2011; Slamon et al., 1999; Slamon et al., 2011). 
Additionally, the percentage of patients with Her2 oncogenic activation grows by an 
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additional 40% as the cancer progresses to the next stage (Meng et al., 2002). Current 
reviews for xenoestrogenic exposures-related breast cancer have now marked the 
epidermal growth family and its receptors (HER) as one of the risk factors for breast 
carcinogenesis (Fucic, Gamulin, Ferencic, Katic, & von Krauss, 2012).  
Further, a population-based study strongly suggested that the Her2 oncogene is 
activated with xenoestrogenic exposures and these patients mostly are ER negative, but 
their breast cancer was more aggressive with a shorter latency period (Gammon et al., 
1999). Studies using mouse models showed that Her2 gene is activated upon 
xenoestrogenic exposures (Aube, Larochelle, & Ayotte, 2011; Jenkins et al., 2009), and 
the activation of the Her2 gene causes accelerated tumor progression (Jenkins et al., 
2009; Johnson et al., 2011). These studies further buttressed the hypothesis that similar 
processes of carcinogenesis maybe are occurring in both humans and mice, making it 
imperative to study the carcinogenetic potential of xenoestrogens for breast 
carcinogenesis in relation to the Her2 gene using human cell with different phenotypes.  
This research project determined that significant (p = .000) increase in the Her2 
copy numbers did occur with persistent xenoestrogenic exposures, occur in all receptor 
types (ER and Her2 positive or negative), and with all four categorical xenoestrogens 
(BPA, DDT, EE, and NPH) in individual and combined exposures. These gains in Her2 
copies occurred at nanomolar concentrations (.001nM) for all four xenoestrogens. 
Chapter 2  reviewed existing literature and discussed how some research has suggested 
an association between Her2 overexpression with xenoestrogen exposure. The chapter 
began with a description of models and theory of carcinogenesis that provided the 
31 
 
foundation and the theoretical framework for this study. A brief overview of estrogen, its 
receptors, and Her2 family of receptors is provided. A detailed discussion of the Her2 
oncogene itself and its oncogenic potential specifically for breast carcinogenesis, as well 
as the chemical connections found between ER and Her2, which play a pivotal role in 
breast carcinogenesis followed. The chapter also discussed the sensitivity and specificity 
of different technologies used in the assessment of Her2 gene. Finally, the chapter ended 
with an in-depth discussion of the research performed (laboratory and population-based) 
on xenoestrogens and breast cancer along with their outcomes, and discussed 
implications of past research for future work. 
Chapter 3 described the methodology used in this project to answer the research 
questions. Further, it discussed the use of nonparametric analysis as a means to analyze 
the relationship between the dependent variable (Her2 oncogene) and the independent 
variables (differential concentration and durations of exposures with individual 
xenoestrogen as well as a combined exposure of all four xenoestrogens). The chapter also 
included a description of the cell-lines, experimental protocols, ethical considerations, 
measures, and analysis of the data. 
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Chapter 2: Literature Review 
Introduction 
This literature review established the need for research in the area of 
xenoestrogenic exposures, especially with respect to how persistent and combinatorial 
exposure influence oncogenic expression of Her2 in relation to breast cancer. The review 
encompassed the current knowledge of the carcinogenesis process and Her2 as an 
oncogene for breast cancer, which provided the theoretical construct of this proposal. 
Because xenoestrogens have estrogenic properties, the review provided a broad overview 
of the ER and the cross-communication between Her2 and ER. I discuss the properties of 
xenoestrogens, especially the research done using animal models that has shown Her2 
gene activity upon xenoestrogenic exposures. The review then ends with the main focus 
on the epidemiologic studies conducted using xenoestrogens, mainly organochlorines and 
pharmaceutical estrogens, and a summary providing the existent gaps that need to be 
filled by continued research such as this one. 
The papers and some books used for this review were either accessed 
electronically through databases such as Pubmed Central, Medline, Google Scholar, 
Partners Healthcare Library, and Academic Search Premier (Walden University), or they 
were obtained from various books and journals that the Cytogenetics Core Laboratory at 
Brigham and Women’s Hospital (BWH) subscribes to. The terms used in the various 
databases were xenoestrogens, breast cancer, estrogen receptor, EGFR2, Her2-neu or 
Her2/neu, Her2, and Her2 oncogene. The search was conducted in English. Primary 





Cell-division is a process by which normal cells reproduce in tissues. Under 
normal circumstances, this process is tightly controlled by genes and chemical 
messengers, such as growth factors and hormones that relay messages to specific genes 
(Duronio & Xiong, 2013; Park & Lee, 2003; Sherr, 1996). When genes guarding the cell-
division processes undergo genetic changes either by mutation, amplification/increase in 
gene copy numbers, or chromosomal translocations, genetically aberrant cells are formed 
and the cell-division process is perturbed, which leads to uncontrolled cellular 
proliferation and differentiation resulting in carcinogenesis (Collins, Jacks, & Pavletich, 
1997; Knudson, 2001; Sher, 1996; Valente, Gray, Michalak, Pinon-Hofbauer, & Scott, 
2013; Vogelstein & Kinzler., 2004). Cancer is principally a genetic disease of somatic 
mutations with a latent phase of up to 30 years (Anderson et al., 1992; Barrett, 1993; 
Knudson, 2001; Nadler & Zurbenko, 2012; Vogelstein & Kinzler., 2004).  
Models and Mechanisms 
Carcinogenesis occurs in multiple steps (Barcellos-Hoff, Lyden, & Wang, 2013). 
Cancer initiation occurs when genes controlling either normal cellular growth and/or 
death (i.e., apoptosis) undergo genetic changes (i.e., mutation) forming genetically 
aberrant cells and its progression occurs when the genetically aberrant cell multiplies and 
further undergoes a series of genetic changes (Armitage & Doll, 1954; Fearon & 
Vogelstein, 1990; Lee & Muller, 2010; Moolgavaskar & Knudson, 1981). Carcinogenesis 
occurs due to an accumulation of genetically altered clones arising from a single 
34 
 
transformed cell that undergoes secondary and/or tertiary changes (Croce, 2008; Hanahan 
& Weinberg, 2011). 
Mechanisms for carcinogenesis are characterized by three stages. First, initiation 
is an irreversible change in a cell, usually genetic. Genetic changes can be amplification, 
mutations, chromosomal rearrangement, or aneuploidy. Second, promotion is the process 
by which the initiated neoplastic cell divides resulting in its clonal expansion. Third, 
progression marks the irreversible onset from benign to malignant form (Barrett, 1993; 























Figure 1. The process of carcinogenesis. The illustration shows the genetic events 





Histopathology on breast tumor sections bears evidence to the multistep processes 
of carcinogenesis (Xu et al., 2002). For example, dysplasia occurs during the initial 
stages of breast cancer in which only the cellular morphology changes without 
metastasis, and carcinoma marks its later stages; here the cancer has metastasized to other 
organs (Barett, 1993; Hartmann et al., 2014; Pitot et al., 1993; Virnig, Tuttle, Shamliyan, 
& Kane, 2010; Xu et al., 2002). Ductal hyperplasia is when the cells of the mammary 
duct are proliferating at a faster rate than normal, but the cellular structure and form (i.e., 
cellular morphology) remains normal (Wagoner, Laronga, & Acs, 2009; Xu et al., 2002). 
Atypical hyperplasia occurs when the cellular proliferation and morphology become 
deviant from the norm and this is a precursor of carcinoma in situ (Hartmann et al., 2014; 
Virnig, Tuttle, Shamliyan, & Kane, 2010). Carcinoma in-situ occurs when there is 
uncontrolled cellular proliferation and the cellular morphology is abnormal, but these 
cells are still within the tissue itself. Invasive carcinoma occurs when the cells from the 
carcinoma in-situ have starting invading other tissues or have now metastasized to the 
surrounding tissue/s. In this specific case the abnormal/cancerous cells are now not only 
in the mammary duct but have also metastasized to other parts of the breast and lymph 
nodes (Virnig, Tuttle, Shamliyan, & Kane, 2010; Xu et al, 2002). 
Two classes of genes are involved in the process of carcinogenesis: oncogenes 
and tumor-suppressor genes (TSGs). Both these types of genes provide different cellular 
responses (Gutierrez & Schiff, 2011; Lee & Muller, 2010). Proto-oncogenes are the 
normal counterparts of an oncogene and are required for normal growth and development 
(e.g., the Her2 proto-oncogene is necessary for normal breast growth and development; 
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Slamon et al., 2011). Proto-oncogenes promote normal cellular growth in numerous 
ways. Some proto-oncogenes produce hormones or mitogens effecting signal 
transduction, whereas others produce cellular receptors and are sensitive to hormones 
(Anderson, Reynolds, You, & Maronpot, 1992; Croce, 2008; Gutierrez & Schiff, 2011). 
The proto-oncogene can mutate into its oncogenic form with excessive or continued 
exposure to chemicals or ligands, such as hormones and xenoestrogens (Barrett, 1993; 
Davis et al., 1999; Montemurro, Di Cosimo, & Arpino, 2013). The transformation of a 
proto-oncogene into its oncogenic (e.g., Her2) form confers a growth and survival 
advantage to the cells that carry the mutated gene. Due to this growth advantage, the 
mutated cells accumulate over time leading to tumor formation (Bishop, 1991; Croce, 
2008; Gutierrez & Schiff, 2011; Lee & Muller, 2010). 
Contrastingly, TSGs control the cell-death processes of an abnormal or mutated 
cell, and when TSGs become dysfunctional they cannot block the cancerous cells from 
growing, thus the cancerous cell loses its capacity to senesce and keeps on proliferating 
(Lee & Muller, 2010; Valente et al., 2013). Usually, both oncogenes and TSGs are 
required in tumorigenesis (Barrett, 1993; Croce, 2008, Lee & Muller, 2010; Vogelstein et 
al., 2004). This has been observed in the case of breast cancer where p53, a TSG is 
deleted, and Her2 an oncogene is overexpressed simultaneously in patients suffering with 
the disease (Ismail, Aly, Khaled, & Mohamed, 2009). TSGs are also known as anticancer 
genes, because inserting TSGs suppresses uncontrolled cellular growth and induces 
normal morphological characteristics in neoplastic (i.e., cancerous) cells (Huang et al., 
1988; Valente & Strasser, 2013). 
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Another contrasting feature of TSGs when compared to oncogenes is that while 
oncogenes are dominant, meaning a single mutational event can activate them; the TSGs 
are functionally recessive requiring a “two-hit” inactivation process, meaning that genes 
found in both of the chromosome homologs must undergo a mutational event in order for 
the TSGs to become inactivated. This process is known as the Loss of Heterozygosity 
(LOH). In the case of oncogenes, the mutation is a somatic event; whereas in TSGs this 
event can either be somatic or inherited or both (Knudson, 1971; Knudson, 1973; Lee & 
Muller, 2010). The proteins coded by the TSGs suppress the cell cycle and/or promote 
cell senescence or both by deregulating the signaling pathways. The diverse functions of 
the TSG proteins can be categorized as follows: 
1. Repress gene expression required for cell division when a cell’s DNA is 
damaged and cannot be repaired (Lee and Muller, 2010). 
2. When DNA damage occurs and cannot be repaired, TSGs then initiate 
processes of programmed cell death (apoptosis and autophagy, a type of cell 
death were cytoplasmic processes engulf a cell is found to be controlled by 
p53, a TSG) (Sherr, 2004; Maiuri, Malik, Morselli, Kepp, Criollo, Mouchel, ... 
Kroemer, 2009; White & DiPaola, 2009; Hotchkiss, Strasser, McDunn, & 
Swanson, 2009).  
3. Some TSG proteins maintain contact inhibition and thereby suppress 
metastasis. Contact inhibition is a process by which normal cell arrest their 
cellular growth and proliferation when they come in contact with other cells. 
These processes are found to be lost in cancerous cells (Partanen, Nieminen, 
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& Klefstrom, 2009; Hirohashi & Kanai, 2005; Beltrami, Kim, & Gordon, 
2013).  
4. Mutations in the DNA repair proteins are also categorized as tumor 
suppressors because mutations in the DNA repair genes increases cancer risk 
(Brady, Jiang, Johnson, Jarvis, Kozak, … Attardi, 2011; Valente & Strasser, 
2013). It has also been observed that mutation rates increase with decrease in 
DNA repair genes, this further leads to inactivation of additional TSGs and 
the activation of oncogenes (Markowitz, 2000; Saal, Gruvberger-Saal, 
Pearson, Lovgren, Jumppanen,  Staaf, … Borg, 2008; Valente & Strasser, 
2013). 




Main Attributes of Oncogenes and TSGs  
Oncogenes    Tumor Suppressor Genes (TSGs) 
   Dominant    Recessive, Loss Of Heterozygosity (LOH)                             
   Gain of cellular function (e.g., proliferation)    Loss of function (e.g., programmed cell death) 
   Somatic origin    Somatic or inherited or both in origin 
 
Note: Self-made on Microsoft Word, 2007, using cited information on Oncogenes and 
TSGs. 
 
Loss of TSGs increases chromosomal instability and the life of a cell in normal and 
transformed human cells (Dalton, Yu, &Yang, 2010). Some oncogenic mutations may 
also disrupt the normal apoptotic processes of a cell, thereby leading to initiation, 
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progression, and metastasis (Angelini, Fluck, Pedersen, Parra-Palau, Guiu, … Arribas, 
2013; Shortt & Johnstone, 2012). Contrastingly, other oncogenic changes promote 
apoptotic processes hence promoting selective proliferation and survival of certain cells 
by blocking programmed cell senescence of these cells thus immortalizing specific clones 
of cells that have the growth advantage (Lowe, 2000; McDonnell, Deanne, Platt, Nunez, 
Jaeger, McKearn, … Korsmeyer, 1989; Vaux, Cory, & Adams, 1988). Comparative 
genomic technologies have also revealed genes are duplicated or deleted in cancers 
corresponding to the amplifications found in oncogenes and deletions of TSGs in the 
human genome (Bell, 2010) 
Cancer is also a latent disease. Cancer latency has been studied in mouse and 
human models. Marsden, Wright, Carrier, Moroz, & Rowan (2012) injected tumor cells 
from bone marrows of mice with breast cancer into mammary fat pads of normal mice; 
which resulted in tumor formation in the disease-free mice in two months after injection. 
These tumors were found to be highly metastatic as tumors were also observed in 
kidneys, lungs, and livers of the normal mice. Olsson, Jansson, Holmund, & Gunnarson 
(2013) had performed DNA analysis on 17 women suffering with breast cancer, who had 
undergone radiation therapy. Studying the S-phase (Synthesis phase of the DNA 
replication cycle), they found that the median S-phase index for radiation induced tumors 
was 14%, corresponding to a median latency period of approximately 22 years. The 
researchers found that a high S-phase index correlated to a shorter latency period and 
vice-versa for a low S-phase index.  
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Nadler & Zurbenko (2012) developed a model called the Weibull Model 
Extension to study cancer latency. This model uses survival analysis curves to estimate 
cancer latency. This model is assumption free and relies only on the hazard distribution 
of cancer development, thus making it a flexible model to study cancer latency. Using 
this model for various cancers, they found that pancreatic, lung and liver cancers have 
short latency period (range: 8.5-13.5 years), whereas other cancers such as myeloid 
leukemia, stomach, melanoma, and breast have the longest latency period (range: 22.8-30 
years). 
Human Epidermal Growth Factor Receptor 2 (Her2) 
Attributes, Role in Development, & Interactions with Her Family of Receptors 
Human epidermal growth factor 2, also known as Her2, Her2-neu, or ErbB2 is a 
proto-oncogene, and that plays a critical role in signal transduction for the normal growth 
and development of the breast tissue. The Her2 gene encodes for the Her2 receptor 
protein. It belongs to human epidermal receptor (Her) family. The Her2 protein is one 
member of a family of closely related proteins, composed of Her1, 2, 3, and 4 (Lupu, R., 
Cardillo, Harris, Hijazi, & Rosenberg, 1995; Slamon et al., 2011; Yardin & Sliwkowski, 
2001). After a ligand binds to the Her receptor, the receptor binds to another receptor 
closely related or similar in structure, a process called dimerization initializing 
phosphorylation, activating signal transduction processes, resulting in various cellular 
processes such as cellular growth and proliferation. When the receptor binds to a similar 
receptor, it is called homodimerization; and when it binds with a closely related receptor, 
it is heterodimerization (Ghosh, Narasanna, Wang, Liu, Chakrabarty, Balko, … Arteaga, 
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2011; Tzahar, Waterman, Chen, Levkowitz, Karunagaran, Lavi, … Yarden, 1996). 
Biochemical research showed that these receptors interact with a wide-range of growth 
factor ligands. The ligand and the receptor form ligand-receptor complexes and modulate 
signal transduction and gene transcriptional activities of a cell (Akiyama, Sudo, Ogawara, 
Toyoshima, & Yamamoto, 1986; Gutierrez & Schiff, 2011). 
Ligands of the EGF family of growth factors binding to the various Her family of 
receptors fall into the following 3 categories: a) EGF and heparin-binding (EGF-HB) 
bind only to Her1/EGFR (Aceto, Duss, MacDonald, Meyer, Roloff, Hynes, & Alj, 2012; 
Higashiyami, Abraham, Miller, & Klagsburn, 1991), b) Betacellulin (BTC) binds to Her1 
and 4 (Riese et al., 1996; Emede, Kostler, & Yarden, 2010), and c) Neu differentiation 
factors (NDFs), like Heregulin bind to Her3 and 4 (Aceto et al., 2012; Plowman et al., 
1993; Witsch, Sela, & Yarden, 2011). Although Her2 itself does not have a ligand-
binding site, but it alone can partner with all of the other receptors of the Her family (i.e., 
Her1, 3, or 4) forming dimers and inducing receptor tyrosine phosphorylation (DeFazio-
Eli, Strommen, Dao-Pick, Parry, Goodman, & Winslow, 2011; Emede, Kostler, & 
Yarden, 2012). Further, Her3 does not have a kinase site, and requires Her2 to activate 
the phosphorylation process in order to achieve its cellular end-point (Emede, Kostler, & 
Yarden, 2012; Fisman & Jasnis, 2011; Tzahar & Yarden, 1998). In fact, Her2 is the most 
preferred co-receptor for dimerization found in Her receptor family (Graus-Porta, Beerli, 
Daly, & Hynes, 1997; Fiszman & Jasnis, 2011; Emede, Kostler, & Yarden, 2012). Her1, 
3, and 4; especially Her1 and 3 compete to dimerize with Her2 (Aceto et al., 2012; 
Pinkas-Kramarski et al., 1998). By way of its association with different Her family 
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receptors and dimerizing with them, the Her2 molecule has achieved a wide array of 
signals transmitted into the cell. Her2’s fluid dynamics have achieved many more cellular 
processes (e.g., proliferation, invasion, migration) compared to any of the other Her 
molecules (Emede, Kostler, and Yarden, 2012; Fiszman & Jasnis, 2011; Tzahar et al., 
1997; Witsch et al., 2010). In fact, heterodimers formed with Her2 are more stable and its 
signaling is more potent compared to any other homodimers or heterodimers formed 
within the Her family of receptors (Emede, Kostler, & Yarden, 2012; Fiszman & Jasnis, 
2011; Karunagaran, Tzahar, Beerli, Graus-Porta, Ratzkin, …Yarden, 1996). 
Another important characteristic of the Her2 molecule is its slow rate of 
endocytosis, and furthermore they are recycled to the cellular surface where they become 
active all over again, resulting in increased activity sustained over a much longer time-
period and is proposed to play a role in breast tumorigenesis (Lenferink et al., 1998). Her 
family receptors’ mitogenic index examined by its proliferative capacity has shown that 
Her2-Her3 heterodimers have the highest mitogenic potential followed closely by Her1-
Her2 (proliferative index of 10.5 and 9.6 respectively), when compared to all of the other 
Her family homo and heterodimers (proliferative index ranging from 0-5). Further, these 
hetero-dimers (i.e., Her2-with 1 and 3) have been found mostly in breast carcinomas. 
Interestingly, it was also observed that Her2-Her2 homodimers do possess some 
mitogenic potential (proliferative index of 3.5) even though they do not have any ligand-
binding domain (Ghosh et al., 2011; Pinkas-Kramarski et al., 1998). This property of 
Her2 may have important implications, especially in the case of breast cancer where 
these ligandless receptors could induce a positive feedback loop for phosphorylation 
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resulting in cellular proliferation without any outside stimuli also known as the autocrine 
loop (Aceto et al., 2012; Witsch, Sela, & Yarden, 2010). Proximity Ligation Assays 
(PLAs) detects the formation of protein-protein complexes in a single molecule. PLAs 
performed on 321 patient tumors detected Her2-Her2 and Her2-Her3 complexes 
allowing for the in vivo detection of these molecules, a significant association (p = 
<.00001) was noted between homodimerization (Her2-Her2 complex) and gene 
amplification of Her2 (Spears, Taylor, Munro, Cunningham, Mallon, Twelves, … 
Bartlett, 2012). 
Aceto et al. (2012) studied the role of Her2/Her3 activation as a unit in breast 
cancer. They induced normal mammary cells with Her2 and Her3 vectors, Her2, and 
Her3 vectors. Normal mammary cells with empty vehicle were used as the control. After 
culturing the cells for two weeks they performed a3D morphological analysis of the 
culture revealed that the normal cells formed small round structures and so did the cells 
that only had Her3. But, most of the cells (~70%) with Her2 alone became larger 
structures, and almost all of the cells (~90%) that were co-expressing Her2 and Her3 
showed complete lack of polarity; which characterizes highly invasive cellular structures.  
Because the Neu gene was initially found in rat neuroblastoma, and later, its 
normal counterpart was discovered in rats and humans, thus, work done in rat models 
could bear important implications for the human (Hung, Schechter, Chevray, Stern, & 
Weinberg, 1986; Witsch, Sela, & Yarden, 2010; Yamamoto et al., 1986). Her2 homologs 
are also involved in the origin and development of erythroblastoma in chickens (ErbB) 
(Vennstrom & Bishop, 1982; Witsch, Sela, & Yarden, 2010). 
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Her2 gene and protein 
The Her2 proto-oncogene spans a 190 Kilobase (Kb) region mapped to 
chromosome 17q11.2 - q12, encoding a 185 kilo Dalton (kDa) trans-membrane 
glycoprotein (Emede, Kostler, & Yarden, 2012). A healthy breast cell has two copies of 
this gene (Akiyama, Sudo, Ogawara, Toyoshima, & Yamamoto, 1986; Witsch, Sela, & 
Yarden, 2010). When activated, Her2 initiates the tyrosine kinase activity which results 
in a signal that is sent from the membrane of the cell where these receptors (i.e., Her2 
protein product) are located to its nucleus. This signal transduction ultimately leads to 
gene activation and various other cellular processes depending on the dimerization 
molecule involved with Her2 (Fiszman & Jasnis, 2011). Basically, Her2 sends control 
signals to the nucleus from the membrane, thereby instructing them to grow, divide, and 
make repairs. It has great networking capabilities and kinase capacity, which makes it a 
potent activator of cellular functions (Fiszman & Jasnis, 2011). 
An initial correlation study on the Her2 gene and its protein product was 
performed by Slamon et al. (1989) on 51 samples breast cancer that over-expressed Her2 
using Southern, Western, Northern blots and IHC to assess the gene amplification, RNA, 
and the protein status respectively. The correlation between gene amplification and its 
over expression was found to be significant (p = <.0001). In all 51samples (100%), two 
of the three measures (i.e., Western blot, Northern blot, and IHC) used to assess the 
protein product showed concordance with its gene amplification. Complete concordance 
was observed in 46 samples (90%) by all three measures. The discordance in the 
remaining four samples occurred due to a dilution factor in Western blot; where the 
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tumor sample is mixed with normal stroma. Another study by Dressman et al. (2003) also 
performed expression profile analysis of Her2 amplification in primary breast tumors 
which showed a significant correlation between gene amplification and its protein 
expression (r = 0.76, p = .005), further validating that the high expression levels is 
occurring due the amplification of the Her2 gene in breast cancer. 
Her2 Oncogene and Breast Carcinogenesis 
Amplification or copy number increase of the Her2 oncogene in breast cancer 
leads to genomic instability (Ellsworth et al., 2008; Szasz, Li, Eklund, Sztupinzki, 
Rowan, Tokos … Kulka, 2013). Genomic instability leads to increased cellular 
proliferation, and motility/migration (Asrani, Keri, Galisto, Brown, Morgan, Ghosh, … 
Winkles, 2013). These factors further translate in to tumor invasiveness and metastases 
(Laurin, Huber, Pelletier, Houalla, Park, Fukui, … Cote, 2013; Johnson, Seachrist, 
DeLeon-Roderiguez, Lozada, Miedler, Abdul-Karim, & Keri, 2010), as well as increased 
angiogenesis and decreased cell death (Konecny et al., 2004; Ye & Lu (2010). 
Her2 Amplification and Genomic Instability 
Amplification of the Her2 can be used as a proxy for the lack of stability in the 
entire genome. Ellsworth et al. (2008) investigated the changes found in the entire 
genome in relationship to the Her2 copy number status in patients suffering from 
invasive breast cancer.  
Her2 copy number changes were assessed by FISH in 181 patients (n = 181). The 
FISH uses the centromeric as well as the Her2 gene probe. The number of signals of the 
centromeric (CEP), and the Her2 probe were analyzed and compared. An amplification 
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was defined when the ratio of the Her2 vs. CEP was >2 signals. For allelic imbalances 
spanning the entire genome micro satellite markers (two markers per chromosome) were 
used. Allelic imbalance (AI) was determined using the following criteria: when a given 
marker showed less than or equal to 0.35 allelic ratios. Co-relation between Her2 status 
and AI was done non-parametrically. Non-parametric assessment does not confer to any 
assumptions (Cubash, Hanish, Schuz, Neugut, Karsdaedt, … Jacobson, 2013; Paxton, 
Chang, Courneya, & Pierce, 2012; Siegel & Castellan, 1988, p.34) thus making them less 
stringent, however, since they digress from tight associations or assumptions they are 
more flexible to accommodate complex data-sets as they can grow along with its 
complexity. Mean allelic levels for Her2 positive patients were significantly more when 
compared to patients that were Her2 negative (27% vs. 19% respectively, p = <.005). 
Also, stratifying by chromosome regions, Her2 positive tumors had more AIs. 
Additionally, AI patterns downstream of the Her2 gene (i.e., 17q12 to q21) using markers 
D17S250 and D17S579 found in this area showed that half of all Her2-positive tumors 
had allelic imbalances for both markers. This area has other genes of importance in breast 
cancer (e.g., TPO2A, BRAC1, and BRCA2). This indicates that many genes from the 17q 
area of the genome are altered in Her2 positive tumors. 
Amplification of the Her2 can be used as a proxy for the lack of stability in the 
entire genome. Ellsworth et al. (2008) investigated the changes found in the entire 
genome in relationship to the Her2 copy number status in patients suffering from 
invasive breast cancer. Her2 copy number changes were assessed by FISH in 181 patients 
(n = 181). The FISH uses the centromeric as well as the Her2 gene probe. The number of 
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signals of the centromeric (CEP), and the Her2 probe were analyzed and compared. An 
amplification was defined when the ratio of the Her2 vs. CEP was >2 signals. For allelic 
imbalances spanning the entire genome micro satellite markers (two markers per 
chromosome) were used. Allelic imbalance (AI) was determined using the following 
criteria: when a given marker showed less than or equal to 0.35 allelic ratios. Co-relation 
between Her2 status and AI was done non-parametrically. Non-parametric assessment 
does not confer to any assumptions (Cubash et al., 2013; Siegel & Castellan, 1988, p.34; 
Paxton, Chang, Courneya, & Pierce, 2012) thus making them less stringent, however, 
since they digress from tight associations or assumptions they are more flexible to 
accommodate complex data-sets as they can grow along with its complexity. Mean allelic 
levels for Her2 positive patients were significantly more when compared to patients that 
were Her2 negative (27% vs. 19% respectively, p = <.005). Also, stratifying by 
chromosome regions, Her2 positive tumors had more AIs. Additionally, AI patterns 
downstream of the Her2 gene (i.e., 17q12 to q21) using markers D17S250 and D17S579 
found in this area showed that half of all Her2-positive tumors had allelic imbalances for 
both markers. This area has other genes of importance in breast cancer (e.g., TPO2A, 
BRAC1, and BRCA2). This indicates that many genes from the 17q area of the genome 
are altered in Her2 positive tumors. 
Szasz, Qiyuan, Sztupinszki, Rowan, Tokes, Szekely, ... Kulka, J. (2013) 
conducted another correlation study using ER+, PR+, and Her2+ tumors to evaluate the 
correlation between genomic instability with respect to receptor status. The researchers 
assessed chromosome instability in 4 genes (FOXM1, TOP2A, TPX2, AURKA) also 
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known as CIN4, using gene expression arrays in 186 tumor samples. Receptor positive 
cells were defined using IHC for ER and PR positive status, and Her2 was measured 
using FISH. The level of CIN was defined by the patient’s clinical outcomes (size, 
vascular invasion, necrosis, disease-free survival). It was observed that ER+ and PR+ 
tumors had an inverse relationship with CIN4 expression (p=.001 and .017 respectively); 
whereas the Her2 expression and amplification correlated inversely with the CIN4 
expression (p =.001 and .013 respectively). These results show that ER-negative and 
Her2-positive expressions are associated with increase in CIN4 expression and worse 
clinical outcomes.  
Cellular Proliferation, Migration, Invasion, & Directional Persistence  
Her2 amplification can induce cellular growth and migratory activities. 
Dimerization activated via ligands recruits different partnering molecules in a signaling 
cascade which relay different types of messages to produce various cellular responses, 
and each message is specific for a particular response. 
In a large study, Zhang et al. (2005) ingeniously provided for the cause and effect 
relationship in biological systems using mass spectrometry (MS) together with wound-
healing assays plus fluorescent imaging to decipher phosphorylation of effector 
molecules, cellular proliferation and migratory response. First, to determine the activation 
or deactivation of effector molecules (clusters of peptides) a Human Mammary Epithelial 
Cell (HMEC) line with normal Her2 expression, a Her2 over expressed line, and sera-
free control were used. All were stimulated with EGF (100ng/ml) or HRG (80ng/ml) (i.e., 
ligands), and their phosphorylation sites compared with MS. The MS data-set projected 
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different molecules with increased or decreased phosphorylation levels. When Her2 is 
amplified it activates and deactivates various effector molecules providing regulatory 
functions for the internalization, degradation, and recycling of the receptor. Decreased 
phosphorylation leads to decreased ubiquitinization of the receptor. Ubiquitinization is a 
process that modifies and degrades proteins; its decreased activity marks an increase in 
time before the receptor is degraded. 
Second, cellular proliferation was quantified in all three lines using tritiated 
thymidine uptake after the stimulation with ligands. Only the Her2 over-expressed was 
noted with significant increase in cellular growth compared to the control (30,000 & 
40,000 CPM with HRG and EGF treatments respectively vs. 15,000 CPM in control, p = 
<.05). Third, quantification of cellular migration models by wound healing projected that 
cellular migration is highest with EGF stimulus when Her2 is over-expressed. 
Interestingly, the Her2 over-expressed line always showed increased migratory activity 
(0.3 inches in 6 hours) when compared to the parent line (0.1 inch in 6 hours). The results 
of this study provide evidence that increased expression of Her2 is the driving force for 
cellular proliferation and migratory response. Hence, Her2 may not only be involved in 
the cancer initiation, but also its progression. 
Aceto et al. (2012) performed migration assays using normal mammary cell line 
(MCF-10A) induced with Her2, Her3, or Her2 and Her3 vectors. Control had empty 
vehicle as vector. These assays showed that a significant number of cells migrated with 
Her2 alone (three and a half times more than the control, p = <.003), but a much greater 
number of cells migrated when Her2 and 3 co-expressed (5 times more than the control, p 
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= <.002). Another recent study by Asrani et al. (2013) found that the fibroblast growth 
factor-inducible 14 (Fn14) , a member of the Tumor Necrosis Factor (TNF) receptor 
super family is also over expressed in breast cancers that over express Her2. This growth 
factor increases the migratory and invasive capacity of Her2 over expressed tumors. In 
transgenic mice, Her2 directly induces the expression of Fn14. Carrying this forward on 
human breast cancer cell line (MCF7) transfected with Her2; the researchers found that 
the human line also has increased Fn14 and MMP9 expression. Ablation of Fn14 
expression with siRNA (RNA sequences that silence the expression of specific genes) 
decreased the migratory and invasion response even when Her2 was being over 
expressed and suggested that Fn14 is an important downstream effector molecule for 
Her2 in its migratory and invasive cellular response.  
Tumor metastasis is a two-way process requiring not only cell movement, but also 
cellular invasion. Her2 has shown to play a pivotal role in the invasion processes of 
breast carcinogenesis. Kumar et al. (2000) investigated Her2 mediated cellular migration 
and invasion using cell-lines with or without Her2 receptor. Using time-lapse 
photography the researchers examined cellular processes produced by cell-lines in the 
presence and absence of Her2 receptors when exposed to EGF family peptides (i.e., 
NDF, BTC, and EGF). It was observed that in the absence of Her2, the cellular migration 
was comparable to the control. Exposing the cells with Her2 not only increased the 
tyrosine kinase activity compared to the control, but the increment was much more 
prolonged (>2 hours) when compared to a transient peak (30-40 minutes) found in the 
cells without Her2. Also, the migratory response started almost immediately (~5 minutes) 
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in lines with Her2 receptors. A reduction in cell-to-cell contact was noted within a half-
hour, leading to tissue breakdown and hap-hazard cellular movement; whereas cells 
without Her2 receptors failed to participate in migratory processes, maintaining their 
original cell-to-cell contact. The cells without Her2 did not invade the basement 
membrane at all with any of the treatments. 
Johnson et al. (2010) highlighted one such mechanism is the activation p120 
Catenin, which further induces activation of Rac1. The expression of p120 mRNA was 
found to be four times more in Her2/Neu-positive mice mammary tumors compared to 
the wild type tumors (p = <.001). Performing migration and invasion assays using Her2 
over expressing human breast cancer lines and the same lines were silenced for p120 
Catenin using shRNA (silences target genes by RNA interference) showed that both 
cellular migration and invasion was significantly reduced (80% reduction, p = <.05) in 
the silenced lines even though these lines over expressed Her2. The Rac1 expression was 
also reduced by half (p = <.05) in the p120 Catenin silenced lines. These experiments 
indicated that Rac1 activated metastatic response of Her2 positive breast cancer required 
for the activation of p120 Catenin, and that p120 Catenin is the mediated the Rac1 
metastatic response when Her2 was over expressed. 
Catenin using shRNA (silences target genes by RNA interference) showed that 
both cellular migration and invasion was significantly reduced (80% reduction, p = <.05) 
in the silenced lines even though these lines over expressed Her2. The Rac1 expressed 
was also reduced by half (p = <.05) in the p120 Catenin silenced lines. These experiments 
indicated that Rac1 activated metastatic response of Her2 positive breast cancer requires 
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activation of p120 Catenin, and that p120 Catenin is the mediator of the Rac1 metastatic 
response when Her2 is over expressed. 
Aceto et al. (2012) studied the effects of Her2 and Her3 co-expression and 
cellular invasion in breast cancer. Their research revealed that when Her2 and Her3 co-
express, this increases the expression of IL-8; a critical factor that is involved in the 
invasion, migration, and proliferative processes of Her2 over expression. They performed 
invasion assays using normal mammary cell line (MCF-10A) and induced it with Her2, 
Her3, or Her2 and Her3 vectors. Control was induced with empty vehicle. Although 
Her2 alone showed an upward trend for the invasion assays, but it did not reach 
significance. The invasion assays only reached significance when Her2 and 3 co-
expressed (three fold more than control, p = <.002). Furthermore, gene expression 
profiling of Her2 and Her3 co-expression using an Affymetrix array platform identified 
80 genes that were up-regulated forming the Her2/Her3 unit gene signature. Of special 
mention here is the increased expression of IL-8, which was up-regulated the most (11 
fold). Gene ontology analysis using Ingenuity® software showed that Her2/Her3 gene 
signatures are enriched with pathways involved in cellular motility, invasion, migration, 
proliferation, apoptosis, and signaling. Interestingly, IL-8 was found to be involved in all 
of the aforementioned processes. To further confirm this finding whether IL-8 induces 
cellular invasion, they treated normal mammary cells (MCF-10A) with increasing 
concentrations (10ng/ml to 50ng/ml) of IL-8. Control was unexposed. Results revealed a 
positive linear relationship between increasing concentrations of IL-8 and induced 
invasiveness in the normal mammary cells. Twenty percent cells were found to be 
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invasive at 10ng/ml of exposure of IL-8, reaching 50% cells that were invasive with 
50ng/ml of IL-8 exposure compared to the control (p = <.05). However, these invasive 
structures were not greater in numbers than those found with the co-expression of Her2 
and 3 (90% invasive structures, p = <.05). Also, analysis of 1,881 primary breast cancers 
(public dataset) showed that the Her2 over expressed tumors always had increased IL-8 
expression. 
Her2 Over-expression and Vascular Endothelial Growth Factor (VEGF): 
VEGF plays an important role in disease progression by aiding in the infusion of 
blood vessels to other tissues (angiogenesis) in the metastatic process of breast cancer 
cells. In a clinical cohort (N = 603) of primary breast cancer patients, Konecny et al. 
(2004) evaluated the association between Her2 and VEGF expression, and the clinical 
outcomes with their expression levels. ELSA was performed using antibodies for VEGF 
isoforms and Her2, and the patients were divided according to their Her2 and VEGF 
status into: a) normal Her2 expression with no VEGF in low-risk group, b) Her2 over 
expressed with no VEGF; and c) normal Her2 expression with VEGF were both in the 
intermediate risk, and d) Her2 over expressed plus VEGF constituted high risk group. A 
significant association (p = <.001) was noted between Her2 over-expression and VEGF 
expression, with almost 80% (463/603) of the patients that over expressed Her2 also had 
detectable VEGF expression profiles. Survival analysis showed significant differences 
between the four groups, with increased mortality for those in the high risk group and the 
most favorable survival indices found in the low risk group (log rank test p = <.0092). 
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Thus, Her2 over expression is not only associated with VEGF expression, but in 
conjunction with VEGF results in high mortality rates. 
Ye & Lu (2010) also found similar results on their assessment of the expression of 
Her2 and VEGF on 117 post-operative breast cancer patients using IHC. Fifty patients 
with mammary gland hyperplasia were used as controls. Positive expression of Her2 and 
VEGF was noted in the sample compared to the controls (p = <.05). A positive 
correlation was found between Her2 and VEGF expressions (p = <.05, r = 373). 
Pathologically, both Her2 and VEGF correlated to lymph node metastasis (p = <.05), 
however, no correlation was found with age, histological type, grade, and stage (p = 
>.05). 
Schoppmann, Tamandl, Roberts, Jomrich, Schoppmann, Zwrtek, ... Birner (2010) 
further validated that Her2 over expression is associated with an increase in VEGF. 
Using IHC, they studied the expression of VEGF (factor C), lymphatic microvessel 
density, lymphovascular invasion and Her2 over expression on 150 randomly selected, 
node-positive breast cancer patients. Mann Whitney U test results showed that the cases 
that over expressed Her2 (3+ IHC score) also expressed significantly greater (p = .0006) 
amounts of VEGF compared to those patients that did not over express Her2. 
Additionally, the lymphatic microvessel density showed a significant (p=.012) correlation 
with VEGF expression. This data suggests that Her2 protein over expression influences 
tumor metastasis by increasing the production of VEGF factor C. 
The aforementioned studies (Aceto et al., 2012; Asrani et al., 2013; Johnson, 
Seachrist, DeLeon-Roderiguez, Lozada, Miedler, Abdul-Karim, & Keri, 2010; Konecny 
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et al., 2004; Lauren et al., 2013; Schoppmann et al., 2010; Ye & Lu, 2010) performed on 
the mechanistic insights of how Her2 mediated its carcinogenic potential have now 
elucidated how Her2 effectively used many effectors (downstream elements) and 
mediated diverse singular effects―metastasis via migration, invasion, proliferation, and 
angiogenesis. 
Accruing Her2 Amplification with Disease Progression 
Historically, clinical data has shown that Her2 gene amplification occurs in 
approximately a third (30%) of patients suffering from breast cancer (Slamon et al., 1989; 
Emede, Kostler, & Yarden, 2012). However, this diagnosis of Her2 over-expression has 
been done only on primary tumors, whereas the remainders of the patients who do not 
show Her2 gene amplification initially have not re-assessed for Her2 amplification 
during their later stages. However, as the disease progresses it there could be more 
patients with Her2 amplification. 
Indeed, this is the case as many studies have shown that Her2 over expression is a 
dynamic process, and it can be acquired over a period of time with disease progression. 
Meng et al. (2004) followed 24 breast cancer patients who were Her2 negative for it’s 
over expression. Their Her2 amplification status was assessed prospectively before, 
during, and after treatment, or when the patient became chemo- refractory (i.e., the 
chemotherapy stops working on the tumor cells and the disease progressed to the next 
stage) using FISH probes (Her2 and CEP17) on their circulating tumor cells (CTCs) in 
their blood. A total of 9 patients of the 24 (37.5%) did end-up with a Her2 over-
expression in their CTCs during disease progression. Another study by Hayes et al. 
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(2002), also using FISH techniques to quantify Her2 levels in the CTCs evaluated 19 
patients for their Her2 over expression levels with disease progression that were initially 
Her2 amplification negative. It was observed that in 7 of the 19 patients (i.e., 40% of the 
patients) a rapid rise in Her2 gene copies did precede disease progression. 
Genomic instability and acquisition of Her2 amplification with disease 
progression has been corroborated by Ismail,  Aly, Khaled, & Mohammed (2009) where 
they evaluated the correlation p53, a tumor suppressor gene (TSG), and Her2 and myc 
oncogene expression levels on breast tumor samples (n = 34) using FISH technology. 
Increase in copies or amplification of Her2 and myc oncogenes, and deletions in the 
copies of p53 gene (TSG positivity rates) were assessed by scoring signals for each with 
respect to the centromeric signals. All three of these genes showed a significant 
correlation with each other, more so with regards to Her2 over-expression (Her2 and myc 
r = .511, p = .002; Her2 and p53 r = .432, p = .01; myc and p53 r = .356, p = .03). 
Additionally, the frequency of the number of patients with Her2 oncogene amplification 
or increase in its copy numbers did increase with advancement of the disease. Using 
tumor size, disease stage, and lymph node status as parameters of disease advancement, it 
was observed that 70%, 40%, and 50% of the patients showed positivity for Her2, myc, 
and p53 genes respectively when the size of the tumor was small (<3 cm) which 
ballooned-up to 92% (Her2, p = .005), 87% (myc, p = .0006), and 71% (p53, p = .01) 
with a larger tumor size (>3 cm). Similarly, for disease stage, the Her2, myc, and p53 
expressions jumped from 75%, 56% (for both myc and p53) of the patients in early stages 
(I & II) to 95%, 89%, and 72% of the patients respectively for later stages of the disease 
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(III & IV). Noteworthy here is that only Her2 over expression levels increased 
significantly between the early and the late stages (p = .008). For lymph node status from 
negative to positive, once again statistically significant increase only in Her2 over-
expression were noted (node negative mean = 1.69 ±0.25, node positive mean=2.49 
±0.22, p = .038), although the number of patients with a p53 deletion did increase 
tremendously from 42% in the node negative to 77% for the node positive category, but it 
still not statistically significant (p = .05).  
Measuring Her2 Using FISH Technology 
This molecular technique is DNA based and detects targeted gene sequences. 
(Garimberti & Tosi, 2010). It is a DNA based technology which makes use of the fact 
that a DNA molecule consisting of two homologous strands, and can be denatured to 
single strands. The denatured DNA strand can only be re-natured with its homolog, thus 
remaking an exact replica of the initial double strand (Liehr, 2009, p.26-28; Garimberti & 
Tosi, 2010; Gasparini & Malazzi, 2006). A FISH probe is made of specific DNA 
sequences that renature to the gene in question. The target DNA is fixed on a glass-slide, 
and the probe DNA is tagged with a fluorescent reporter molecule. Then, both these 
single-strands are unified in a hybridization reaction and visualized under a fluorescent 
microscope (Liehr, 2009, p.26-28; Varga, Noske, Ramach, Padberg, & Moch 2013). 
Detection of the exact in-situ chromosomal location of a gene and its copy number 
changes can be delineated, quantified, and assessed (Liehr, 2009, p.26-28; Varga, Noske, 
Ramach, Padberg, & Moch, 2013). FISH can be studied in metaphase spreads or 
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interphase nuclei (Bishop, Garimberti & Tosi 2010; Gozetti & Le Beau, 2000; Pinhel et 
al., 2012). 
Press et al. (2002) compared the accuracy between FISH and IHC tests employed 
for testing Her2 levels. Gene amplification was first assessed using Southern blots 
(NCBI, 04) in 117 (n) breast cancer samples. FISH (Her2/CEP17 probe set, Vysis) and 
IHC (DAKO Hercep), sensitivity and specificity was evaluated compared to Southern 
blotting. Three or more signals marked amplification. Forty-two samples (36%) were 
amplified. FISH sensitivity was 95.4% (42/43 samples) and specificity 98.6% (72/73 
samples). One hundred and fourteen samples were correctly identified by FISH for 
accuracy of 97.4%. Concordance (κ) with Southern blotting was 0.945 (CI=0.88-1.0). 
With IHC, only 30 of the 43 samples were identified for over expression of the protein, 
making its sensitivity 69.8%, however, all of the cancers that showed low expression 
were accurately categorized with this test yielding a specificity of 100%, and accuracy of 
88.9%. Concordance (κ) values between IHC and Southern blots was only at 0.745 (95% 
CI=0.618-0.871). Other studies (Mass et al., 2005; Olsson, Jansson, Holmlund, & 
Gunnarson, 2013; Sauter et al., 2007) have also yielded very high predictive values 
(sensitivity: 95% to 97%, and specificity: 97% to100%) for the assessment of Her2 with 
FISH.  
FISH is the preferred technology over IHC is partly due to the fact that while IHC 
is subjective, FISH is quantitative (Bartlett et al., 2001; Jacobs, Gown, Yaziji, Barnes, & 
Schnitt, 1999; Thomson et al., 2001). A proficiency test conducted in 146 clinical 
laboratories, using Her2 amplified / over expressed and low Her2 amplification / low 
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expression showed that all laboratories using FISH were in 100% agreement; whereas 
those using IHC only 72% agreed (Pinkel et al., 1986). Due to these discrepancies 
between the two tests, American Society of Clinical Pathologists (ASCO) reviewed and 
changed its guidelines in 2011 for IHC scoring of Her2 from 2+ and 3+ staining to be 
observed in 30% of the cells instead of 10% cells that was done previously (2005-2010). 
These changes in IHC scoring criteria has lowered its false-positive rates considerably, 
and increased the positive concordance rates between IHC and FISH from 72% to 95% 
(1083/1118 cases retrospectively analyzed using IHC and FISH). However, the cases 
where discrepancy still exists between the IHC and FISH results, the confirmatory 
analysis is still done using FISH technology, and the FISH results for Her2 are 
considered definitive. Importantly, the guidelines for FISH analysis of Her2 have 
remained constant over the past 12 years, and so has its specificity, sensitivity, and 
accuracy (Varga, Noske, Ramach, Padberg, & Moch, 2013). Another advantage with 
FISH technology is that besides interphase nuclei, it can be performed on metaphase also 
which allows a researcher to pin-point the exact chromosomal location of the aberration 
(Bishop, 2010; Gozetti & Le Beau, 2000).  
The probe-set used for Her2 testing is FDA approved (Park, Park, Koo, Yang, 
Kim, & Park, 2010; Wulfkuhle, Berg, Wolff, Langer, Tran, Illi, … Petrcoin, 2013), and is 
currently being used for clinical diagnosis, prognosis, and management of breast cancer 
patients (Burris, Rugo, Vukelja, Vogel, Borson, Limentani, … O’Shaughnessy, 2011; 
Fleming, Sill, Darcy, McMeekin, Thigpen, Adler, … Fiorica, 2010; Ohlschlegel, Zahel, 
Kradolfer, Hell, & Jochum, 2011; Slamon et al., 2011). Specifically, in this kit the probe 
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sequences are tagged by fluorescently labeled probes which recognize both the genetic 
sequences for the Her2 gene and chromosome 17 centromeric regions. The Her2 gene 
and the centromeric regions are labeled with different colored fluorochromes for an easy 
scoring of disparate signals (e.g., orange and green respectively) (Olsson, Jansson, 
Holmlund, & Gunnarson, 2013). The Her2 amplification can be quantified using a 
fluorescent microscope by counting the Her2 gene copies, and the CEP17 is used as an 
internal control to check for aneusomy (i.e., increase of the entire chromosome) of 
chromosome 17 (Nitta et al., 2008; Gutierrez & Schiff, 2011). 
Estrogen and Its Receptor: An Overview 
Human estrogen (E2) is synthesized in 3 forms by the ovary: a) estrone (E1), 
produced during menopause, b) estradiol (E2) predominantly found in non-pregnant 
women, and c) estriol (E3) produced during pregnancy. E2 mediates its effect via its 
receptors, estrogen receptor alpha (ERα) and beta (ERβ). ERs are nuclear receptors 
(NRs), meaning that it is found in the nucleus of a cell (Tora, White, Brou, Tasset, 
Webster, Scheer, & Chambon, 1998). Biologically, the function of ERα has been 
extensively studied in the case of breast cancer (Jung, Park, Jun, Kong, Kim, Kim, ... Im,  
2010; Palmieri, Cheng, Saji, Zelda-Hedman, Srri, Weihua, ... Gustafsson, 2002). Both 
ERα and β are found in the normal mammary epithelium, but an increased level of ERα is 
noted in breast cancer. Almost 70% of breast cancers with ER-positive status expressed 
ERα (Renoir, Marsand, & Lazennec; 2013). Basically, E2 forms a complex with its 
receptor, known as a ligand-receptor complex. When ER is unbound to a ligand, it is 
found as a monomer bound to a protein called the heat-shock protein. Upon binding with 
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a ligand, hsp gets disrupted producing conformational changes of the receptor molecule, 
which induces receptor activation (Gutierrez & Schiff; 2011; Le Goff, Montano, Schodin, 
& Katzenellenbogen, 1994; Montemurro, Cosimo, & Arpino, 2013).  
Classically, when activated, they form a homodimer with other co-regulatory 
agents. Together, they bind to the estrogen response element (ERE) contained in the 
promoter region of specific genes, and have the capacity to modulate the transcriptional 
activity of those genes (Kumar & Chambon, 1988; Montemurro, Cosimo, & Arpino, 
2013). Besides the classical pathway of the ER functioning as transcriptional regulator, it 
is also proposed that E2 exerts its effect non-genomically (non-classical pathway) by 
interacting with growth factor receptors [e.g., epidermal growth factor (EGF), and insulin 
growth factor (IGF)], and cell signaling molecules (Kahlert et al., 2000). Furthermore, 
different ligands can change the conformation of the ER in differential ways 
(Montemurro, Cosimo, & Arpino, 2013; Osborne et al., 2003). Thus, ER transcriptional 
activity is controlled by specific ligand, co-regulatory molecules, their phosphorylation 
(i.e., activation), and promoter sequences present in distinct set of genes. 
A study by Grober, Mutarelli, Giurato, Ravo, Cicatiello, DeFillppo, …Weisz 
(2011) was conducted using ERα positive cell line (MCF7). The researchers found that 
this line co-expressed ERβ. Analysis of their transcriptomes with CHIP-Sequencing 
(CHIP-Seq) technology for the entire genome surprisingly showed that there are 9702 
ERβ sites vs. only 6402 ERα binding sites in the MCF7 line when it is stimulated with 
estrogen (E2). Further analysis of the binding sites by sequencing showed the presence of 
estrogen receptor elements (EREs) in ERα and ERβ. Additionally, ERα and β share 
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similar genomic targets, and in co-existence they compete for these genomic targets. 
However, the cellular response is opposite for ERβ vs. ERα. Cell proliferation assays for 
the MCF7 using miRNA line show that ERβ down regulates cell growth, unlike ERα 
which promotes cell growth. Thus, the ERβ receptors were able to modulate the effects of 
ERα receptors on gene transcription and cellular growth as was noted in the MCF7 cell 
line. 
Signaling Pathways: Cross-Talk between ER and Her2 
Phosphotidyl Inositol 3-Kinase/Akt Pathway (PI3-K/AKT Pathway) 
Cellular signaling for the activation and control of gene expression by estrogen 
was found to be complex as well as multifaceted to say the least. Two major pathways of 
ER signal transduction were: a) phosphotidylinositol 3-kinase [PI 3-K/Akt], and b) 
MAPK pathways. Estradiol was able to bind to ERα directly. The estradiol bound to ERα 
interacted with Her2 followed by the activation of the PI 3-K/Akt was indicative of the 
cross-communication that occurred between ERα and Her2. 
An extensive research by Stoica et al. (2003) examined the activation of various 
signaling molecules, and their pathways upon stimulation by exogenous estradiol in ERα 
positive (MCF-7), and ER-negative (MCF-7/ADR) breast cancer lines. They determined 
the requirement of ERα itself, by exposing MCF7/ADR cells to17β estradiol, and 
immunoblots probed them with anti-phospho-Akt. A nine-fold increase in Akt activity 
was noted in the ER-positive line. No Akt activity was observed in the ER-negative line, 
and transfection with ERα restored the Akt activity. Further, the MCF-7 cells treated with 




The researchers elucidated the mechanism and the kinase responsible for Akt 
activity, by treating MCF-7 cells with 17β estradiol that had been exposed to AG825 
which selectively blocks Her2, and AG30 an EGFR inhibitor. The cells treated with Her2 
inhibitor did not induce any Akt activity; however, this response was not inhibited by the 
EGFR inhibitor, suggesting that Her2 is a critical element for Akt pathway activation. As 
Akt also exists in three isoforms (1, 2, and 3), treatment with antibodies specific to each 
showed that ERα positive line (MCF-7) Akt 1 is expressed, and ER negative line (MDA-
MB-231) produced activity with Akt 3, this indicated that different isoforms of Akt can 
be selectively activated depending on the ER availability, thus involving two distinct 
mechanisms for protein and gene expression. It can also be inferred from this data that in 
cells where Her2 co-exist with ER (e.g., breast cells), exposure of the cells to estrogen 
itself or estrogen-like compounds (xenoestrogens) can activate their cellular growth and 
survival via these pathways. 
Mitogen Activated Protein Kinase Pathway (MAPK Pathway/ERK) 
 Jung et al. (2010) found that co-activators, such as Matrix metalloproteinase-1 
(MMP-1) expression increases when crosstalk occurs between the ER and Her2 receptors 
via the MAPK pathway. These co-activators act as molecules that relay the message from 
the ER to the Her2 receptors. 
ER is mainly found in the nucleus of an ER-positive cell. However, when 
stimulated with estrogen, the ER interacts with Her2 and initializes the MAPK pathway 
by inducing extra cellular signal regulated kinase 1 and 2 (ERK 1/2) activity (Lemmon & 
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Schlessinger, 2010). This further prompts re-localization of the ER from the cell’s 
nucleus into its cytoplasm, increases Her2 expression, aids in the progression of breast 
cancer, and makes the cancer resistant to therapy. Yang, Barnes, & Kumar (2004) had 
investigated the communications that occurred between Her2 and ER, the signaling 
cascade in breast cancer cells, and the indispensable role that Her2 plays in breast cancer 
pathogenesis. Breast cancer cells that did not express any Her2, as well as those that 
over-expressed Her2 were used to perform confocal microscopy using 
immunofluorescence after their exposure to 17β estradiol. It was observed that upon Her2 
amplification there was physical movement of the ER from the nucleus into the 
cytoplasm. Vice-versa effects occurred when Her2 expression was de-regulated with 
anti-Her2 antibody, which is that ER, moved back into the nucleus from the cell’s 
cytoplasm. Western blots plus confocal immunofluorescence with anti-ERK 1/2 showed 
that ERK 1/2 increased (8 fold) with the increase in Her2. This data shows that ER 
relocation from its primary position; the nucleus to the cellular cytoplasm is a 
downstream effect of increased Her2 expression, and Her2 interacts with the ER to 
produce this effect. Also, ERK 1/2 activity provides the fuel for the relocation of ER. 
Jung et al. (2010) found that co-activators, such as Matrix metalloproteinase-1 (MMP-1) 
expression increased when crosstalk occurred between the ER and Her2 receptors via the 
MAPK pathway. These co-activators acted as molecules that relayed messages from the 
ER to the Her2 receptors. 
PI-3K, MAPK, and Her2 Over Expression 
How the PI-3K and MAPK pathways interacted withHer2 over expression was 
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further detailed by Serra, Scaltriti, Prudkin, Eichhorn, Ibrahim, Chandarlapaty, … 
Baselga (2011). Using PI-3K inhibitors (BEZ235) on Her2 over expressing cell lines 
(BT474 and SKBR3) resulted in a dose-dependent inhibition of PI-3K catalytic activity 
(i.e., phosphorylation) within 24 hours (p = <.05). In addition, a simultaneous increase 
was noted of a downstream effector (P90RSK) of the MAPK/ERK pathway. When 
similar tests were performed using Her2-negative lines (MCF7 and MDA-MB-468), 
activation of ERK/MAPK was not pronounced. To confirm the involvement of Her2, 
both BT474 and SKBR3 (Her2+ lines) were treated with anti-Her2 agents; this prevented 
the phosphorylation of the ERK/MAPK pathway to occur.  
Unique Properties of Xenoestrogens: Insights from Animal Models, Lines and 
Assays 
Activate Protein Kinase Genes 
Valeron, Pestano, Luzardo, Zumbado, & Boada (2009) used RNA arrays and 
studied the expression of protein kinase genes after they exposed human mammary cell 
line with DDT analogs, alderin and dieldrin at 0.18, 90, and 180 nM concentrations for a 
period of 96 hours (4 days). Their arrays results showed a sharp increase in the 
expression of protein kinase genes; such as KIT, ALK-1, and ERRB3/Her3. Noteworthy, 
is the finding of an increase in ERRB3/Her3 kinase, but an inherent physical property of 
the ERRB3/Her3 receptor is that the receptor itself does not have a kinase site, so it 
dimerizes with Her2 for kinase activity in order to reach the cellular proliferative end 
point (Aceto et al., 2013; Fiszman & Jasnis, 2011; Ross et al., 2005; Tzahar et al., 1998). 
Thus, it may be that here also Her2 mediated the kinase activity for Her3 since Her2 is its 
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preferential dimerization partner, and Her3 cannot possibly activate the kinase on its own 
since it is physiologically incapable to do so on its own.  
Estrogen Receptor Agonist that Activates Cellular Signaling 
Xenoestrogens are estrogen receptor (ER) agonist. Exposure to small amounts of 
xenoestrogens leads to receptor (estrogen receptor) binding with the ligand 
(xenoestrogenic compound) forming a receptor-ligand complex. This receptor-ligand 
binding rapidly initiated activation of cell signaling molecules (ERKs). Bulaveya & 
Watson (2004) demonstrated the rapid changes that occur in cell signaling pathways 
specifically when xenoestrogens, such as DDE, bisphenol A (BPA), endosulfan, 
nonylphenol (NPH), coumestral, and dieldrin bind to estrogen receptors (ERs). Changes 
that had occurred during intracellular signaling were measured by performing ELISA for 
dose-dependent phosphorylation using prolactinoma lines. Time-periods used were 
between three to thirty minutes after exposure with concentrations from 10-8 to 10-10 M. 
Administration of an agonist at different concentrations in a dose-response experiment 
exhibited an uphill curve as one proceeds from the left to the right of the graph. Any 
activity of ≥120% compared to the control (ethanol) was considered statistically 
significant (p = <.05). Each xenoestrogen, except BPA produced rapid phosphorylation 
of the estrogen receptor kinases (ERKs) within 30 minutes after application reached 
statistically significant levels of response. Each xenoestrogen activated the ERKs in a 
unique fashion. Some (e.g., NPH and coumestral) produced dual activity peaks; whereas 
others (e.g., endosulfan) produced activity at all times with all concentrations tested, but 
none of these compounds was able to exactly copy the phosphorylation patterns of 
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estrogen (E2) itself. Nevertheless, they all initiated ERK activity in low dosage 
concentrations (i.e., nanomolar and picomolar amounts). 
Differential ERK activity patterns were observed. The time of activation for the 
various xenoestrogens were divided into two groups: a) fast-phase responders with one 
activity peak in the first half or 6-10 minutes (e.g., DDE), and b) slow-phase responders 
that produced a single delayed peak in 30 minutes (e.g., endosulfan and nonylphenol). 
However, E2 was different, as it produced a bimodal ERK phosphorylation response with 
distinct periods of phosphorylation and deactivation; whereas all xenoestrogens produced 
only a monophonic response. Importantly, the study found that although xenoestrogens 
activated the ERK, but they had different dose-dependent patterns. Two basic patterns 
had emerged: 
1) Some compounds were active in nano-molar as well as sub-pico molar 
concentrations (e.g., coumestral, E2, endosulfan, and nonylphenol), and  
2) Others were active only at nano-molar concentration (e.g., DDE and dieldrin). 
Since the ERK pathway is also activated by Her2overexpression (Fiszman & Jasnis, 
2011), it is biologically plausible that in the above experiments Her2 is also being over 
expressed with xenoestrogenic exposures. 
Cellular Proliferation & Nuclear Compartmentalization 
Xenoestrogens initiated cell growth. A study conducted by Mercado & Bigsby 
(2008) examined the role of PBDEs found widely in the environment, and act as 
endocrine disruptors. The study was conducted in vivo, and measured estrogenic activity 
with response to different dosage with various time intervals in two strains of mice. They 
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were either wild type (naturally occurring), or those in which the ERα gene had been 
removed (knockout) mice. All mice were injected with 75, 150, and 300 mg/Kg of DE-71 
for 3 and 34 (persistent exposure) days respectively, and then their reproductive tracts 
were weighed as estrogen bioassays. An in-vitro assessment of the effect of these 
treatments was also done using MCF-7 breast cancer cell line and conducting cell 
proliferation assays. Cell proliferation assays found a significant increase in cell counts. 
A three-fold increase of DE-71 treated cells was obtained at 10uM concentration 
compared to DMSO control (p = <.01). Albeit, the cellular growth observed in the E2 
treated cells was much higher (five-fold increase) with a much lower concentration 
(0.01nM). A noteworthy observation was that treatment with >2.5 x 10-5M concentration 
of DE-71 results in a sudden drop in the cell growth, indicative of its noxious effect to the 
cells beyond this strength. The estrogen assays revealed that only persistent treatment of 
34 days increased the uterine weight substantially with estradiol treatment (8-12 times 
compared to the control, p = <.001), and with DE-71 (23% more than control, p = <.05). 
The knocked out mice had not produced any effect, which suggested that ERα is the 
receptor that got actively recruited. 
Recchia et al. (2004) also examined the estrogenic nature of xenoestrogens, 
specifically BPA and 4-Nonylphenol (NPH). To assess this, the investigators created an 
estrogen response element (ERE) in MCF7 and T47D breast cancer cell-lines. An ERE is 
the promoter that initiated gene transcription when an estrogen agonist (ligand) binds to 
the ER (Klinge, 2000). Both lines were treated with 10 μM of BPA and NPH for 5 
consecutive days, and then cell proliferative and transcriptional assays were performed. 
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Both BPA and NPH transactivated ERα. Nuclear compartmentalization had occurred 
when BPA and NPH were added to MCF7 cells. Furthermore, proliferative activity 
induced by BPA and NPH was observed for both MCF7 and T47D cell-lines were 
assessed by cell-proliferative assays. It was noted that similar amounts (i.e., 
concentration) of xenoestrogens induced transcriptional and proliferative response in the 
lines. However, when compared to the natural estrogen hormone, the proliferative 
activity of both xenoestrogens was reduced. It is noteworthy here that cellular 
proliferation were also induced and promoted with the over expression of Her2 
(Ellsworth et al., 2008; Szasz et al., 2013). Hence, the overlapping cellular growth and 
proliferation further provided biological plausibility that the Her2 gene is also involved in 
the circuit of molecules when the xenoestrogens are applied to reach the specific cellular 
endpoints. 
Induction of Cellular Growth at Low Concentrations 
Cellular growth was characteristic of estrogenic effect. Xenoestrogens can induce 
cellular growth at very low concentrations. Maras et al. (2005) investigated the estrogenic 
properties of five perfluorinated compounds (xenoestrogens) by using a combination of 
in vitro assays. The capacity of these compounds to induce cellular growth in growth 
arrested MCF-7 breast cancer line was measured by E-screen assay, and the cell cycle 
analysis was done by flow cytometry. The E-screen is based on the ability of MCF-7 
growth arrested cells to initiate growth in the presence of estradiol, and this is compared 
to the compound under scrutiny (Soto et al., 1995). De-regulated cellular cycle can lead 
to tumorigenesis due to increased cellular growth or decreased cell-death. Normally, 
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apoptosis occurs after a cell goes into its resting phase (Elledge, 1995). When the resting 
MCF-7 cells were exposed to fluorotelomer alcohols as they re-entered the synthesis 
phase (S-phase) within a day. A 35% increase was noted with exposure to estrogen, and 
4-Nonylphenol (4-NP). There was a 31% and 29% increase in cells with 8:2 and 6:2 
fluorotelomer alcohols respectively. Additionally, low concentrations (e.g., 10 μM) of the 
fluorotelomer alcohols induced cellular growth.  
Changes Mammary Tissue Morphology 
Increased cellular activity due to chemical exposure increased cancer 
susceptibility. It has now been known for more than a decade that some xenoestrogens 
can change the morphology of the mammary tissue, and initiate the proliferation of its 
cells in animal models. Brown & Lamatinere (1995) investigated these properties by 
conducting a case-control study on Sprague-Dawley rats. The experimental group of rats 
was subjected to acute exposures of 50ug/gm body weight of DES, DDT, genestin, and 
25ug/gm body weight of TCDD, Arcolor 1221 and 1254. Controls were given sesame oil. 
Each group was assigned equal number (6) of rats, and exposed to the xenoestrogen for a 
week. Morphological changes were assessed on whole mount preparations of breast 
tissue. Cell proliferation was quantified using proliferating cell nuclear antigen (PCNA) 
an indicator of mitotic activity, and cell differentiation was analyzed using IHC. 
Genestin and DES did significantly increased mammary cell growth as well as its 
differentiation when compared to controls (cell growth observed: 149 ± 7 mm2 Genestin 
vs. 122 ± 10 mm2 control, p = <.05, and gland differentiation observed: 43 ± 8 lobules 
with genestin; 43 ± 6 lobules with DES; 10 ± 1 lobules in control,  p = <.01 and <.001 
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respectively). Although, not statistically significant, but, Arcolor 1221 and 1254 showed 
cellular proliferation. This could be due to insufficient dosage of these chemicals due to 
their weaker estrogenic properties. Interestingly, it was noted that TCDD inhibited the 
cellular proliferation of the mammary cells (81 ± 9 TCDD vs. 132 ± 6 mm2 control, p = 
<.01). This could have occurred because TCDD’s toxicity was killing the cells. 
Latent Effects in Mammary Tumor Development 
Exposure to xenoestrogen (e.g., BPA) during gestational age in minute amounts 
resulted in carcinogenesis of the breast tissue during adulthood. Murray, Maffini, Ucci, 
Sonnenschein, & Soto (2007) investigated the effects of prenatal exposure to BPA, and 
whether BPA exposure independently resulted in breast carcinogenesis during adult life. 
Sprague-Dawley rats were exposed to 2.5, 25, 250, or 1,000 micrograms (ug) of BPA per 
body weight per day from embryonic day 6 until day the first day after delivery via 
implanted pumps. Control rats were given a dose of 50% dimethyl sulfoxide. Female 
mice were specifically sacrificed on the 50th day or the 95th day after delivery, because 
mammary gland ductal growth and extension of the ducts into the fat pads is noticed on 
these days respectively. IHC on whole sections showed ductal hyperplasia in all of the 
animals. Three to four-fold increment was found in the formation of hyperplasic ducts in 
the experimental animals compared to the controls. The ductal size had also increased 
due to the active proliferation specifically of the luminal epithelial cells. H & E staining 
suggested differences in chromatin pattern, presence of nucleoli, and secondary lumina. 
A much larger study conducted by Jenkins et al. (2009) utilized rats and 
investigated whether oral BPA exposure as a neonate could cause breast cancer with a 
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single carcinogenic exposure in the adult life. They exposed 32, 34, and 24 female rats to 
sesame (control), 25 ug/Kg body wt/day (25), and 250 ug/Kg body wt/day (250) of BPA 
respectively. Totally, 15 treatments were given. Eight rats from each group were taken on 
21st and 50th days, and their mammary gland was excised to examine tumor progression 
in live tissue. On the 50th day, a rat from each litter was also exposed to a dose (30mg/Kg 
body weight) of DMBA, a known cancer causing agent, and sacrificed for tumorigenesis 
study. Mammary gland proteins were observed by immunoblots. Cell-death and growth 
was assessed by IHC on terminal end buds (TEDs), and confirmed by Ki-67 analysis. 
Tumorigenesis was measured in two ways: a) tumor latency, and b) tumor burden. 
An increase in the tumor formation was noted with increasing doses of BPA (2.84, 3.82, 
and 5 respectively). Rats given doses of BPA 250 had a tumor burden that was 
statistically significant compared to control (p = .004). Additionally, tumor growth was 
observed in 65, 53, and 36.5 days for BPA 25, BPA 250, and controls respectively (p = 
.025) showcasing an inverse relationship that existed between tumor latency and BPA 
dosage. Noteworthy here is that although BPA 25 did show an increased tumor burden 
and decreased latency when compared to controls, it did not reach statistical significance 
for either (p = .131 and .058 respectively). However, this does not mean that the tumors 
were not forming at all or that they were forming earlier in rats that were not subjected to 
this xenoestrogen at all. Hence, it is plausible that if these exposures were carried out for 
a longer period of time (persistent exposures) the tumor burden and latency may have 
reached levels of significance.  
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Further, mammary terminal end buds (TEBs) were significantly more in the 50 
day old rats when compared to the control (22% increase in cellular proliferation of 
TEBs, p = <.001), and a decrease in apoptosis was observed for the 50 day old rats 
compared to control (40% less apoptosis, p = .001). Apoptotic and proliferation proteins, 
Akt and phosphorylated Akt (pAkt) for 50 day old rats showed significantly higher 
expression levels (2- fold, p = .001; and ~ 2 fold, p = .050 increase in expression 
respectively) compared to control. Analysis of Progesterone receptor A and B (PR-A and 
PR-B), their co-activators (steroid receptor co-activator; SRC-1, 2, and 3), and Her 
family of tyrosine kinases using Western blots showed a 54% increment in PR-A protein 
expression in TEBs of 50 day old rats compared to controls. SRC-1, 2, and 3 were all 
found to be significantly over-expressed compared to control (3.5 fold, p = .001; 1.5 fold, 
p = .003; and 3.5 fold, p = <.001 increased expression respectively). Although there was 
an increase in Her2-neu, PR-B (a third more for both), and Her3 (~2 fold increase), but 
only Her3 reached significance (p=0.01). Once again, it is possible that Her2 over 
expression could reach levels of significance once the exposures are persistent. 
Interestingly, since the Her3 receptor itself does not have a kinase terminal required for 
phosphorylation to induce cellular changes, and to bring about these cellular responses 
Her3 partners with Her2 (Akiyama et al., 1986). Thus, the increase in Her3 and Her2 
should be similar, but strangely enough only Her3 reached levels of significance and not 
Her2. Further, the down regulation (a third) of ERα was observed which also occurs 
when Her2 amplification reaches its autocrine potential.  
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Although this study was done in a rat model, it was the first to prove how early 
exposures to a xenoestrogen like BPA by lactation can have harmful effects during 
adulthood for the offspring with only a single dose of carcinogenic exposure. This study 
elucidates the manner in which BPA acts for breast tissue carcinogenesis. Further, the 
increased cellular proliferation and decreased cellular death plays a crucial role in 
tumorigenesis. Importantly, studies done in humans on breast cancer patients also showed 
that an increased expression of the steroid receptor co-activator-3 (SRC-3/A1B1) is 
linked to an increased expression of the Her2 oncogene. Thus, it is likely that this study 
maybe carried over to the human model. 
In a recent study, Johnson et al. (2012) had directly linked Her2 gene expression 
with exposures to two metabolites of DDT (o’p’ DDE and p’p’ DDE) in a mouse model 
with the Her2-Neu proto-oncogene. Of these two metabolites, one (o’p’ DDE) is an 
estrogenic isomer; whereas the other (p’p’ DDE) is antiandrogenic. They locally injected 
5 μg pellets of the DDT derivatives, individually and in combination for two months into 
the mammary fat pads (total: 4) of prepubertal mice. These exposures were at 
concentrations that have been found in the human mammary tissue. It was observed that 
the control mice also developed mammary tumors, suggesting that the breast cancer 
incidence was similar in all groups, but the p’p’ DDE antiandrogenic isomer significantly 
increased the breast cancer progression rate (shorter latency period) compared to the 
control mice (90 vs. 147 days respectively, p = <.02). Although the rate of tumor 
progression was greater with o’p’ DDE as compared to the control, but it not found to be 
significantly higher (126 days vs. 147 days respectively, p = >.05). These results 
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indicated that p’p’ DDE accelerated breast cancer progression via hormonal and other 
actions, and the DDT isomers aided in breast cancer progression not initiation. 
Interestingly, the combinatorial exposures of both isomers had no affect on latency when 
compared to the control, suggesting that the actions of these two isomers are not 
synergistic.  
Differential Estrogenic Strength of Different Xenoestrogens  
Different xenoestrogens exhibited a diverse range of estrogenic activity. Some 
were mildly estrogenic whereas others were far more effective at a similar dosage of 
exposure. Due to this attribute, it is deemed important that each xenoestrogen be assessed 
individually. Silva, Scholze, & Kortenkamp (2007) studied the low dose (nanomolar 
dosage) responses in 24 known xenoestrogens using the E-screen assay. They found that 
estriol (E2) produced the highest level of proliferative response with the lowest dose (4.0 
X 10-4 nM). Coumestral, a phytoestrogen was a hundred times less effective compared to 
estriol, and produced an effect at 0.55 nM. Surprisingly, in the case of β-endosulphan, it 
was noted that the concentration at which it produced a 1% effect was lower (140 nM) 
than its concentration required for no effect (150 nM). More so, many of the steroidal 
estrogens (e.g., estrone, estriol, hexestrol, and dienestrol) produced shallow dose-
response curves, whereas many of the synthetic xenoestrogens did not. 
Additive Effects in Combination 
Xenoestrogens produced an additive effect when they were present in a 
combination as mixtures of different estrogenic compounds. However, this effect 
occurred only when each of the individual compounds formulating that mixture had equal 
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strength. Payne, Rajapakse, Wilkins, & Kortenkamp (2000) investigated whether additive 
effects of different estrogenic compounds could be calculated by individual dose-
response effects of each compound found in the mixture using YES assay. 
Dose-response assays were performed using equal strength of various 
xenoestrogens (e.g., o, p’DDT, genestin, 4-Nonylphenol (4-NPH), and n-4-octylphenol), 
individually and in combinations, using E2 as a positive control. Best-fit model predicted 
by absorbance readings for an individual chemical showed that 4-NPH produced a 
maximum response, similar to E2 (control). Individually, the chemicals showed a wide-
array of effects. Even when the estrogenic compound showed the lowest maximal effect 
individually, it produced a large additive effect when it was combined with other 
estrogenic compound/s. A major drawback noted was that the best fit of the model and 
the readings on combined effects were quite similar only for binary mixtures, but with 
three compound mixtures the effects were a little under estimated; whereas it was vice-
versa for four compound mixtures. Nonetheless, additive effects were observed in all the 
mixtures. This data could prove to be extremely important, especially in the case of 
estrogenic compounds that barely produced any detectable effects individually, albeit 
they could produce significant effects when applied in combination. 
Following suite to this study, Rajapakse, Ong, & Kortenkamp (2001) used the 
YES bioassay and tested whether BPA and o, p’DDT produced an additive impact when 
each of these xenoestrogen is combined with the naturally occurring hormone 17 β-
estradiol (E2). The researchers hypothesized that even weakly estrogenic compounds; 
such as BPA and DDT can affect the functioning of the steroid hormone based on their 
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concentration and strength in relation to the hormone. Hence, the impact would be 
dependent upon the potency of the xenoestrogen in comparison to the natural hormone. 
Mathematical models of concentration addition (CA) and independent action (IA) for 
fixed ratios of mixtures were used that predicted the dose-response relationship, and 
synergy between the two compounds was assumed. Then, predictions made were tested 
experimentally. The IA model defined the maximal effect of a xenoestrogen; whereas the 
CA model estimated concentrations of 2 xenoestrogens combined to yield a 
predetermined additive effect using regression analysis. According to the IA data, all 3 
compounds activated human ERα in a dosimetric fashion, reaching maximal effects at 
1.59, 1.65, and 0.45 for E2, BPA, and o, p’DDT respectively. This followed well with the 
experimental data. The maximal effects of BPA and E2 matched well at 1.65 and 1.59, 
the maximal effect obtained for o, p’DDT was low comparatively to the hormone at 0.45 
and 1.59.  
The predicted CA data for 2-compounds mix, regression yielded a shift in the 
dose-response graphs to lower concentrations that becoming more and more pronounced 
when the amount of E2 were consistently increased in the mix for both E2 and BPA as 
well as E2 and o, p’DDT, until the hormone completely over-shadowed the effects in 
each mixture. Then, changing gears by increasing the relative strength of each weak 
estrogen in the 2-compound mix showed that their effects at low concentrations (1:5000 
molar ratios of E2 vs. BPA or o, p’DDT) were almost negligible, but, when each of the 
weak estrogenic compound was consistently increased while E2 was kept at a constant 
concentration (1:20000 molar ratios of E2 vs. BPA and o, p’DDT). The prediction curves 
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started to shift in favor of the weak estrogenic compound. The CA models were similar 
for E2 and BPA, but only over-lapped in low level effects for E2 and o, p’DDT. Upon 
testing this model experimentally, the E2: BPA mix corresponded completely with the 
predictions made by the CA mathematical model. The response of the mix far exceeded 
the 95% CI of the E2 regression line. In the case of E2: DDT mix the experimental 
effects observed were well-matched with the predicted models only in the low effect 
range (up to 0.45 absorbance levels), but neither model was accurately depicted for the 
high effect range. The researchers owed this to the low solubility of o, p’DDT which 
hindered its absorbance by the yeast cells. To further test this possibility, they added 2% 
DMSO in the E2: DDT mixture; as DMSO had previously shown to increase 
permeability of the yeast cell-wall, thereby increasing the solubility of o, p’DDT within 
the yeast system. With this mix there was a 40% increase observed in the maximal effect 
of o,p’DDT, and now the CA model prediction and the experimental were in sync until 
1:50000 ratio of E2: o,p’DDT, or 1.2 absorbance levels after which the responses started 
to plateau off. 
In all, these studies provided support that weak estrogenic compounds were able 
to add to the already strong effects of the endogenous sex steroid action. As this study 
provided external validity to the study that was conducted by Payne, Rajapakse, Wilkins, 
& Kortenkamp (2000), proposed that action of weak estrogens or xenoestrogens found in 
combination were additive in nature. The health implications of these additive effects of 
xenoestrogens should be seriously considered. 
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Resistance to Chemotherapy 
Chemotherapeutic resistance can play a crucial role in breast cancer therapy, and 
thereby its survival. BPA has the property of being a chemo-resistant for breast cancer 
therapeutic agents even when it occurred in low (nanomolar) concentrations. LaPensee 
Tuttle, Fox, & Ben-Jonathon (2009) investigated this property of BPA with various 
chemotherapeutic agents (e.g., cisplatin, vinplatin, and doxorubicin) used for breast 
cancer by conducting cytotoxicity assays on ERα positive cell line T47D (estrogen 
responsive), and ERα negative line MDA-MB-468 (estrogen non-responsive). MTT 
cytotoxicity assay showed that the viability of ERα positive and ER negative cancer cells 
increased in a dose-dependent manner. Even at low dosage BPA (range: 1nM to 10nM) 
significantly (P=<0.05) protected both of the lines from the cytotoxicity mediated by 
doxorubin. Additionally, when the lines were subjected to BPA in the presence of ICI and 
PHTPP, blocking ERα and β receptors respectively, BPA still inhibited the action of the 
chemotherapeutic agents, exhibiting that this action occurs via other pathways besides 
just the classical ERα and β. Protein analysis by Western blots indicated an increased 
expression of anti-cell death proteins such as BcL-2, Bc1-xL, and Survivin upon BPA 
exposure indicative of an anti-apoptotic action. 
Modulate VEGF 
Experiments revealed that some xenoestrogens increased the production of 
VEGF, more so in the presence of high levels of ERα, thus increasing the angiogenic 
capabilities of the breast cells. Buteau-Lozano, Velasco, Cristofari, Balaguer, & Perrot-
Applanat (2008) assessed whether xenoestrogens incorporated ERs in their ability to 
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regulate the secretion of this factor by performing dose-response experiments. The 
researchers exposed two breast cancer lines (i.e., MELN which over-express ERα and 
MELP with low levels of ERα) to various xenoestrogens (e.g., E2, BPA, DEHP, BBP, 
genestin, OP, and various phthalates) for 24 hours, and then quantified VEGF using 
immunoassay. Ethanol was used as the control. 
For the MELN cells with high ERα expression, the VEGF expression patterns 
showed that E2 is the most sensitive, inducing VEGF production (two and a half time 
more,  p = <.05) in extremely low amounts (10-10 M concentration). A similar induction 
was observed in the case of genestin, but with increased concentration (10-7 M, p = <.05). 
A significant increase (twice that of control, p = <.05) in VEGF secretion was also noted 
with dieldrin, BBP, OP, DEHP, and BPA although they did so at even higher 
concentrations ranging from 10-4 to 10-6 M. Contrastingly, some pesticides (e.g., 
vinclozin, atrazine, HCH), and phthalates (e.g., DIDP, DINP) did not produce any effect 
even with increased concentration. Whereas, for the MELP cells with low ERα 
expression, there was only a significant increase (twice that of control, p = <.05) with E2. 
All other xenoestrogens, the amount of VEGF secreted did increase, but to a lesser 
amount (one and a half times). Interestingly, Her2 amplification also increases VEGF 
production, and once again it is possible that Her2 is involved in these processes 
alongwith ER because it cross-communicates with it during tumorigenesis of the breast 
tissue. 
To ascertain whether VEGF increase had occurred in the presence of ER, the 
different xenoestrogens were treated in the presence of ICI; which blocks ER. Results 
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showed a 50% to 70% reduction in VEGF secretion (p = .05) between the various 
xenoestrogens, suggesting that ERα is needed for its secretion. It was further determined 
if this activity was mediated by ER regulated kinases, the MELN cells were treated with 
various kinase inhibitors (e.g., SB2035580 inhibits MAPK, and Wortmannin inhibits PI3-
K/Akt pathway). It was observed that different xenoestrogens used different kinases for 
modulating VEGF secretion in breast cancer. For example, for BBP, OP, and dieldrin, the 
VEGF secretion was reduced by the MAPK inhibitor and the PI-3/Akt inhibitor; whereas 
only MAPK inhibitor reduced VEGF in the case of genestin suggesting similar and 
different pathways are involved for different xenoestrogens. Interestingly, VEGF also 
modulated with the increase in Her2 expression/copy numbers (Konecny et al., 2004; Ye 
& Lu, 2010), and once again the cellular endpoints reached with the applications of 
xenoestrogens overlapped with those observed when Her2 is over expressed, thus, 
making it biologically plausible that this oncogene was being activated in this process. 
Mediate Cellular Proliferation by Other Pathways (Androgenic Pathway) 
Xenoestrogens, such as DDE utilized various cellular pathways and augmented 
breast cancer progression. Principally, it has been known that xenoestrogens used the 
estrogenic signaling pathway to produce cellular proliferation. Another direction explored 
by Aube, Larochelle, & Ayotte (2008) studied the effects of DDE on cellular growth by 
opposing the androgenic pathway using CAMA-1 cell-lines that expressed both ERα as 
well as androgen receptors (AR), and MCF-AR line that was genetically manipulated to 
express AR. Cell proliferation assays captured cellular growth. The cells were grown in 
DDE alone, or with E2 and Dihydrotestoterone (DHT). Steroid dependant gene 
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expression; such as ESR1, CCND1 (Cyclin D1), and AR was studied using RT-PCR or 
immunoblotting. Notably, an inverse concentration response relationship between 
increasing DHT (androgen) concentration and cell growth (coefficient β=0.887, p=< 
0.001) was observed. When combined with E2, DHT decreased the proliferation response 
at 27% (p = <.05), 54% (p = <.001), and 60% (p = <.001) with 100, 500, and 1,000 
picomolar concentrations of AR respectively. Additionally, DDE alone had the capacity 
to induce cellular growth response (3 to 3.5 times at 5 and 10uM respectively, p = <.001). 
Gene expression levels for E2 treated cells had up-regulated CCND1 mRNA (50% 
increase, p = <.01), but adding DHT (androgen) in nanomolar quantity (1nM) 
significantly decreased this expression (p = <.01). The CCND1 gene regulates the 
passage of cells from G1 (resting phase) to S (synthesis phase) in breast cell growth. E2 
plus DHT markedly decreased ERα (>50% decrease, p = <.05), and CCND1 (~60% 
decrease, p = <.01) expression levels compared to adding E2 alone whereas AR 
expression was significantly heightened (~50% increase, p = <.01). Adding E2 alone 
decreased (28%) AR expression significantly (p = <.05). Results of this study bear 
evidence that DDE can significantly increase cellular growth of breast cancer line by 
modulating not only its estrogenic response, but also its anti-androgenic responses. Thus, 
more than a single pathway could be used by various xenoestrogens to induce cell 
growth. 
A confirmatory study to this end was performed by Aube, Larochelle, & Ayotte 
(2011), where they studied the androgenic and estrogenic effects of organochlorine (OC) 
mixtures in human breast cancer lines using reporter gene assays. For the estrogenic 
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assay, MCF7 line was exposed to various concentrations (0.05-5 µM) of OC mixture for 
24 hours in the presence of 1 nM estrogen (E2), and for the androgenic assay, the 
CAMA-1 line was exposed to various concentrations (0.01-10 µM) of OC mixture for 24 
hours in the presence of testosterone (DHT). Receptor expression assays showed that 
both of these lines had equal amounts of the estrogen receptors (ERs), but CAMA-1 line 
had greater amount of the androgenic receptors (ARs) when compared to the MCF7 line. 
The results of the gene reporter assays showed that the OC mixtures induced the 
estrogenic pathway in the MCF7 line that had a lower expression of the androgenic 
receptors, whereas the OCs inhibited the androgenic pathway in the CAMA-1 line which 
had a higher expression of androgenic receptors compared to the MCF7 line. 
Increase Intracellular ERα 
La Rosa, Pellegrini, Totta, Acconcia, and Marino (2014) studied the effects of 
BPA, a synthetic xenoestrogen vs. Naringinin (Nar), a plant derived xenoestrogen on 
intracellular ERα levels when stimulated by estrogen (E2). Using MCF7 line, they 
performed dosimetric analysis on the ERα protein (mRNA) expression after stimulating 
the cells either with E2, BPA, and Nar for 48 hours. The mRNA expression on ERα was 
then assessed by Western blots. The results showed that while Nar prevented intracellular 
ERα from degradation, BPA promoted ERα degradation. Additionally, cell proliferation 
assays performed on both xenoestrogens, it was observed that BPA increases cell growth 
with highest proliferative index observed at 10-5 M concentration (p=<.001), whereas Nar 
decreases cell growth which is dose-dependent with significant decreases (p=<.001) 
occurring between 10-7 to 10-4 M concentrations compared to the control. Comparing the 
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proliferation rates with E2, it was noted that E2 also increased cellular growth, and BPA 
reached similar growth curves as E2 at 10-5 M concentration. Together, these experiments 
elucidated how synthetic xenoestrogens and plant derived xenoestrogens had activated 
and modulated ERα levels in opposing ways. 
Xenoestrogens and Breast Cancer Risk: Population-based Studies 
Population-based studies using Xenoestrogens have been conducted mainly on 
organochlorines and their derivatives or pharmaceutical estrogens. The data is confusing 
since most of these studies; especially with organochlorines have yielded negative results, 
but a handful of these studies were showing positive results also and cannot be ignored. 
In the following section, first, the studies performed using organochlorines and their 
derivatives will be described and assessed for their strengths and limitations, followed by 
the same for studies conducted using pharmaceutical estrogens.  
Organochlorines 
Demers, Ayotte, Brisson, Dodin, Robert, & Dowally (2000) assessed the risk of 
breast cancer initiation as well as cancer progression in relation to various 
organochlorines using case-control study design. Plasma concentrations of 11 chlorinated 
and 14 polychlorinated biphenyl congeners was measured in 315 newly diagnosed cases, 
and 526 controls matched on age and residence. Of the controls, 219 were gynecological 
disease-free hospital-based, and 307 were randomly chosen. Cases were stratified mainly 
by tumor-size and metastasis. Organochlorines levels were divided into tertiles, based 
upon their distribution found in the controls. Mean concentrations of the organochlorines 
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between the cases and the controls were similar, showing no increase in risk of disease 
initiation.  
Statistical analysis was performed on cases classified by disease status to address 
if potential risk of disease progression is present. After confounding (age, parity, body 
mass index, residence, and breast feeding) adjustments, results indicate that the odds of 
having a more aggressive tumor was significant in women with increased exposure of the 
following: a) β-HCB (OR = 2.25, 95% CI = 1.12-4.51), b) trans-nonachlor (OR = 2.27, 
95% CI = 1.11-4.65) showed an increased tumor size (≥2 cm) comparing the highest (4th) 
to the lowest (1st) exposures; whereas c) p-p’DDE (OR = 2.9, 95% CI = 1.43-5.91), d) 
oxychlordane (OR = 2.34, 95% CI = 1.10-4.97), and e) PCB congener 153 (OR=2.12, 
95% CI=1.05-4.30) showed increased metastasis comparing 1st and 3rd exposure tertiles. 
Relationship between cancer aggressiveness and p-p’DDE was further dissected for 
dosimetric effects. Both, tumor progression characteristics increased in a dose-dependent 
fashion. The OR for 2nd compared to 1st tertile was 2.23 (95% CI = 0.94-5.77), and 
comparing the 3rd to the 1st generated an OR of 3.51 (95% CI = 1.41-8.73). Similarly, β-
HCB (OR = 3.91, 95% CI = 1.47-10.35), and oxychlordane (OR = 3.22, 95% CI = 1.18-
8.80) also showed an increased risk for higher levels of exposure. 
A prospective case-control study by Hoyer, Jorgensen, Grandjean, & Hartvig 
(2000) suggested that repeat measurements of xenoestrogens like organochlorines 
provided for a more accurate method of breast cancer risk assessment compared to a 
single measure, and that multiple exposures to xenoestrogens can change the risk of 
breast cancer over time. Totally, 155 cases and 274 matched controls from Denmark 
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participated. Sera collected over a 5 year period was subjected to gas chromatography for 
isomers of DDT, total DDT, and PCBs. Trend analyses with two measurements yielded a 
significant dose-response relationship only with p, p’DDT and PCB138. More than a 
three-fold increase in breast cancer risk was noted only for p,-p’DDT (OR (1st exam) = 
1.9, 95% CI = 0.9-4.3; OR (2nd exam) = 3.6, 95% CI = 1.1-12.2, Ptrend = 0.02), and for 
PCB congener 138 the risk for breast cancer increased by 2.5 times (OR (1st exam) = 1.4, 
95% CI = 0.8-2.6; OR (2nd exam) = 2.1, 95% CI = 1.0-4.4, Ptrend = 0.04). No 
associations were observed with any other isomer. A significant dose-response 
relationship was noted only with p, p’DDT and PCB138.  
Another study by Hoyer, Jorgensen, Rank, & Grandjean (2001) has shown that 
exposure to xenoestrogens does not necessarily lead to ER positive breast cancer. To 
evaluate the influence of organochlorines on breast cancer risk according the hormone 
receptor status, a case only study (n=161) was done. Tumor characteristics were obtained 
from the hospital. Paraffin-embedded sections showed 7:3 ratios of ER positive and 
negative tumors. Interestingly, even though a vast majority of the tumors were ER 
positive, but, a higher tumor stage (RR = 5.4, 95% CI = 1.8-15.9), size (RR = 4.6, 95% 
CI = 1.7-12.3), and metastasis (RR = 6.0, 95% CI = 2.1-16.9) were found to be 
significantly associated with ER negative tumors. For ER negative women, a 7-fold 
increased risk of developing breast cancer was noted for the highest levels of dieldrin 
exposure when compared to those with the lowest level (OR 1st vs. 4th quartile = 7.6, 95% 
CI = 1.4-46.1, Ptrend = 0.01), and the risk was two and a half times more with PCBs (OR 
1st vs. 4th quartile = 2.6, 95% CI = 1.1-5.7, Ptrend = 0.02). This study indicated that 
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exposures to certain organochlorines increased the risk of developing ER negative 
cancers which represent a poor prognosis for the patients, because these tumors are larger 
and have a high metastatic grade. A limitation of this study was that the numbers of ER 
negative patients (n = 45) was small leading to insufficient power, and should be 
interpreted with caution. 
Warner et al. (2002) used a historical cohort from the 1976 industrial accident in 
Seveso, Italy and studied the association between TCDD and breast cancer risk. Archival 
samples from 981 women between 11 to 40 years were studied. Cases were ascertained 
by in-person interviews and medical records. Biopsies were reviewed by a pathologist, 
and TCDD levels assessed by gas chromatography. A double-blinded study was 
conducted which added to the validity due to lack of bias. Hazard modeling was done on: 
a) categorical variables; where the categories of exposure were <20 parts per trillion 
(ppt), 20.1 to 44 ppt, 44.1 to 100 ppt, and >100 ppt, and b) continuous variables as log10 
TCDD. Fifteen of the 981 women (15/981) developed breast cancer. Three (3/981) died 
due to it, and were not included. The average age at the time of explosion and diagnosis 
was 30 years (range: 14 to 39 years), and 45 years (range: 31 to 57 years) respectively. 
Therefore, it took almost 15 years for the disease to have occurred, thus marking its latent 
period. Median TCDD levels observed in the cases vs. controls were much higher (71.8 
ppt vs. 55.1 ppt respectively). The continuous variable projected doubling of hazard rates 
for every 10 fold increment in exposure (e.g., from 10 ppt of exposure to 100 ppt of 
exposure) in TCDD exposure levels (HR = 2.1, 95% CI = 1.0 to 4.6, p = 0.05).  
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Again, a limiting factor of this study was the small number of cases present. 
However, an important point raised by the researchers was that the expected age-specific 
incidence rates for breast cancer for Seveso between 1988 through 1992 should be 11 
cases, but they report 15, making the standardized incidence rates (SIR) higher than 
expected (1.36). Furthermore, if the three women who died were included, the SIR would 
be even greater than 1.36. Although, this study showed that acute xenoestrogen exposures 
like TCDD were significantly associated with breast cancer incidence, but it cannot 
provide for everyday low to moderate levels of exposures that most women are subjected 
to. 
Aschengrau, Rogers, & Ozonoff (2002) investigated the association between 
perchloroethylene (PCE) found leaching from the drinking water-pipes into the water 
system, and the risk of developing breast cancer. They hypothesized that PCE acts as a 
genotoxic agent either directly or indirectly via metabolites, hence increased the risk of 
breast cancer. Cases comprised of 672 women diagnosed with breast cancer, and 616 
controls matched for location and age. Exposure was an estimated amount of PCE 
entering residences by water-pipes. Measurements were based on a PCE leaching model; 
which relies on the rate of water flow estimated by pipe attributes and the amount of 
water that it can distribute called pipe-load. Geographic information systems (GIS) 
mapped the participants thus aiding locating participants with different pipe-line 
characteristics (e.g., diameter, composition, year installed). Only a small to moderate risk 
was observed for women that were exposed between 75th percentile, and 90th percentile 
exposure levels (OR (adjusted) = 1.3 to 2.8, and 1.5 to 1.9 respectively).  
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In 2002, Gammon et al. conducted a case-control study to evaluate the risk of 
breast cancer associated with various organochlorines with disparate estrogenic 
properties (e.g., p, p’DDT, p, p’DDE, dieldrin, PCBs). Cases (n = 415) were newly 
diagnosed with breast cancer, and controls (n = 406) were matched for age and residency. 
Like the previous study, this study also found only a small increment in risk between the 
highest vs. the lowest exposure groups for DDE (OR = 1.20, 95% CI = 0.76 to 1.90), and 
dieldrin (OR = 1.37, 95% CI = 0.69 to 2.72). Effect modifications could not be 
ascertained as the sample size became too small to investigate their effects. 
Charlier et al. (2003) evaluated the risk of breast cancer with organochlorine 
exposure by measuring blood levels of DDT and hexachlorobenzene (HCB). All 
participants were White women. Cases (n = 159), and controls (n = 250) matched for 
smoking, age, residence, breast-feeding, menopause, and reproduction history. Mean 
DDT and HCB concentrations obtained by gas chromatography were significantly more 
in cases compared to controls (3.94 vs. 1.83 parts per billion(ppb) for DDT, p = <.0001; 
and 0.79 vs. 0.09 ppb for HCB, p = .0005 for cases and controls respectively). Notably, 
the blood concentrations of DDT and HCB were independent of the smoking status (50% 
vs. 44% respectively, p = .54), or residence (56% vs. 52% respectively, p = .66). 
Surprisingly, the ER status did not co-relate with DDT (r = 0.02, p = 0.08) or HCB 
concentrations (r = 0.09, p = .49). However, since all their data comes from White 
women only, the generalizability of the research conducted was limited, especially since 
another study (Rosenberg et al., 2008) indicated that interethnic variations can play an 
important role in breast cancer.  
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Another factor that played a role towards an increased susceptibility to breast 
cancer with xenoestrogenic exposure is age at which the exposure occurred. Cohn, Wolff, 
Cirillo, & Scholtz (2007) used a prospective case-control design and examined if p, 
p’DDT exposure in early adolescence (<14 years of age) increased breast cancer risk later 
during adult life. A 1:1 ratio of cases and controls (n = 258), were matched for age and 
residence. Commercial grade DDT with p, p’DDT (active ingredient), o, p’DDT 
(contaminant), and p, p’DDE (metabolite) were analyzed. A five-fold increased risk of 
breast cancer was found only for women that were less than 14 years of age during 
exposure (OR = 5.2, CI = 1.7 to 17.1, p = <.001). Further, only p, p’DDT showed an 
increased risk for breast cancer (OR = 2.9, CI = 1.1 to 8.0, p = .04). Once again, the 
possible mechanism indicated for p, p’DDT being associated with the increased risk is 
genotoxicity. 
Xenoestrogens affected the biological nature of the fat tissue found in the nearby 
stroma to where the breast tumor occurs. This could bear important implications in the 
progression of breast cancer. Using a case only design, Munoz-de-Toro et al. (2006) 
examined the burden of organochlorines from various pesticides and PCBs in invasive 
breast carcinomas (n = 55). Gas chromatography measured organochlorine content, and 
IHC assessed biomarkers of breast cancer within the breast tumors plus the stroma 
surrounding it. Results showed that all the patients had increased levels of organochlorine 
residues with the highest values of DDE and β-HCH at 4,794 parts per billion (ppb), and 
1,780 ppb respectively. Post-menopausal women had higher levels (≥2,600 ppb) of 
organochlorine concentrations in the surrounding stroma; and vice-versa for the pre-
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menopausal women (<2600 ppb). A positive association between dietary fat intake and 
tumor growth (Fischer’s exact, p = .025) was also revealed. As this study was performed 
in vivo, it brings about a real-time facet of the diverse effects that organochlorines can 
have on different cells that compose the breast tissue. 
In a recent case-control study conducted by Boada et al. (2012), the researchers 
assessed the association between exposures to mixtures of organochlorines and the risk of 
developing breast cancer. The study was conducted in Spain (Gran Canaria Islands) using 
103 healthy women and 121 women that were diagnosed with breast cancer. The 
organochlorine pesticides (OCPs) examined were p,p´-DDT, o,p´-DDT (DDT isomers), 
p,p´-DDE, o,p´-DDE, p,p´-DDD, and o,p´-DDD (DDT metabolites), aldrin, dieldrin, 
endrin, cyclodienes, and lindane. There was a statistically significant difference in the 
demographics of the study population, specifically, the mean age (58±11.7 vs. 45.3±13.8 
years for controls, p = <.001), and the BMI of the cases as compared to the controls 
(27.7±4.8 vs. 26.3±4.3 kg/m2 respectively, p = .031).  
The results showed that median values of DDT were higher among the healthy 
controls compared to the women with breast cancer (217 vs. 153 ng/g of lipid 
respectively; p = < .001). But, vice-versa results were noted for DDE and DDD as their 
levels were higher among breast cancer cases compared to the healthy controls (DDE: 
300 vs. 167ng/g lipid; DDD: 0.0 vs. 551 ng/g lipid, respectively, p = <.001 for DDE & 
DDD). Consequently, it follows that the body burden of total DDT residues were found 
to be significantly greater in women with breast cancer when compared to the healthy 
controls (979 vs. 665 ng/g lipid respectively, p = <.001). However, contrastingly, the total 
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cyclodienes and lindane burden was found to more in the healthy controls compared to 
the women suffering with breast cancer (91.4 vs. 80 ng/g lipid respectively, p = .027). 
An interesting set of results were observed in this study, mainly, the two groups 
had a differences that were statistically significant body burden for different sets of OCPs 
between the case and the control groups, that is, none of the healthy controls had a 
combination of aldrin and DDE and DDD, and none of the women with breast cancer had 
a combination of lindane and endrin residues. Also, it was observed that the main 
ingredient of DDT (i.e., p, p’DDT) was detected in the serum of more than 70% of both 
the groups (cases and controls), but DDT has been banned in Spain since 1970s; similar 
to the USA. This indicates that DDT residues still exists even though it has been almost 
three decades since its effective ban.  
Furthermore, their findings were comparable to those observed by Aube, 
Larochelle, & Ayotte (2011), where the researcher performed gene reporter assays after 
exposing MCF7 breast cancer cell line to mixtures of 15 different organochlorines; and 
found that DDT and its analogs caused cellular growth and division of the MCF7 cells. 
Besides these studies that have found positive associations between 
organochlorine exposures and breast, there are others that have yielded a negative result. 
A list of these studies appears in Table 2. 
Table 2 
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Note. OCs=Organochlorines, OCPs=Organochlorine pesticides, AAW=African American 
Women, WW=White Women, ^=Controls with Breast Disease [Benign Breast Disease 
(BBD) or mammomegaly], ^^ =Mean differences in the amount of DDE found between 
the cases and the controls was statistically significant (p=.005 and .006 for serum and 
lipid, respectively), *=Study used race-specific Body Mass Index (BMI). In this study, 
stratification for BMI showed a positive association in the highest levels of BMI for 
AAW for total PCBs (OR=4.92, 95% CI=1.63-14.83) & DDE (OR=1.90, 95% CI=0.71-
5.09). (Table was made by self using Microsoft Word, 2007). 
 
A major shortcoming in several of the larger case-control studies that have 
yielded a negative association between organochlorine exposures and breast cancer risk 
(Zheng et al., 1999; Bagga et al., 1999; Zheng et al., 2000; and Stellman et al., 2000) is 
the usage of controls that suffer with breast disease; either benign breast disease (BBD) 
or mammomegaly (MM). A study by Dupont et al. (1994) reported that women that have 
had a history of BBD have a greater probability of developing breast cancer, and 
97 
 
enrolling a control population with a previous breast condition may have skewed the 
results towards the null by acting as possible confounders in these studies. Furthermore, 
in the study conducted by Bagga et al. (1999) the mean values of lipid and serum DDE 
between the controls and the cases were found to be significantly different (serum: 642 
vs. 693.6 ng/g, P=.005; lipid: 709.1 vs. 800 ng/g, P=.006 respectively), however, the odds 
ratios were found to be non-significant. The use of unmatched controls for the study may 
have caused this discrepancy in the study result.  
Interestingly, the study conducted by Millikan et al. (2000) overall did not show a 
positive association, but when the AAW were stratified using race-specific BMI, then the 
women with the highest BMI values were found to be at risk for breast cancer with 
exposures to PCBs and DDE. These facts may add up since xenoestrogens 
(organochlorines) are stored in the adipose (fat) cells in the body, so a person with higher 
BMI values may have a greater risk of developing breast cancer upon exposure to 
xenoestrogens.  
Some case-control studies conducted on organochlorine (DDE) exposure for their 
associated risk for breast cancer in the 1990s (Djorveck et al., 1994; Falck, Ricci, Wolff, 
Godbold, & Deckers, 1992) had shown a positive association between the variables, but 
the sample size was too small (<20 subjects in each group). Falck et al. (1992) had 
enrolled 20 cases and controls, and the study conducted by Djorveck et al. (1994) the 
sample size consisted of only 5 cases and control subjects. In another study conducted in 
Canada by Dewailly et al. (1994), the researchers found a positive association of DDE 
exposures and breast cancer risk, but only in women with breast cancer that had a 
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positive ER status, but this study only had 18 cases and controls, of which 9 case subjects 
were ER-positive. Due to the extremely small sample sizes in these aforementioned 
studies the positive results will need to be viewed with extreme caution. 
Pharmaceutical Estrogens  
Gammon et al. (1999) utilized a case-control design to evaluate the relationship 
between the use of oral contraceptives (OCs) and Her2 protein over-expression. Her2 
expression was assessed by IHC on paraffin-embedded tissue on a cohort of women 
between 20 to 44 years, with newly diagnosed invasive breast cancer. Information was 
obtained by in-person interviews from 509 cases and 462 controls. Confounders assessed 
were contraceptive use, body mass index (BMI), reproductive and family history. IHC 
experiments were successfully conducted only in 371 of the 509 cases. Among those that 
were tested, 159 (43%), cases showed an over-expression of Her2 receptor, and these 
women had a more aggressive disease. Furthermore, when compared to controls, these 
women were mostly ER negative. The study had also demonstrated that the risk of having 
a Her2 positive cancer is heightened by more than two-fold when contraceptive usage 
begins early (<18 years) (OR = 2.39, 95% CI = 1.08 to 5.30, p = <.05). A Her2 positive 
status indicated that the Her2 proto-oncogene found in two copies in each human cell 
(i.e., Her2 negative state) had mutated into its oncogenic state, and resulted in the copy 
number increase/amplification of the Her2 gene. In its mutated or oncogenic form in the 
breast tissue, this gene causes breast cancer with a more aggressive disease and high 
mortality rates (Hynes et al., 1994; Meng et al., 2004; Slamon et al., 1989). This study 
found that a significant amount of risk is associated with the use of oral contraceptives 
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when their usage had started at an early age (<18 years old), and the risk of having a 
Her2 over-expressed tumor increased when the usage of contraceptives had begun during 
adolescence. 
Von Hoften et al. (2000) conducted a case-control study in the Netherlands, where 
309 histology confirmed cases of breast cancer were compared to 610 disease-free 
controls with respect to oral contraceptive use. Questionnaires were administered to study 
participants capturing information to oral contraceptive usage, medical and reproductive 
history, and demographic and behavioral data (e.g., weight, height, diet). The study found 
that women who used an OC for more than a decade had twice the risk of breast cancer 
(OR = 2.1, 95% CI = 1.1 to 4.0), nevertheless, it was non-significant. The authors noted, 
however, that 13.6% of cases and 9% of control participants were also using oral 
contraceptives. This may have skewed the OR values. Additionally, the type of oral 
contraceptive was not determined, which made it impossible to assess whether one oral 
contraceptive increased the risk of breast cancer more than the other. 
To answer this question and reduce recall bias, Kumle et al. (2000) specifically 
designed a population-based prospective study. Women that were between the ages of 30 
to 49 years from Norway and Sweden were randomly enrolled to study the associated risk 
of breast cancer in relation to the type of oral contraceptive preparation and the duration 
of its use in pre-menopausal women. The sample consisted of 103,027 women, 1008 of 
which had developed breast cancer. Exposure information was based on a questionnaire 
filled during enrollment. Contraceptive use was defined as the various time-periods an 
oral contraceptive was used and the type of contraceptive pill that was used. Summing all 
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of the time-periods yielded the duration of oral contraceptive usage. A significant 
interaction (p = .031) was noted between current use of oral contraceptive and age at 
follow-up, so the sample was further stratified into two age-groups: 30 to 39, and 40 to 49 
years with respect to their possible menopausal status at the end of follow-up. Regardless 
of the type of oral contraceptive used, the current users were at an increased risk (RR = 
1.6, 95%CI = 1.2-2.1). Similar risk estimates were noted for women using a combination 
of estrogen and progestin pills, as well as for those who used progestin pills alone (RR = 
1.5, 95% CI = 1.0-2.0). Trend data compared women who had used oral contraceptives 
for more than five years to those that were never users showed that women that had used 
oral contraceptives for an extended period of time (≥5 years) were at an increased risk of 
developing breast cancer compared to those that had never used any oral contraceptives 
in their lives (p = .005). 
Weiss et al. (2002) investigated the risk associated with hormone replacement 
therapy (HRT) regimens, recent use, and duration in relation to breast cancer in post-
menopausal women between the ages of 35 and 64 years. Cases (n = 1,870) of breast 
cancer were histologically graded, and age and residence matched to the controls (n = 
1,953). Exposures were stratified by estrogen replacement therapy (ERT), combined 
HRT, and ERT plus combined HRT. An increased risk of breast cancer was associated 
only with an HRT regimen that consisted of a progestin component, and had been used 
for five or more years. The risk of developing breast cancer was almost one and a half 
times more when combined HRT was used for five or more years (OR = 1.45, 95% CI = 
1.09 to 1.91), and statistically significant (p = .01). Trend analysis also showed an 
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elevated risk with increased usage duration of the combined (Ptrend = .003), and 
continuous combined HRT (Ptrend = .01) regimens. Similarly, trend analysis between past 
and recent users demonstrated that combined as well as continuous combined HRT 
represents a significant risk (p = .04 and .03 respectively). No risk was noted with ERT. 
In this particular instance, the evidence suggested that progestin and the duration of 
therapy increased the risk of developing breast cancer. Importantly, this study suggested 
that all oral contraceptives (xenoestrogens) may not incur a similar level of risk of breast 
cancer and that they had different carcinogenic potential. 
Althuis et al. (2003) examined the relationship between breast cancer risk and 
various strengths and types of oral contraceptives pills in women between the ages of 25 
and 54 years. A sample of newly diagnosed breast cancer patients (n = 1,640) were 
compared to randomly selected controls (n = 1,492). Results showed that women who 
were younger than 35 years who had used birth control pills within five years of their 
diagnoses had the greatest risk of developing breast cancer (RR = 2.22, 95% CI = 1.4 to 
3.5) compared to older women (35 to 44 years) (RR = 1.44, 95% CI = 1.30 to 1.80). 
More than 35 micrograms of EE was associated with a significant risk of breast cancer 
for women under 35 years of age (RR =3.62, 95% CI = 1.7 to 7.9) compared to women 
between the ages of 35 and 44 years (RR=1.52, 95% CI=.8 to 2.8, Ptrend = <.01). When 
the type of hormone was examined, an increased risk was observed in women under the 
age of 35 years using high strength progestin (RR = 8.11, 95% CI = 2.1 to 31.6) and 
estrogen (RR = 2.56, 95% CI = 0.7- to .9) pills. 
To take stock of the various studies conducted in this area of research, 
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Kahlenborn, Modugno, Potter, & Severs (2006) conducted a meta-analysis by pooled 
data from 34 studies and examined the risk of breast cancer with OC usage in younger 
women (less than 50 years old). The analysis included 14 hospital-based studies, 19 
population-based studies, and 1 study that was a combination of both conducted in 
several countries around the world (e.g., Brazil, England, France, Taiwan, Sweden, 
Slovenia to name a few), thereby constituting a truly international sample with much 
genetic and environmental variation. Studies that were published in or after the 80s were 
taken into consideration for this analysis. Statistical analyses were done using the random 
effects model which incorporated the differential variance observed between various 
studies to estimate effects (Der Simonian & Laird, 1986). The major findings of this 
meta-analysis were: 
1) An overall increase in risk of breast cancer was associated with the use of oral 
contraceptives (RR = 1.19, 95% CI = 1.09 to 1.29). 
2) In 21 out of 23 (91%) retrospective studies, the risk of breast cancer was 
greater in women who had used oral contraceptives prior to their first full-
term pregnancy (FFTP) (OR = 1.44, 95% CI = 1.28 to 1.62) compared to 
women who were on oral contraceptives after their first full-term birth (OR = 
1.15, 95% CI = 1.06 to 1.26).  
3) The risk was highest among who had used oral contraceptives for four or 
more years prior to their FFTP (OR = 1.52, 95% CI = 1.26 to 1.82). 
Despite these compelling findings, the meta-analysis was limited for four (4) reasons. 
First, only crude (vs. adjusted) odds ratios were calculated, hence they did not adjust for 
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potential confounders; such as age at FFTP, menarche. Secondly, a survivor bias could be 
involved due to exclusion of women who had previously died from breast cancer and as 
such could not participate in the study. Such non-participation may have attenuated the 
value of the combined OR, thereby skewing the results towards the null hypothesis of no 
association between oral contraceptive use and breast cancer. Thirdly, in the random-
effects model a population mean is calculated by the odds ratio where the population 
means are normally distributed. However, due to substantial variation of race and 
ethnicity (i.e., genetic variation) in the study population, some sub-populations could be 
at a greater risk for breast cancer; hence shifting the normal distribution of the population 
means (μ). Lastly, because there were retrospective case-control studies included recall 
bias is possible which could have been excluded if only prospective studies were used for 
the analysis.  
In a more recent study, Rosenberg, Zhang, Coogan, Strom, & Palmer (2008) 
investigated whether there is an increased risk for women using the newer lower strength 
progestin and estrogen oral contraceptives compared to the original higher strength ones. 
The study also examined whether there was an increased risk associated with hormone 
receptor status and ethnicity, and focused specifically on White and Black women and 
contraceptive use. Drawing on a hospital-based participant pool comprised of 907 cases, 
and 1,711 controls between the ages of 25 to 67 years were interviewed. Eighty percent 
of the cases (n = 731) and sixty-seven percent (n = 1152) controls were Whites. Notably, 
although not statistically significant, Black women had a higher risk of developing breast 
cancer with each duration category of oral contraceptive use compared to White women. 
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Specifically, Black women had approximately five fold increased risk (OR = 5.3, 95% CI 
= 1.6 to 17.4) compared to White women (OR = 1.4, 95% CI = 1.0 to 1.9) with five to 
nine years of contraceptive use. Overall, the odds of developing breast cancer with OC 
use were highest for women who had previously used the pill for five to nine years (OR = 
2.7, 95% CI = 1.7 to 4.5). Furthermore, the risk increased to one and a half times for 
women that had used OCs for 15 or more years when compared to those that has used it 
for less than a year (OR = 1.5, 95% CI = 1.2 to 1.8). These findings suggested that the 
risk of breast cancer associated with certain xenoestrogens could vary according to 
ethnicity and contraceptive use. Importantly, there may be a different genetic liability 
underlying breast cancer risk with exposure to oral contraceptives (xenoestrogens).  
Summary of Past Research 
This literature review has described how and why the Her2 proto-oncogene is 
required for the normal growth and development of the breast tissue, and can mutate into 
a potent oncogene for breast cancer when activated (Slamon et al., 1989). Xenoestrogens 
are shown to interact with the ER, thereby increasing the normal estrogen levels found in 
a tissue (Bulaveya & Watson, 2004). Her2 can cross communicate with ER, which in 
turn activates the PI-3K pathway for cellular signal transduction (Stoica et al., 2003). The 
oncogenic amplification of Her2 also initializes the MAPK pathway, further impacting 
the re-localization of ER from the nucleus to the cellular cytoplasm and forming a 
positive feedback loop that continuously re-localizes the ER from the cytoplasm into the 
nucleus leading to uncontrolled proliferation of breast cells (Yang et al., 2004). It has 
been hypothesized that increasing the estrogenicity of the breast tissue with 
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xenoestrogens leading to mutation of the breast cancer genes found in 17q chromosomal 
loci; one of these genes is the Her2 gene (Davis et al., 1997). In a study performed by 
Jenkins et al. (2009) on a rat model that developed breast cancer, an increased Her2 and 
Her3 levels and activity were observed when exposed to xenoestrogens. Importantly, a 
case-control study by Gammon et al. (1999) using IHC observed increased Her2 
expression levels in women with breast cancer with oral contraceptives (xenoestrogens), 
and these women were noted to have a more aggressive disease. 
Laboratory studies on animal models, cell-lines, and bioassays have proved that 
although compounds mimicking endogenous estrogens are broadly categorized as 
xenoestrogens, but they have differential estrogenic potentials (Silva et al., 2007), and 
can differentially activate cellular signaling (Bulaveya et al., 2004). The activation of 
cellular signal transduction further resulted in nuclear activity of cell division processes 
(Recchia et al., 2004) that consequently activated cellular growth and proliferation 
(Mercado-Feliciano & Bigsby, 2008). The initiation of cellular activity had occurred even 
at low doses of some xenoestrogenic compounds (Maras et al., 2005). The increased 
cellular activity promoted changes in breast tissue morphology which can lead to breast 
carcinogenesis (Brown & Lamartinere, 1995).  
Some of the population-based studies have indicated that organochlorine 
(xenoestrogen) exposures are a risk factor for breast cancer and its progression (Demers 
et al., 2000; Charlier et al., 2003) and attest to the aforementioned observations in the 
laboratory using cell-lines and animal models. A prospective study by Hoyer, Jorgensen, 
Grandjean, & Hartvig (2000) used a Danish cohort established a dose-response 
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relationship with p, p’DDT, and this feature of xenoestrogens has been observed in 
laboratory based research (Rajapakse, Ong, & Kortenkamp, 2001). 
Exposures to xenoestrogens increased susceptibility to breast cancer, especially 
when these exposures occurred at an early age (<14 years old) (Cohn, Wolff, Cirillo, & 
Scholtz, 2007), and when exposed to even minute or acute amounts of single 
xenoestrogen during gestation or neonatal period could lead to breast cancer during 
adulthood (Murray, Maffini, Ucci, Sonnenschein, & Soto, 2007; Jenkins et al., 2009). 
Epidemiological studies conducted on pharmaceutical estrogens (oral 
contraceptives) and their associated risk of breast cancer have suggested that the type of 
contraceptive, duration of their use, and recency of use can incur an increased risk of 
breast cancer (Van Hoften et al., 2000; Kumle et al., 2000; Weiss et al., 2002). The risk 
was found to be greater in women under the age of 35 years than those that are older 
(Althuis et al., 2003). This risk further increased especially in those women who had used 
a contraceptive pill for four or more years prior to their first full-term pregnancy 
(Kahlenborn, Modugno, Potter, & Severs, 2006). An increased risk was also found in the 
newer contraceptive pill that has a lower potency compared to the older ones, and 
although not statistically significant, but this risk was found to be more pronounced in 
African-American women when compared to White women (Rosenberg, Zhang, Coogan, 
Strom, & Palmer, 2008). 
A population study indicated that accidental, acute exposures with dioxin were 
associated with a two-fold increase (HR = 2.1) in breast cancer risk for women with ten-
times the levels of dioxin in their blood (Warner et al., 2002). In contrast, another study 
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reported only a moderate increase (OR (>75percentile) = 1.5) in the risk of developing breast 
cancer with PCE exposures leaching from PVC water pipes that distributed water in Cape 
Cod homes in Massachusetts (Aschengrau, Rogers, & Ozonoff, 2002), and yet another 
study found no increased risk with exposures to organochlorines like DDE, dieldrin, total 
PCBs, and chlordane, although, a slight increase in risk (OR = 1.2) was noted when 
comparing the highest exposure levels (4th tertile) with the lowest exposures (1st tertile) 
(Gammon et al., 2002). 
Overall, the population-based data was found only on limited xenoestrogens, was 
inconsistent and somewhat confusing since some studies indicated organochlorines to be 
a risk factor for breast cancer (Charlier et al., 2003; Warner et al., 2002), while others 
reported a minimal risk (Aschengrau, Rogers, & Ozonoff, 2002; Gammon et al., 2002), 
and yet others did not show any risk at all (Hunter et al., 1997; Snedkar et al., 2001). 
Additionally, some population-based studies showed an overall negative result, however, 
when the data was stratified then some sub-populations showed an increased risk for 
developing breast cancer when exposed to xenoestrogens over others (Hoyer, Jorgensen, 
& Grandjean, & Hartvig, 2001; Millikan et al., 2000; Rosenberg, Zhang, Coogan, Strom, 
& Palmer,  2008).  
Most epidemiological studies have shown negative results between xenoestrogen 
exposures and the risk of developing breast cancer (Table 2), only some of the studies 
showed a positive association (Boada et al., 2012; Charlier et al., 2003; Cohn, Wolff, 
Cirillo, & Scholtz, 2007; Hoyer, Jorgensen, & Grandjean, & Hartvig, 2001; Hoyer, 
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Jorgensen, Rank, & Grandjean, 2000; Warner et al., 2002), but these studies simply 
cannot be ignored and discarded. 
Implications of Past Research for Present Research 
In conclusion, population-based studies have revealed that the relative risks (RR) 
for xenoestrogen exposures associated to breast cancer are small to moderate 
(Aschengrau, Rogers, & Ozonoff, 2002; Kahlenborn, Modugno, Potter, & Severs, 2006; 
Rosenberg, Zhang, Coogan, Strom, & Palmer, 2008; Weiss et al., 2002) . Nevertheless, 
these substances are environmentally ubiquitous and affect every woman in some way, 
suggesting that identifying a modifiable risk factor and controlling their sale and use by 
introducing policy level changes would end-up saving thousands of lives translating into 
a large public health impact. However, a key problem with small relative risks found in 
the epidemiological data is the translation of the risk estimates into actionable clinical as 
well as policy level decision making. One way to buttress the findings of the 
epidemiological data that could assist both clinical as well as policy decision making is 
by elucidating the biologic mechanism/s or processes by which xenoestrogens can 
promote carcinogenesis. 
Additionally, although population-based studies have led to policy level changes, 
but in the case of xenoestrogens they leave many unanswered questions because the 
results of various studies were found to be inconsistent. The overall negative results of 
some may not be enough to close down the chapter on future research with 
xenoestrogens, because then there are also some studies that yielded positive results 
(Boada et al., 2012; Charlier et al., 2003; Warner et al., 2002), and yet others that were 
109 
 
positive only with effect modifications, but, in these studies the sample-sizes had become 
too small to answer the research question/s asked with much confidence (Hoyer, 
Jorgensen, Rank, & Grandjean, 2001; Kumle et al., 2000; Van Hoften et al., 2000). 
Furthermore, population-based studies have shown low reproducibility and were 
tremendously expensive making them difficult to pursue in further research (Brody, 
Tickner, & Rudel, 2005). Due to these reasons, no two epidemiological studies were 
found to be alike. Thus, even though there were only some studies that yielded positive 
results with xenoestrogen exposure and the risk of developing breast cancer; these studies 
simply cannot be over-looked.  
Although some epidemiological studies yielded a positive association, but since 
these studies relied on self-reports or interviews for exposure categorization the précis 
exposures were difficult to be quantified using these techniques (Boada et al., 2012; 
Charlier et al., 2003; Demers et al., 2000). Whereas, studies performed using cell-lines, in 
vitro assays, and animal models have provided us with insights to the unique attributes of 
xenoestrogens all while using précis measurements (Aube, Larochelle, & Ayotte, 2011; 
Brody, Tickner, & Rudel, 2005.; Brown & Lamartinere, 1995., Jenkins et al., 2009; 
Johnson et al., 2012; Payne, Rajapakse, Wilkins, & Kortenkamp, 2000., Rajapakse, Ong, 
& Kortenkamp, 2001), and these studies provided biological validation (Jenkins et al., 
2009; Johnson et al., 2012) to the epidemiological data (Gammon et al., 1999; Rosenberg, 
Zhang, Coogan, Strom, & Palmer, 2008). 
Due to the chemically diverse nature that was observed in the xenoestrogens 
(Payne, Rajapakse, Wilkins, & Kortenkamp, 2000; Rajapakse, Ong, & Kortenkamp, 
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2001; Maras et al., 2005; LaPensee et al., 2009), it will not only be deemed important that 
the précis exposure measurements be evaluated, but also the metastatic/carcinogenic 
potential of the xenoestrogen be assessed in order to make policy-level changes (Snedkar 
et al., 2001). Assessing the carcinogenic potential will provide us with the lowest 
exposure levels of xenoestrogens that does not incur any breast cancer risk and is safe to 
use, and this information will be extremely important to make policy level changes for 
common household products (e.g., plastics).  
In a commentary, Davis et al. (1993) hypothesized the role of oncogenic 
activation in the 17q loci due to increased estrogenicity exerted by xenoestrogenic 
exposures, and emphasized that this hypothesis requires to be evaluated carefully. Her2, a 
proto-oncogene found in the 17q loci in humans, is required for normal breast 
development, but becomes into a potent oncogene upon unregulated stimulation (Slamon 
et al., 1989., Tzahar et al., 1989). Of note, ER and Her2 have been shown to cross-
communicate with each other via signaling pathways (Stoica et al., 2003), making it 
biologically plausible that exposure to xenoestrogen/s activated Her2 via this crosstalk, 
led to over-activation of Her2. This then resulted in excessive cellular proliferation and 
growth for tumorigenesis. Hence, it plausible that xenoestrogenic exposures maybe 
activating Her2 pathway via this crosstalk that occurred between these two receptors and  
activated and over-activated Her2, this further resulted in excessive cellular proliferation 
and growth for tumorigenesis. Intriguingly, research also indicated that the cellular end-
points upon xenoestrogenic exposures; such as ERK1/2 activity, cell growth, metastasis, 
and angiogenesis observed using biochemical assays are similar to those when Her2 
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oncogene copies increase or amplify during its oncogenic activation during breast 
carcinogenesis.  
Some population data pointed to elevated Her2 expressions with xenoestrogenic 
exposure (Gammon et al., 1999). However, this study was done only using IHC assay 
that have high inter-observer variability and low accuracy (Press et al., 2002; Varga, 
Noske, Ramach, Padberg, & Moch, 2013). Another study in which increased Her2 
oncogene was observed with persistent exposures to a single xenoestrogen was 
performed in an animal model (Jenkins et al., 2009), and not in a human model using 
sensitive techniques. 
Interestingly, some population studies indicated that the phenotypic 
characteristics of the breast cell-type maybe a feature that could impact disease type 
(Gammon et al., 1999). Another study showed that women not only with an ER-positive 
status are impacted with xenoestrogen exposures, but those having an ER-negative status 
are also impacted, in fact the women with an ER negative status had a more aggressive 
disease when compared to women with an ER-positive status (Hoyer, Jorgensen, Rank, & 
Grandjean, 2001). These studies indicated that there may be a genetic liability involved 
with xenoestrogenic exposures which needs to be further dissected and understood in 
future research endeavors. 
In all, past research has shown that xenoestrogens are a diverse group of 
chemicals with varying estrogenic potentials. They activated potent oncogenes; such as 
the Her2 oncogene in the development of breast cancer. They incurred small to moderate 
relative risks for breast cancer upon exposures. Furthermore, they reacted differently in 
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different mammary cellular phenotypes (ER-positive and ER-negative). What has yet to 
be established in the literature is: 
1) The carcinogenic potential of commonly used xenoestrogens with respect to 
their précis amount/s, duration, type. 
2) Deciphering whether a specific cellular phenotype is more at risk of 
developing breast cancer upon xenoestrogenic exposures. 
3) The mechanistic insights which provides biological validation of their 
carcinogenic properties, utilizing a technique with high reproducibility and a 
validated biomarker for breast cancer which can be used as tools for future 
research endeavors.  
The design for the present study was chosen based upon a careful review of existing 
literature in the areas of breast cancer and xenoestrogens. The next chapter entails 
detailed discussions on the methodology, sample, instrumentation, and analysis used to 
conduct the study. 
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Chapter 3: Research Method 
Introduction 
This chapter includes a description of this study’s design, sample, 
instrumentation, data analysis, and ethical considerations. It will entail a detailed 
discussion on the research design, instruments, materials, and protocols used in 
performing the experiments, and how the data generated were analyzed to answer the 
research questions asked.  
Research Design and Approach 
The purpose of this exploratory research study was to dosimetrically assess the 
carcinogenic potential of four commonly used synthetic xenoestrogens (i.e., BPA, DDT, 
EE, and NPH) with respect to the Her2 gene expression. Further, the study further 
investigated whether specific cellular phenotypes of the mammary cell have greater 
susceptibility to oncogenic copy number increase. This was done using breast cancer cell-
lines that differentially express the ER and Her2 receptors. The xenoestrogens were 
applied in increments of their log10 ratios to examine the concentration at which 
xenoestrogens induced changes in Her2 gene expression. To capture chronic low to 
moderate exposures that women are most likely subjected to everyday, the xenoestrogens 
were applied daily for a time-period of 7 weeks.  
A RBD was appropriate for this study. In RBD, blocks of homogenous groups are 
further stratified into subgroups (Jefferey & Cooks, 2011; Piston, Gil-Humanes, 
Roderiguez-Quijano, & Barro, 2011; Rivera, Monsalve, Moran, & Suazo, 2013; Wu et 
al., 2013), and then the experimental design that the researcher wants to incorporate into 
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his or her project is implemented within each block. This is basically done in order to 
reduce noise due to variability present between each block, and doing so produces a 
better effect estimate overall than without its application. Because each cell line is 
phenotypically disparate, each line was stratified according to their receptor status (e.g., 
ER+/Her2+, ER-/Her2-). This design is analogous to a stratified design (Piston et al., 
2011; Rivera et al., 2011; Trochim & Donnelly, 2007, p. 189-200; Wu et al., 2013). Then, 
for each line, the cells were randomly assigned to the case and control groups. The case 
flasks were exposed to xenoestrogens (i.e., different type, concentration, and duration), 
whereas the control flasks remained unexposed. This allowed comparison of differences 
in the Her2 gene activity within each subgroup as well as overall when the synthetic 
xenoestrogen is applied (cases) as opposed to the nonexposed (control) group. This 
design ensured that the primary independent variables of interest―xenoestrogen type, 
concentration, and duration―could be precisely controlled and measured (Trochim & 
Donnelly, 2007, p. 187). The random assignment aided in making both groups (i.e., cases 
and controls) similar before treatment ensued, thereby increasing the internal validity of 
the study design (Trochim & Donnelly, 2007, p. 191).  
In addition, to reduce researcher bias, all four lines were coded A, B, C, and D by 
a technologist not involved in the study as soon as they were received (Sackett, 1979). 
After the cell lines were treated to various exposure conditions, FISH experiments were 
conducted on interphase nuclei using the Her2/CEP17 probe-set (Abbott Molecular, Des 
Plaines, IL) to molecularly assess Her2 gene copy number changes (i.e., increase in copy 
numbers or amplification) that incurred with the differential xenoestrogenic exposures. 
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FISH provides for the assessment of the Her2 oncogenic copy number changes or 
amplification at the gene level (Ohlschlegel et al., 2014; Olsson et al., 2010). It also 
provides for greater accuracy and sensitivity of Her2 testing, compared to other tests such 
as IHC that could be used to assess Her2 values (Olsson et al., 2010; Press et al., 2002). 
Figure 2 shows the copy number patterns observed using the Her2/CEP17 probe set in a 
normal and Her2 amplified mammary cell using a fluorescent microscope. In a normal 
mammary cell, two CEP17 signals (labeled in green) and two Her2 gene copies (labeled 
in orange) are observed; whereas when there is an increase in the copy numbers or gene 
amplification, an increase in the number of signals is noted. Counting the number of 
copies using fluorescence microscopy, one can quantify the number of gene copies found 
in the sample and the control and calculate the differences between the two groups 
(Ohlschlegel, Zahel, Kradolfer, Hell, & Jochum, 2011; Ohlschlegel Zahel, Kradolfer, 





Figure 2. Normal and over expressed Her2 gene. N example of a mammary cell with two 
orange signals represents normal Her2 gene expression (left), and another with multiple 
orange signals shows copy number increase of the Her2 gene (right). The green signals 
represent the centromeres of chromosome #17 on both cells. FISH was performed using 
the Her2/CEP17 dual probe kit from Abbott Molecular for Her2 analysis on breast 
carcinoma tissue microarray (Image courtesy of the Cytogenetics Core Laboratory, 
Brigham and Women’s Hospital, Boston, MA). 
 
Setting and Sample 
The study was laboratory-based. The research was conducted in the Cytogenetic 
Core Laboratory. This laboratory is a licensed laboratory of the Brigham and Women’s 
Hospital (BWH) in Boston, Massachusetts. 
Cell-Lines 
The sample utilized human breast cancer lines, assessing the cell-line specific 
effect with the application of multiple and varied xenoestrogenic exposures. Because the 
xenoestrogens typically exert their effect by binding to ERs, and the ERs can further 
engage in cross-communication with Her2 (Jung et al., 2012; Slamon et al., 2011; Yang, 
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Barnes, & Kumar, 2004), hence the breast cell lines for this study were selected on the 
basis of these two receptors types. As women can either have an ER- and Her2-positive 
or -negative receptor status, the cell-lines selected reflected all the different combinations 
of these two receptors. That is, ER+/Her2+, ER+/Her2-, and so on (Chang et al., 2006; 
Johnson et al., 2010; Wang et al., 2010). 
ER-positive and -negative status: Normally, about 30% of breast cells express ER 
(alpha), but in breast cancer cells that are ER-positive almost all of the breast epithelial 
cells express the ER (alpha). Thus, in ER-positive breast cancer cell lines almost all the 
cells have been found to express high levels of ER (alpha), whereas the ER-negative 
indicates normal levels of ER (alpha) found in the breast epithelia (Allred et al., 2004; 
Johnson et al., 2010; Wang et al., 2010). 
Her2-positive and -negative status: Her2 gene makes the Her2 protein. In normal 
breast epithelia only two copies of this gene is found; whereas in breast cancer cells that 
are Her 2 positive too many copies of the Her2 gene are found and the gene is known to 
be amplified, which results in its protein overexpression (Figure 2). The Her2-negative 
lines indicate normal levels of the gene copies (i.e., 2 copies) and the Her2-positive lines 
have increased gene copy numbers (Grushko et al., 2002). Additionally, the Her2 protein 
overexpression can be tested using immunohistochemical (IHC) staining. This staining 
test can be negative (0, 1+ score), borderline (2+), or positive for Her2 protein 
overexpression (3+) (Pinhel et al., 2012). 
Considering all of the different combinations that can be obtained with these two 
receptors, the samples consisted of the following four breast cancer cell-lines: 
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• MCF7 line (ER-positive and Her2-negative) (Chang et al., 2006; Choi, Fan, 
Deng, Zhang, & An, 2012; Wang et al., 2010). 
• BT474 (ER-positive and Her2-positive) (Garrett, Sutton, Kuba, Cook, & 
Artega, 2012; Johnson et al., 2010). 
• MDAMB231 (ER-negative and Her2-negative) (Chang et al., 2006; Wang et 
al., 2010). 
• SKBR3 (ER-negative and Her2-positive) receptor status (Chang et al., 2006; 
Garrett et al., 2012; Johnson et al., 2010). 
As studies such as this one would be unethical to perform in a population-based setting, 
accounting for the all the different combinations of these two receptor types found in the 
mammary cell assisted in generalizability of the results obtained from the different data-
sets. Further, it ascertained whether there are any differences in the risk levels that may 
occur with the different receptor phenotypes. 
All of the above mentioned cell lines (Chang et al., 2006; Johnson et al., 2010; 
Wang et al., 2010) are human breast cancer lines that were obtained by American Tissue 
Culture Collection (ATCC) from patients that consented to the use of their biopsied 
materials. The cells from these biopsies were cultured, propagated, and frozen down right 
after the surgery by ATCC. The breast cancer cell lines are publicly known and used by 
researchers nationally and internationally for breast cancer research. ATCC is a well 
renowned bioresource center (BRC) that specializes in culturing and maintenance of cell 
lines. They also maintain patient data for each line. 
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The cell-lines were ordered from ATCC. Some advantages of procuring the lines 
from ATCC are: a) they have been procured and cultured immediately after biopsy, and 
b) these cell-lines have been frozen down at low passage levels, so the cells used in the 
experiments are not genetically far removed from the original tissue obtained from the 
breast cancer patient at the time of biopsy or surgery. This is important because high 
passage numbers (>40) can add stress to the cells due to their culturing environment, thus 
bringing about changes in their chromosomal constitution, cellular morphology, and 
response to external stimulus (ATCC, 2007).  
To avoid application of any extraneous estrogen, all of the lines were maintained 
in media devoid of estrogens from extraneous sources; such as from media and the serum 
which is added to the media for maintaining the cells in culture. This process further aids 
in increasing the internal validity of the experiments. The media used did not contain any 
phenol red, because phenol red has estrogenic properties and can preferentially enhance 
the growth of cells expressing estrogen receptors (Berthois., Katzenellenbogen, & 
Katzenellenbogen, 1986; Aube, Larochelle, & Ayotte, 2011). The serum used was 
charcoal-stripped (Aube, Larochelle, & Ayotte, 2011, Buteno-Lozano, Velasco, 
Cristofari, & Perrot-Applanat, 2008; Maras et al., 2005; Valeron, Pestano, Luzardo, 
Zumbado, & Boada, 2009). The process of charcoal stripping utilizes filtering of the 
serum through charcoal for the removal of materials such as hormones (e.g., estradiol, 
progesterone, cortisol, testosterone and insulin) and growth factors (Life Technologies, 
Grand Island, NY). Both, the media and its serum were ordered from Gibco (Life 
Technologies, Grand Island, NY). Upon arrival, each line was coded (e.g., cell line 1, cell 
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line 2, etc) and these codes remained blinded to the researcher to reduce experimenter 
bias (Sackett, 1979). Flasks from each line were typically assigned to control (unexposed) 
and case groups randomly for the application of various exposure settings described later 
in this chapter. 
Xenoestrogens 
The xenoestrogens included in the study were obtained from Fischer Scientific; a 
company that provides biological chemicals and reagents. The following xenoestrogens 
were used for this research project: 
1) DDT (catalog # 801175033196): is absorbed and retained by soil particles, 
and is being used as a malarial vector control in some countries (ATSDR, 
n.d.). 
2) EE (catalog # 10166001): is an estrogen used contraceptive pills, but recently 
the EE part of the pill has been reduced to five times lesser amount (Chu, 
Zhang, Gentzchein, & Lobo, 2007). 
3) BPA (catalog # S-509): is a chemical used in making plastics and resin (e.g., 
plastic containers, formula and soda bottles, plastic tubing, and dental sealants 
(Jenkins et al., 2009).  
4) NP or NPH (catalog # AC41624-0010): used in industrial detergents and 
surfactants, and is added to many consumer products; such as pesticides, 
household cleaners, and cosmetics (Calafat et al., 2005). 
For both, BPA and NP, in a sample consisting of 1,000 participants, it was observed that 
95% (950 persons), and 51% (510 persons) had more than 0.1ug/L urine concentrations 
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of these two chemicals in their body (Calafat et al., 2005). These results indicate that 
most people are being exposed to at least 100ng/mL concentrations of BPA and NP. 
Treatment/Exposures 
For treatment with xenoestrogens, each cell-line were equally divided into two (2) 
sets of flasks, one set for single, short-term exposures and the second set for multiple, 
long-term exposures. Both of these sets of flasks were further divided according to their 
treatment conditions into A) Individual xenoestrogenic exposure, B) Combinatorial 
xenoestrogenic exposure, and C) Control flasks (unexposed). 
FIRST SET OF FLASKS: Single, Short-Term Exposure Treatment Conditions 
A. For individual xenoestrogenic exposure, one flask from each of the four breast 
cancer cell-lines were exposed to either BPA, EE, DDT, or NP/NPH in 
increasing concentration of log10 ratios with each xenoestrogen (i.e., .1nM; 
.01nM; and .001nM).  
B. For combinatorial xenoestrogenic exposure, one flask from each line was 
exposed to .1 nM, .01nM, or .001nM concentration of all four xenoestrogens. 
C. For control, one flask from each line (total of four flasks) remained 
unexposed.  
All of the flasks (total = 64 flasks) were kept in the incubator at 37°C after their 
respective treatments they were harvested on the fifth day. This batch represented the 
single, short-term exposure. 
SECOND SET OF FLASKS: Multiple, Long-Term Exposure Conditions  
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A. For individual xenoestrogenic exposure, one flask from each of the four lines 
was exposed to BPA, EE, DDT, or NP/NPH with increasing concentration of 
log10 ratios of each xenoestrogen (i.e., 0.1nM; 0.01nM; and 0.001nM).  
B. For combinatorial xenoestrogenic exposure, one flask from each line was 
exposed to 0.1 nM, 0.01nM, or 0.001nM concentration of all four 
xenoestrogens. 
C. For control, one flask from each line (total of four flasks) remained 
unexposed.  
All of the flasks (total = 64 flasks) were treated with the aforementioned conditions daily 
for 50 days. The cells were maintained in the incubator at 37°C after the respective 
treatments, and then harvested. This batch represented multiple persistent exposures. A 
grand total of 128 flasks were obtained for the entire sample set consisting of the four 
breast cancer cell lines used with the various exposure settings. The following diagram 






Schematic Representation of Exposure Setting for Each Line 









































































Total: 32 Flasks / Line 
Grand Total: 128 Flasks for all 4 lines 
Concentrations of Xenoestrogens used: .001, .01, and .1 nM (nanomolar)  
 
The sample set of the four breast cancer cell lines (MCF7, BT474, MDA-MD-
231, and SKBR5) was divided into four homogeneous groups, each group representing a 
cell-line (coded as 1, 2, 3 and 4). Each homogeneous group or cell line was randomly 
assigned to cases (exposed) and controls (unexposed) groups. Each cell line was further 
divided into two sets of flasks, the first batch received single, short-term exposure and the 
second multiple, long-term exposures. For each batch, the four xenoestrogens were 
applied individually and in combination (i.e., all four xenoestrogens) at concentrations of 
.001nM, .01nM, and .1nM respectively, while the control flask remained unexposed. 
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The treatment with xenoestrogens of the samples was done using micro-pipetors. 
These pipetors are manufactured and calibrated annually by Rainin (Rainin Instruments, 
CA) for precision and accuracy for laboratory usage. Then, the cells were harvested to 
obtain interphase nuclei. Slides were made from the cells obtained from each exposure 
setting on each of the four cell lines. FISH experiments were then conducted on the 
nuclei using the Her2/CEP17 (Abbott Molecular) probe-set. Signals from the FISH 




FISH is a molecular technique by which precise DNA sequences can be targeted 
within the genome, and this technique is currently being used in many areas of genetics 
and genomics. Using this technique one can target the entire genome of a particular 
species, whole chromosomes, specific regions of a chromosome or chromosomes, and 
single copy or multiple copies (gene amplification) of unique gene sequences, depending 
on the probes used in the experiment (Liehr, 2009, p. 26-28; Garimberti & Tosi, 2010). 
The technique is rapid, simple to implement, and offers great probe stability. The 
principles of this molecular technique applied are rather simple and straightforward. The 
protocol takes advantage of the fact that a DNA molecule consists of two homologous 
strands which can be denatured to a single-strand of DNA using heat. Under the right 
conditions, this single-strand can re-locate its homologue and re-build an exact replica of 
the initial double-stranded DNA molecule (Liehr, 2009, p.26; Garimberti & Tosi, 2010).  
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Specifically, DNA or RNA sequences from specific are labeled with 
fluorochromes (e.g., spectrum red, orange, green, or aqua). These fluorochromes act as 
the reporter molecules with which the gene can be visualized and counted using a 
fluorescent microscope. The labeled probe DNA and the sample DNA are then denatured 
using heat (Bishop, 2010; Garimberti & Tosi; 2010). The heat used for denaturation 
breaks the bonds of double-stranded DNA molecules of the sample and probe DNA, 
forming single-stranded DNA molecules. These single-strands of DNA are further 
hybridized together; which brings together the exact replica of the labeled probe to locate 
its homologue in the sample DNA placed on the slide. After washing the excess probe 
that maybe present on the slide, the specimen is screened for the presence or absence of 
the reporter molecule/s using a fluorescent microscope (Bishop, 2010; Wolff & Schwartz, 
2005, p.455-458). 
The FDA approved Her2 probe kit (Abbott Molecular Inc., Des Plaines, IL) 
specifically hybridizes to the 17q11.2 to q12 chromosomal region, and each copy of the 
Her2 gene is represented by the presence of a reporter molecule (Ohlschlegel, Zahel, 
Kradolfer, & Jochum, 2011; Ohlschlegel, Zahel, Kradolfer, & Jochum, 2013; Olsson, 
Jansson, Holmund, & Gunnarson, 2013; Wilking, Karlsson, Skoog, Hatscheck, Lidbrink, 
Elonberger, … Berg, 2011). Basically, all of the genetic information in the human 
genome is found in the nucleus of each cell in the human body. Within the nucleus the 
genes are tightly packed in structures called chromosomes, and humans have 23 pairs of 
chromosomes. Thus, all cells in the human body have a nucleus with 23 pairs of 
chromosomes that contains the genetic blueprint (Keagle, 2005, chp.2, p.9). Of the 23 
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pairs of chromosomes, there are 22 pairs of autosomes and a pair of sex chromosomes. 
The autosomal pairs are labeled as chromosome #s 1-22; whereas the sex chromosomes 
are designated as XX or XY for normal female or male respectively (Tharapel, 2005, 
chp.3, p.28). The Her2 proto-oncogene is located in autosomal chromosome#17 of the 
human genome (Akiyama, Ogawara, Toyoshima, & Yamamoto, 1986; Slamon et al., 
2011). Thus, a normal breast cell has two copies of the Her2 gene, and more than two 
signals of the labeled probe would represent an increase in the copy numbers or an 
amplification of the Her2 gene (Gutierrez and Schiff, 2011; McCormick et al., 2002). By 
hybridizing cases (exposure to xenoestrogens) and control groups (unexposed) with the 
Her2 probe one can quantify the number of copies of the Her2 gene present in each 
group. Then, the differences between mean ranks of the Her2 signals between the cases 
and control groups were compared and assessed for significance for each cell line. 
Between the lines, differences were also examined by assessing the magnitude of change 
that had occurred for each line with treatment when compared to the controls. 
Sensitivity, Specificity, and Accuracy of Her2 FISH: 
FISH is a tool that provides for molecular assessment of the Her2 gene; 
specifically Her2 copy numbers and amplification status. Research conducted (Press et 
al., 2002) used the Her2 and CEP17 probes to measure its sensitivity and specificity 
projected these values as 95.4% (42/43 samples), and 98.6% (72/73 samples) 
respectively. Using the Her2/CEP17 probe set, FISH experiments conducted on a total of 
117 samples correctly identified true positives and negatives in 114 samples, thus giving 
it an accuracy of 97.4% (114/117). Other researchers (Mass et al., 2005; Olsson, Jansson, 
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Holmund, & Gunnarson, 2013; Sauter, Bartlett, Slamon, & Press, 2007) have further 
validated the high predictive values obtained using Her2/CEP17 FISH probes, with 
sensitivity measures ranging from 95% -97% and sensitivity ranging from 97% -100% 
for the assessment of Her2 copy number increase or amplification. Due to its high level 
of sensitivity the marking of Her2 gene amplification, the Her2/CEP17 FISH assay was 
optimal to use for this research project as it attenuated type I error rate. Type I errors 
occurs when a negative result is scored as a positive one, thus it is falsely positive. This 
type of an error can have significant consequences in the acceptance of the alternate 
hypothesis when it should actually have been rejected (Munro, 2005, p.88).  
Probes for the FISH Experiments 
The Her2 assay kit from Abbott Molecular consists of dual probes: an alpha-
satellite or repetitive sequence probe (CEP17), and a locus specific or unique sequence 
probe (Her2) (Burris, Rugo, Vukelja, Vogel, Borson, Limentani, … O’Shaughnessy, 
2011; Fleming, Sill, Darcy, McMeekin, Thigpen, Adler, … Fiorica, 2010; Hanna, 
Ruschoff, Bilous, Coudry, Dowsett, Osamura, … Viale, 2014; Schoppman et al., 2010). 
This probe kit is FDA approved for breast cancer (Wulfkuhle et al., 2013). The alpha-
satellite probe sequences are made of tandem repeats of 171 base pairs (bp) called 
alphoid monomers, and are anywhere from 0.1 to 5 Mega base (Mb) in length. The alpha-
satellite probe hybridizes to sequences that are specific to the centromeric and 
pericentromeric region of the chromosome (Bishop, 2013Oliveira & French, 2005). The 
numbers of these alphoid monomers are found to vary in different chromosomes, and due 
to this property they can be tailored to a specific chromosome centromeric region. On the 
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other hand, the locus specific or unique sequence probes are generated from specific 
regions of the genome that contains a single gene or a set of contiguous genes either 
cloned into vectors (e.g., cosmids, yeast artificial chromosomes, bacterial artificial 
chromosomes) or obtained synthetically using sequence specific primers with polymerase 
chain reaction (PCR) (Wolff & Schwartz, 2005, p.455-457). The locus specific probes 
can vary in size from 1 Kilobase (KB) to >1Mb, and are used to examine gene deletions, 
copy numbers, and gene re-arrangements (Bishop, 2013; Oliveira & French, 2005; 
Salmon et al., 2011; Wolff & Schwartz, 2005, p.455-457).  
In the Her2/CEP17 dual probe breast cancer assay kit from Abbott Molecular 
(Abbott Molecular, Inc., Des Plaines, IL, USA), the Her2 probe labeled in spectrum 
orange hybridizes to region 17q11.2 to q12; which is where the Her2 oncogene resides, 
and CEP17 probe labeled in spectrum green hybridizes to 17p11.1 to 17q11.1 
(centromeric region of chromosome 17) (Ohlschlegel, Zahel, Kradolfer, Hell, & Jochum, 
2011; Ohlschlegel, Zahel, Kradolfer, Hell, & Jochum, 2013; Olsson, Jansson, Holmund, 
& Gunnarson, 2013; Wilking, Karlsson, Skoog, Hatscheck, Lidbrink, Elonberger, … 
Berg, 2011). 
Protocols for Harvesting Cell-lines and FISH Experiments 
Harvesting of Cell-lines 
After exposure to xenoestrogens, the cells were harvested with 75mM KCl 
(Potassium Chloride) for 20 min at 37°C, and then fixed in freshly prepared 3:1 
methanol: acetic acid fixative (Ismail, Aly, Khaled, & Mohamed, 2009). 
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FISH on Interphase Nuclei  
FISH was performed using the vendor (Abbott Molecular) instructions for this 
specific probe-set (Ohlschlegel, Zahel, Kradolfer, Hell, & Jochum, 2011; Ohlschlegel, 
Zahel, Kradolfer, Hell, & Jochum, 2013; Olsson, Jansson, Holmund, & Gunnarson, 2013; 
Wilking et al., 2011). In brief, sample slides were prepared from the cell-pellet obtained 
from the harvest. The slides were denatured using 70% Formamide at 72°C for five 
minutes, and dipped in 70% Ethanol for a minute at room temperature to remove all the 
Formamide from it. To remove all the water from the slide they were dehydrated by 
immersion in 90%, and 100% ethanol for two minutes each at room temperature, and 
dried on the slide-warmer at 50°C for two to five minutes. Then, 8 μl of the Her2/CEP17 
probe was applied to the slides and covered with a glass cover-slip. This area was then 
sealed using a sealant, to ensure that the slides do not dry-out. Next, the slides were 
hybridized at 37°C for 14-18 hours in a humidified chamber. After this, to remove excess 
probes off the slides they were washed in 2X SSC/0.3% NP40 solution at 72°C for two 
minutes, and DAPI, a blue counter-stain was applied. The slides were then viewed under 
a fluorescent microscope and scored for orange (Her2), and green (CEP17) signals 
(Perez, Pess, Dueck, Jenkins, Kim, Chen, …Slamon, 2013). This protocol is also 





Scoring of Interphase Nuclei  
The scoring of the nuclei was done as suggested by the vendor (Abbott 
Molecular) for the Her2/CEP17 probe-set (Perez et al., 2013). According to the vendor, 
scoring 20 nuclei for each sample should be sufficient to study Her2 copy number 
increase or amplification (Ismail, Aly, Khaled, & Mohamed, 2009; Press et al., 2002; 
Wolff, Hammond, Hicks, Dowsett, McShane, Allison, …Hayes, 2013). Ortiz de 
Solórzano, Santos, Vallcorba, & Garcia-Sagredo (1998) performed statistical analysis for 
the validation and data correction of automated FISH probe signals. Some of the 
limitations that they found with interphase FISH signals were: i) the nuclei can overlap, 
and so do the signals, ii) some organic residues could auto-fluoresce (i.e., background or 
noise), iii) there could be damage to the nuclei during slide preparation, and iv) 
differential probe hybridization on the slide. These can be summarized as systemic errors, 
as they all can result in false positives. In order to avoid these, and increase the accuracy 
and sensitivity of the test (97%), they emphasize the use of an internal control vs. an 
external control due to its assured accuracy to the chromosome of interest. As the Her2 
gene resides on chromosome 17, in this Her2/CEP17 probe-set, the centromeric probe for 
17 (i.e., CEP17) acted as the internal control.  
Both orange (Her2) and green (CEP17) signals on 20 randomly selected, well 
separated, intact nuclei were counted (Abbott Molecular) using a fluorescent microscope 
with dual band filters for orange and green wavelengths of light (Applied Imaging) and a 
cell counter (Perez et al., 2013). The scoring of all the nuclei was performed using a 100x 
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objective to avoid variability in FISH signal observation and analysis. The Her2 gene was 
then quantified in its absolute value; that is total Her2 copies observed per nuclei (Hanna 
et al., 2014). Equal numbers of Her2 and CEP 17 signals signify the gain of an entire 
chromosome 17 (Grushco et al., 2002; Hegyi, Lonberg, Monus, & Mehes, 2013; Hanna 
et al., 2014; McCormick, et al., 2002). 
Raw Data 
The scoring of the nuclei was formatted in an excel-sheet that projected the 
frequency of the types of orange and green signals noted in each of the 20 nuclei for line 
with each of the exposure conditions utilized in the project. For each FISH experiment, 
the scoring was done manually. The signals were counted using a cell-counter. A 
representative FISH image of nuclei were captured for each exposure condition and 
stored in the imaging system of the Cytogenetics Core Laboratory located in BWH. 
Statistical Analysis of Data 
Descriptive Statistics 
Descriptive statistics included medians, range, and frequencies. Tables and graphs 
(histograms and Q-Q plots) represented the Her2 signals observed all of the lines after 
subjecting them to the differential exposure settings. From the raw data, tables were 
created for each cell-line that marked the percent change values of the Her2 signals 
observed under each exposure condition and control (unexposed) groups for each 
xenoestrogen and cell line using short-term (single exposure) vs. long-term exposures 
(multiple exposures) and different concentrations (.001, .01 and .1nM). Percent changes 
observed between cases and controls for different concentrations and durations were 
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assessed. These tables and graphs allowed easy visualization and comparison of FISH 
signals observed for the varying exposure conditions applied. The tables and graphs were 
created using MS Word and Excel version 2007. 
Inferential Statistics 
The number of green and orange FISH signals found on the 20 individual 
interphase nuclei was treated as continuous variables (Press et al., 2002). Because the 
cell-lines were of non- normal distribution, non-parametric statistical tests were 
performed. Non-parametric tests are those that do not conform to any parameters and are 
thus distribution free (Munro, 2005, p.110-111). Mann Whitney U test; a non-parametric 
equivalent to the t-test analyzes differences between two groups, and Kruskal-Wallis is 
the non-parametric analog to the Analyses of Variance (ANOVA) is used to compare two 
or more groups (Cubash, Joffe, Hanisch, Schuz, Neugut, Karsdaedt, … Jacobson 2013; 
Munro, 2005, p.123). The Kruskal-Wallis test assessed the differences between all the 
groups in the blocks of the RBD; whereas the Mann Whitney U test assessed the 
differences between the cases and control groups (Schoppmann et al., 2010). Significance 
level will be at p = .01. In addition, to evaluate the magnitude of the Her2 copy number 
gains between groups, the Incidence Rate Ratio (IRR) were also computed for Her2. The 
research questions and hypotheses are listed below for review. 
Research question #1) Do increasing concentrations of synthetic xenoestrogens 
significantly increase the Her2 copy numbers? 
Outcome/Dependent Variable: Her2 gene copy numbers  
Predictor/Independent Variable: Concentrations of xenoestrogens (0.000nM or 
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control, .1nM, .01nM, .001nM) and Receptor types (ER and Her2 positive and negative). 
Null (H01): There will be no significant increase in Her2 copy numbers with 
application with increasing concentrations of xenoestrogens. 
Alternate (H11): There will be a significant increase in Her2 copy observed with 
the application of xenoestrogens with increasing concentrations. 
Hypothesis: It was hypothesized that increasing the concentrations of the 
xenoestrogens would increase Her2 copy numbers. It will also do so for each cell line or 
receptor type. 
Research question #2) Do the concentration at which the increments in Her2 copy 
numbers become significant vary between the four xenoestrogens? 
Outcome/Dependent Variable: Her2 gene copy numbers  
Predictor/Independent Variable: Xenoestrogenic exposures of BPA, NPH, DDT, 
and Estrogen using .1nM, .01nM, .001nM concentrations. 
Null (H02): A significant increase in Her2 copy numbers occurred at similar 
concentration levels for all four xenoestrogens (BPA, NPH, DDT, and Estrogen). 
Alternate (H12): A significant increase in Her2 copy numbers occurred at 
different concentration levels for all xenoestrogens. 
Hypothesis: It was hypothesized that Her2 expressions will significantly increase 
for the four different xenoestrogens at different concentrations.  
Research question #3) Overall, is there a significant increase in the Her2 gene 




Outcome/Dependent Variable: Her2 gene copy numbers 
Predictor/Independent Variable: Exposure duration (short-term: single, short-
term vs. multiple, persistent), and Xenoestrogen (BPA, DDT, EE, NPH). 
Null (H03): No significant increase will be found in Her2 copy numbers between 
the short and long term applications of xenoestrogens. 
Alternate (H13): A significant difference in Her2 copy numbers will be found 
between short and long term xenoestrogenic exposures. 
Hypothesis: It was hypothesized that increasing the duration of xenoestrogenic 
exposures would significantly increase Her2 copy numbers overall and for each 
categorical xenoestrogen. 
Research question # 4) Overall, does the Her2 expression vary significantly with 
each specific receptor type (i.e., cell line) upon exposure to xenoestrogens? 
Outcome/Dependent Variable: Her2 gene copy numbers 
Predictor/Independent Variable: Receptor types/Cell lines (ER+/Her2+, ER-
/Her2-, ER+/Her2-, and ER-/Her2+) and Exposure durations (single, short-term vs. 
multiple, long-term). 
Null (H04): Her2 copy numbers will not vary significantly between the different 
receptor types/cell lines upon exposure to xenoestrogens. 
Alternate (H14): A significant difference will be found in the Her2 copy numbers 
between the different receptor types/cell lines upon exposure to xenoestrogens. 
Hypothesis: It was hypothesized that differential Her2 copy number increase will 
be noted between the different receptor types/cell lines when they are exposed to 
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xenoestrogens. However, each cell line would show significant Her2 copy number gains 
with multiple, persistent exposures compared to single, short-term exposures. 
Ethical Considerations 
The administration of xenoestrogens to human participants would be unethical 
since they could prove to be harmful (Brody & Rudel, 2003). Various animal studies 
conducted using xenoestrogens have provided evidence of their harmful effects. In fish, 
Lee, Raisuddin, Rhee, Kim, & Lee (2008a; 2008b) saw an increase in the ras oncogene 
and p53, a tumor suppressor gene in various tissues; such as intestine, liver, gonads after 
treatment with BPA and NPH/NP. Another study performed on rats by Zoeller, Bansal & 
Parris (2005) found that exposure with BPA can increase the levels of thyroid hormone 
signaling in the brain thereby affecting brain function and activity. Experiments done by 
Pandey, Pandey & Sharma (2011) using EE on rat liver lead to its degeneration and 
necrosis (i.e., death), thus, pointing to its toxic effects on liver cells. A recent study on 
female rats by Canales-Aguire, Padilla-Camberos, Gomez-Pinedo, Salado-Ponce, Feria-
Velasco & De Celis (2001) evaluated the effects of DDT on blood lymphocytes and 
mammary epithelia. Exposure to DDT induced genetic damage in both the lymphocytes 
and the mammary epithelial cells. 
The Agency for Toxic Substances & Disease Registry (ATSDR) has classified 
DDT as a probable carcinogen (i.e., a cancer causing agent) (ATSDR, 2011). 
Additionally, the Office of Environmental Health Hazard Assessment California 
Environmental Protection Agency concluded that although more studies are required to 
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determine the carcinogenicity of NPH, but the information available from the studies 
conducted are a cause for concern (OEHHS, 2009). 
The Belmont Report (1978) provides us with the basic framework of the ethical 
principles and regulations used for the protection of human participants in biomedical, 
behavioral, and experimental research. According to this report, there are three ethical 
principles that a researcher should abide by. Beneficence is one of the three principles of 
the report. Within the realm of this principle are formulated two rules. They are: 
1) Do not harm. Initially, this rule was introduced for those in the medical 
profession, but was later incorporated into research by Claude Bernard. He 
clearly stated that one should not harm or injure any person regardless of the 
benefits their research may reap for others. 
2) Maximize benefits and reduce possible harm.  
In summary, careful consideration was given to the nature of the xenoestrogens 
used in this research project, and their possible effects. Because administration of 
xenoestrogens to human participants can prove to be harmful, it is unethical to use human 
subjects for this study. Thus, the only permissible way to perform these experiments was 
in a laboratory-based setting using xenoestrogens in differential exposures on cell-lines 
obtained from regulated resources. The following chapter has provided a brief overview 
of the protocols used and a detailed description of the results obtained from this study. 
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Chapter 4: Results 
Introduction 
The purpose of the current study was to quantitatively assess Her2 copy numbers 
with FISH technology on four phenotypically disparate human breast cancer cell-lines 
that are ER- and Her2-positive or -negative lines (BT474, MCF7, MDA-MB-231, and 
SKBR3) after exposing them to differential exposures with four commonly used 
xenoestrogens (BPA, NPH, DDT, and EE), while the controls remain unexposed. Her2 
gene copy numbers for the cases and controls were counted and their differences 
evaluated for significance. Four research questions and hypotheses were addressed using 
a variety of statistical techniques. This chapter provides an overview of the protocols 
followed to conduct the experiments and summarizes the results of the descriptive and 
inferential analysis and assumptions used for this study. 
Protocols Used 
Harvesting and FISH 
Four breast cancer cell lines (BT474, MCF7, MDA-MB-231, and SKBR3) were 
ordered from ATCC. Upon arrival, these lines were coded by someone not involved in 
this project, and grown in flasks (T-75s) at 37º C with 5% CO2,using media 
recommended for their growth by ATCC. Once confluent, the cells from each line were 
passed into 32 smaller flasks (T-25s) using an enzyme, trypsin-EDTA (.05% for 5 
minutes at 37 ºC), and grown for another 4 days. From this point on, all the cells were fed 
with charcoal-stripped media for the global removal of hormones. Doing this assisted in 
the removal of extrinsic hormones present in the serum. Then, flasks were randomly 
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divided into case and control groups. The case flasks received the various treatments of 
xenoestrogens (BPA, DDT, EE, NPH), concentrations (.001, .01, and .1nM), durations (5 
day single, and 50 days daily), while the controls remained without any treatment. After 
treatment, cells were prepared for FISH analysis by cytogenetic direct preparation after 
trypsinzation (rinsed with Hanks balanced salt solution to get rid of the media, then use 
trypsin-EDTA .05% for 5 minutes at 37 ºC) from cells plated in flasks. Cells were then 
exposed to a hypotonic solution (.075M potassium chloride) for 20 minutes at 37ºC and 
washed thrice with 3:1 methanol: acetic acid fixative at room temperature. Slides were 
made using the fixed cell pellets for each control and treatment condition. FISH 
experiments were performed on cells/interphase nuclei using the Her2 breast cancer 
probe kit obtained from Abbott Molecular using manufacturer’s instructions. As the 
hybridization time given by the manufacturer is a range, the hybridization time used for 
this project was 24 hours at 37ºC. The slides were counter stained with DAPI/antifade 
(Vectashield, Vector Laboratories, Burlingame, California); the dye is absorbed by the 
nuclei and it gives a blue color to the nuclei for scoring purposes. The success rate of 
97.6% or 98% (125/128 experiments) was noted with the FISH results. Twenty nuclei 
were then counted for each case and control group using a fluorescent microscope (Zeiss 
AX-70 with CytoVision software) and cell counter.  
Assumptions for Kruskal Wallis Test 
Tests of Normality and Data Distribution 
The data distribution of signals was found to be non-normal. Figure 3 shows the 
graph and statistics table of Her2 signal distribution found with the normal curve overlay, 
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thus pointing to a non-normal distribution of data. A total of 2,500 nuclei were scored 
(N). Sixty nuclei for three exposure settings were not scored due to lack of hybridization 
in those cultures (missing values, N*). The mean and the median values are 81.2 and 30 
signals respectively, and the standard deviation was found to be higher than the mean 
(93.8 signals). As the data set had a non-normal distribution, conducting non-parametric 
tests (Kruskal Wallis and Mann Whitney U) was optimal to derive better statistical 
inferences as these tests do not conform to parameters (e.g., normal distribution).  
 
Figure 3. Histogram of non-normal distribution of Her2 for all lines. A normal 
distribution curve is shown in the overlay. Descriptive statistics of the Her2 signals for all 
cell lines are in the table on the right; where N is the total number of cells scored and N* 
are the missing values due to no hybridization. A standard deviation (SD) of 93.8 was 
greater than the mean measure of 81.2 for the Her2 signals observed in all the lines. 
 
The histogram for each individual line with the normal curve overlay further 
confirmed that each of the four cell lines have a non-normal Her2 signal distribution 
(Figures 4 a, b, c, and d). This descriptive data from the histograms also revealed that two 
of the lines had standard deviations that were above their means (MCF7 (ER+/Her2-); 
Her2 Signals (All 
Lines)   
N Valid 2,500 







mean: 5.7 and SD: 6.1, and MDA-MB-231 (ER-/Her2-); mean: 8.2 and SD: 11.4) as 
observed in Table 4. 
Table 4 
 
Descriptive Statistics for Histograms of Each Cell Line 




(Missing) Mean  Median SD Range 
BT474 ER+/Her2+ 620 20 165.5952 148 91.43026 567 
MCF7 ER+/Her2- 640 0 5.71 3 6.211 64 
MDA-MB-
231 ER-/Her2- 640 0 8.22 4 11.479 92 
SKBR3 ER-/Her2+ 600 40 152.49 143 60.411 322 
 






















Figure 4d. Histogram of Her2 Signals for Line SKBR3 (ER-/Her2+) 
 
Figures 4 (a-d). Histograms of Her2 signal distributions for individual line. A normal 
distribution curve is depicted in the overlay. All of the lines are observed with a non-
normal distribution. Of note, the standard deviation is greater than the mean for two cell 
lines (MCF7 and MDA-MB-231). N denotes the number of cells scored and N* are the 
missing values due to no hybridization. 
 
Because the histograms of line SKBR3 showed an almost normal distribution, I 
also graphed the Q-Q plots for the dependent variable (Her2 signal counts), and 
performed the Shapiro-Wilk’s test to further check for data normality. These Q-Q plots 
showed that each cell line was non-normally distributed (Figures 5 a, b, c and d). In the 
plots the normal expected values have been plotted in solid black lines and the Her2 
signal count values that were observed for each cell line in circles. It was noted that in 
each of the cell line the count values did digress off from the normal expected values of 
the solid black line. The Q-Q plots and the histograms also showed that the values of the 
Her2 counts were spread out over a wider range in all the samples, but was more 
prominent for lines MCF7 (ER+/Her2-) and MDA-MB-231 (ER-/Her2-) hence lending 
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to standard deviations that were greater than the mean values found in these two lines. 
These widespread values of the dataset further suggested that their means will not be an 
optimal way to measure the central tendency. 
 
 














Figure 5d. Q-Q Plots of SKBR3 (ER-/Her2+) 
 
Figures 5 (a- d). Normal Q-Q plots for individual cell line. The line in each plot shows 
the normal expected signals and the circles overlaying the expected values show each 
Her2 signal observed in each individual line and their digression from normal expected 




The Shapiro-Wilk test of normality was conducted to assess normality of the 
dependent variable (Her2 signal counts) for each cell line. The results of the test statistics 
are represented in Table 5.  
Table 5 
 
Shapiro-Wilk Test of Normality for Each Line 
   
Shapiro-Wilk     




0.894 620 0.000* 
(ER+/Her2+) 
        
MCF7 
0.587 640 0.000* 
(ER+/Her2-) 
        
MDA-MB-231 
0.51 640 0.000* 
(ER-/Her2-) 
        
SKBR3 
0.949 600 0.000* 
(ER-/Her2+) 
 
df = degrees of freedom, Sig. = Significance, * and boldface denotes  
Significant values (p = <.05) 
 
Null and Alternate hypothesis for Shapiro-Wilk test for normal distribution 
Null (H0): The data are normally distributed  
Alternate (H1): The data are not normally distributed  
The Shapiro-Wilk test showed a p value of <.05 for each of the four lines (BT474, 
MCF7, MDA-MB-231 and SKBR3), thus the alternate hypothesis was accepted for each 
line. 
Taken together, the results of the Shapiro-Wilk’s test (p = <.05) (Razali & Wah, 
2011) and a visual inspection of the histograms and the Q-Q plots showed that the Her2 
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signals were non-normally distributed in all four cell lines (BT474, MCF7, MDA-MB-
231 and SKBR3). These sample characteristics further confirmed that non-parametric 
methods (e.g., Kruskal-Wallis and Mann Whitney U) were best suited for the statistical 
assessment of this data-set due to its non-normal distribution. 
Homogeneity of Variances for Kruskal Wallis: Levene’s Test 
Another assumption besides non-normality of data for conducting Kruskal Wallis 
test is that the groups being compared should have homogeneous or similar type of 
variances amongst them. The test used for this is called Levene’s test (Gastwirth, Gel & 
Miao, 2009). Hence this test was performed on the four different types of cell lines used 
in this project. Table 6 represents Levene’s test statistics for the Her2 values found on 
four cell lines. 
Table 6 
 
Test Statistics for Levene’s Test 
Individual 
Differences 





            F        Sig. 
Between 
Groups 
.000                3 .000 .000 1.000 
Within 
Groups 
3.16E+08 2496 126640.51     
Total 3.16E+08 2499       
 
Note. Levene’s Test performed for homogeneity of variances on Her2 values found 
between the four cell lines (Sig. = 1.000 or p = >.05). 
 
Hypothesis for Levene’s test for distribution of variances between cell lines 
Null (Ho) and alternate (H1) hypothesis for the Levene’s test: 
Ho=the variances in Her2 values between the four cell lines were similar 
H1=the variances in the Her2 values between the four lines were dissimilar 
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The null (Ho) was accepted since the Her2 values found on all four cell lines showed that 
the differences in their data variances were similar or non-significant (p = >.05 or 1.00). 
Besides the non-normal distribution of the Her2 counts that were observed in each 
line, the homogeneity of variances data also showed that the variances between each line 
was similar, hence the non-parametric tests for the statistical analyses were used for this 
dataset to compute the inferential statistics.  
Descriptive Statistics for Xenoestrogen Categories, Concentrations, and Durations 
The medians, range and standard deviation (SD) were calculated for Her2 signals 
observed with the various xenoestrogens, concentrations, exposure durations and cell 
lines used. Since the data is non-normally distributed, the mean values were not included 
as it did not represent the central tendency of this dataset accurately. The range of Her2 
signals observed in each category (i.e., type of xenoestrogen used, concentrations, and 
exposures) were large (range: 1 to 597 signals). Interestingly, the lowest (3) and highest 
(579) Her2 signals were noted in BPA. Albeit, the lowest Her2 signals (3) observed were 
tied between control (no exposure), BPA, EE and NPH. The concentration Her2 signal 
values ranged from one observed in control (no treatment) and .001nM concentration, 
and the largest value observed was 597 signals with .01nM concentration. Lastly, for the 
exposure duration, the lowest value was 1 signal noted using a single, short-term 
exposure and the highest value was 597 noted with persistent, long-term exposures. 
Lastly, the lowest value (1) Her2 signal was noted in the two Her2- lines (i.e., MCF7: 
ER+/Her2-, and MDA-MB-231: ER-/Her2-), and the highest (597) Her2 signals were 
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observed in BT474 line which is ER+/Her2+. A summary of the descriptive statistics is 
listed below in Table 7. 
Table 7 
 
Descriptive Statistics Summary of Her2 Signals with Different Xenoestrogens, 
Concentrations, Exposure, and Lines 
Xenoestrogen N N* SE SD Min Q1 Median Q3 Max 
Control 160 0 4 50.54 1 3 25.5 79 210 
BPA 440 40 5.88 123.38 1 3 14 152 597 
DDT 480 0 4.29 94.06 2 5 62.5 128.75 497 
EE 480 0 4.16 91.05 2 3 47.5 156 354 
NPH 480 0 3.9 85.41 2 3 36.5 150 409 
Combined 460 20 3.72 79.83 2 4.25 32 146.75 362 
Concentration 
(nM) N N* SE SD Min Q1 Median Q3 Max 
Control  160 0 4 50.54 1 3 25.5 79 210 
0.001 800 0 2.7 76.48 1 3 37 115 459 
0.01 780 20 3.57 99.75 2 4 25 152 597 
0.1 760 40 3.87 106.82 1 5 32 170 587 
Exposure N N* SE SD Min Q1 Median Q3 Max 
Persistent 1260 20 3.12 110.9 2 5 50.5 180 597 
Single 1240 40 1.89 66.54 1 3 11 112.75 315 
Cell Line N N* SE SD Min Q1 Median Q3 Max 
BT474 
(ER+/Her2+) 620 20 3.67 91.43 30 101 148 205.75 597 
MCF7  
(ER+/Her2-) 640 0 0.246 6.211 1 3 3 6 65 
MDA-MB-231 
(ER-/Her2-) 640 0 0.454 11.479 1 3 4 8 93 
SKBR3            
(ER-/Her2+) 600 40 2.47 60.41 40 107 143 183 362 
 
Note. N = Total nuclei scored, N* = Missing values due to no hybridization, SD = 
standard deviation, SE = standard error, Min = minimum, Q1 = first quartile, Q3 =  




Percentage Change Analysis Using Raw Her2 Count Data 
Cell Lines 
For each cell line, the percent (%) Her2 copy number increase noted varied with 
the type of xenoestrogen used individually or in combination. For BT474 (ER+/Her2+), 
a 50% increase was observed between the lowest value with combined exposure (14,293) 
and the highest value with BPA exposures (23,908). For MCF7 (ER+/Her2-), only a 25% 
increase was observed between the lowest values observed with DDT exposures (15,376) 
and highest were with EE exposures (19,840). Cell line MDA-MB-231 (ER-/Her2-), 
showed a 100% increment in Her2 counts between the lowest values found with 
exposures to BPA (539) and highest values with exposures to DDT (1,629). Lastly, for 
SKBR3 (ER-/Her2+) line there was an 87.5% increase in Her2 signals between the 
lowest counts noted with EE exposures (478) compared to the highest count (1,221) 
found with combined exposures to all four xenoestrogens. 
In addition, the count values for all of the individual exposures to the four 
xenoestrogens in line MCF7 (ER+/Her2-) are within an 80 count range (478-557), except 
for combined exposures which is more than twice when compared to the highest value 
from the individual exposure range (557-1,221). In the case of line BT474 (ER+/Her2+), 
the count values for combined exposures are lower (14,293) compared to those found in 
individual xenoestrogenic exposures (range: 19,003-23,908). A possibility of this 
occurrence could be because the combined (.1nM) persistent exposures in this line 
yielded missing values (no hybridization). Table 8 represents the exact Her2 counts 
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Her2 Count Values for All Four Lines with Individual or Combined Exposures to BPA, 




Receptor              BPA         DDT             EE          NPH 





ER+/Her2+ 23,908 22,551 19,849 19,003 14,293 
MCF7 
 






539 1629 879 681 1,064 
SKBR3 
 
ER-/Her2+ 15,507 15,376 19,840 18,128 18,551 
 
Note. ER+ /- = Estrogen receptor positive or negative respectively, Her2+/- = Her2 
receptor positive or negative respectively. 
 
Exposure Concentrations & Durations 
Comparing percent increase between each type of xenoestrogen at the highest 
concentration of .1nM (nanomolar) to the control group surprisingly showed that the 
lowest (42%) increment in Her2 counts occurred with combined exposures to all 4 
xenoestrogens. The percent increase in Her2 counts were comparable for EE and DDT 
(75% and 72% respectively), and also the percent increase for BPA and NPH were nearly 
similar (65% and 63% respectively). The greatest increase in Her2 copies were found to 





Percent Changes in Her2 for Each Xenoestrogen (.1nM) & Control 
Xenoestrogen & Concentration (.1nM) N N* 
Total (∑) Her2 
counts Increase (%) 
Control (Unexposed) 160 7467 
BPA 140 20 14755 65.60% 
DDT 160 15798 71.63% 
EE 160 16396 74.80% 
NPH 160 14452 63.23% 
Combination 140 20 11392 41.62% 
 
Note. nM = nanomolar, N = total nuclei scored, N* = no hybridization, Total Her2 counts 
= sum of Her2 absolute count values for control and exposed groups. For each percent 
value, the sum of Her2 counts for each xenoestrogen was compared to the control group. 
 
 
Comparing percent increase in Her2 counts between each xenoestrogen exposure 
at the highest concentration (.1nM) with the control group for each cell line further 
showed a decline (2%) in Her2 counts for combined exposures in BT474 (ER+/Her2+), 
however, this may have occurred due to missing values in combined exposures at .1nM 
concentrations (no hybridization). The greatest increase in Her2 counts (121.6%) was 
noted in MCF7 (ER+/Her2-) line with combined exposures. For the individual 
xenoestrogens, the greatest increase for BPA, EE and NPH (97.8%, 87.5% and 80.3% 
respectively) all occurred in line BT474 (ER+/Her2+), and for DDT, the highest percent 
increase (117%) was found in MDA-MB-231 (ER-/Her2-) line. Of note, lines MCF7 and 
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MDA-MB-231 both have a Her2 negative receptor status. These results are represented 
in Table 10  
Table10 
 














BT474  Control 40   3065     
(ER+/Her2+)  BPA  40 8937 97.85% 
DDT  40 8297 92.10% 
EE  40 7832 87.50% 
NPH  40 7177 80.30% 
  Combination  20 20 3008   1.90% 
MCF7  Control  40 151 
(ER+/Her2-)  BPA  40 199 27.42% 
DDT  40 262 53.75% 
EE  40 208 31.75% 
NPH  40 249 49.00% 
  Combination  40   620 121.60%   
MDA-MB-
231   Control   40 189 
(ER-/Her2-)  BPA  40 480 87.00% 
DDT  40 722 117.00% 
EE  40 362 62.80% 
NPH  40 362 62.80% 
  Combination  40   561 99.20%   
SKBR3   Control 40 4062 
(ER-/Her2+)  BPA  20 20 5284 26.20% 
DDT  40 6517 46.41% 
EE  40 7994 65.22% 
NPH  40 6664 48.51% 
   Combination  40    7269 56.6    
 
Note. N=total number of nuclei scored, N* = missing values, nm = nanomolar, no hyb = 
no hybridization, % = percent, Increase/Decrease = total percent increase or decrease 




Comparing each line for the different durations of exposures used in the study 
(single vs. persistent exposures) at the highest concentration used (.1nM) with the 
controls (unexposed). An increase in Her2 was found in single as well as persistent 
exposures. However, the percent increase was greater in single vs. persistent exposures in 
line SKBR3 (ER-/Her2+) for each categorical xenoestrogen assessed (single vs. 
persistent exposures: DDT 61% vs. 67.3%, EE 94% vs. 42%, NPH 78% vs. 25.3%, and 
Combined 70.4% vs. 48%). BPA could not be assessed due to missing values (no 
hybridization) for single exposure condition. Surprisingly, in the case of EE, it was noted 
that the percent gain in Her2 copy numbers for persistent exposures was always lower 
compared to the single exposure in all four lines (BT474: 87.8% vs. 87.3%; MCF7: 
36.2% vs. 29.3%; MDA-MB-231: 73% vs. 58.6%; SKBR3: 94% vs. 42% for single vs. 
persistent exposures respectively), even though in the case of BT474 line the difference 
was very little (.5%). The highest increments between single and persistent exposures 
were found in line MCF7 (ER+/Her2-) combined exposures (139.4 – 23.72 = 115.68%), 
followed by BT474 (ER+/Her2+) BPA exposure, and MCF7 (ER+/Her2-) DDT 
exposure (65.6% and 52% respectively). Notably, the greatest percent increment of Her2 
signals between single vs. persistent exposure occurred in MCF7 line which is Her2- in 






Percent Changes in Her2 Counts between Individual Xenoestrogen (.1nM) & Controls 
for Single and Persistent Exposures 
 
Single Exposure (5 days) Persistent Exposure (50 days) 
Line & 









BT474  Control  20 1175 
 
20 1890 
 (ER+/Her2+) BPA 20 1945 49.2 20 6992 114.9 (65.7) 
 
DDT 20 2533 73.24 20 5764 101.2 (28) 
 
EE 20 3014 87.8^ 20 4818 87.3 
 
NPH 20 2941 85.81^ 20 4236 76.6 
  Combined 20 2942 85.84 no hyb N/A N/A  
MCF7 Control  20 52 
 
20 99 
 (ER+/Her2-) BPA 20 56 7.4 20 143 36.4 (29) 
 
DDT 20 61 16 20 201 68 (52) 
 
EE 20 75 36.2^ 20 133 29.31 
 
NPH 20 69 28 20 180 58.1 (30.1) 
  Combined 20 66 23.72 20 554 139.4 (115.6) 
MDA-MB-
231 Control  20 54 
 
20 135 
 (ER-/Her2-) BPA 20 95 55 20 240 56 (1) 
 
DDT 20 148 93.1 20 574 123.83 (30.73) 
 
EE 20 116 73^ 20 246 58.26 
 
NPH 20 100 59.8 20 262 64 (4.2) 
  Combined 20 141 89.23 20 420 103 (13.77) 
SKBR3 Control  20 1439 
 
20 2623 
 (ER-/Her2+) BPA no hyb N/A N/A   20 5284 67.31 
 
DDT 20 2697 61^ 20 3820 37.2 
 
EE 20 3986 94^ 20 4008 42 
 
NPH 20 3280 78^ 20 3384 25.33 
  Combined 20 3001 70.4^ 20 4268 48 
 
Note. N = total nuclei counted, Her2 = sum of Her2 counts, .1nM = exposure 
concentration in nanomoles, no hyb = no hybridization, Increase = total percent (%) 
increase compared to control for single and persistent exposures, ^ = percent increase 
greater with single compared to persistent exposures, Difference = increase in Her2 for 
persistent exposures compared to single exposure, ER- = estrogen receptor negative, ER+ 




An examination of percent changes that had occurred with the applications of 
each xenoestrogen (individually or in combination) from the lowest (.001nM) to the 
highest (.1nM) concentrations applied showed an increase in Her2 counts regardless of 
the duration of application (5 days and 50 days), except for line MCF7 (ER+/Her2-) with 
single (5 days) combined exposures; where a percent decline was noted (15.4%) in Her2 
counts with increasing concentrations. However, the percent change was found to 
increase (difference: 138) when the combined exposures to xenoestrogens are applied 
persistently (50 days).  
Interestingly, in line BT474, positive for both ER and Her2, all of the categorical 
xenoestrogens studied had a higher percent change with single, short-term exposure 
duration compared to persistent, long-term exposure duration. In this case, combined 
persistent exposures could not be ascertained or compared due to lack of hybridization of 
the Her2 signals. 
The greatest percent increase change of 315% was noted in line MDA-MB-231, 
negative for both ER and Her2, with combined persistent exposures, followed at 204% 
increase with combined persistent exposures in MCF7 line, which is ER-positive and 
Her2-negative. Also, the highest difference in percent change increase between single, 
short-term and persistent, long-term exposures was found in line MDA-MB-231 with 
combined persistent exposures at 250. Notably, both MDA-MB-231 and MCF7 lines are 
Her2-negative. 




Percent Changes in Her2 Counts with Lowest (.001nM) and Highest (.1nM) 
Concentrations of Xenoestrogens 
 
 
Single Exposure (5days) 
 

























BT474 BPA 20 1344 20 1945 44.7^ 20 5534 20 6992 26.34 
ER+/Her2+ DDT 20 1756 20 2533 44.24^ 20 4463 20 5764 29.15 
 
EE 20 1895 20 3014 59.05^ 20 3052 20 4818 57.86 
 
NPH 20 1782 20 2941 65.03^ 20 3396 20 4236 24.73 
 Comb 20 2447 20 2942 20.22   20 2501 0 NH N/A  
MCF7 BPA 20 47 20 64.47 37.17^ 20 115 20 143 24.34 
ER+/Her2- DDT 20 59 20 61 3.38^ 20 145 20 201 38.62 
 
EE 20 56 20 75 33.92 20 62 20 133 114 (80) 
 
NPH 20 52 20 69 32.69 20 76 20 180 136 (103) 
 Comb 20 78 20 66   15.4 20 182 20 554 204 (138) 
MDAMB231 BPA 20 93 20 95 2.15 20 85 20 240 
182.35 
(180) 
ER-/Her2- DDT 20 105 20 148 40.95 20 263 20 574 118 (77) 
 
EE 20 67 20 116 73.13 20 177 20 246 110 (37) 
 
NPH 20 72 20 100 38.88 20 91 20 262 
187.91 
(149) 
 Comb 20 85 20 141 65.88   20 101 20 420 315 (250) 
SKBR3 BPA 20 2757 0 NH N/A 20 2867 20 5284 84.30 
ER-/Her2+ DDT 20 2094 20 2697 28.79 20 2127 20 3820 78.6 (50) 
 
EE 20 2525 20 3986 57.14 20 2420 20 4008 65.61 (9) 
 
NPH 20 2690 20 3280 21.93 20 2709 20 3384 24.91 (2) 
 Comb 20 1718 20 3001 74.67^   20 3018 20 4268 40.48  
Note: Xeno = xenoestrogen, N = total nuclei counted, Her2 = sum of Her2 counts, .001 
and .1 = nanomolar concentrations, % = percent, Inc & Dec = % increase & decrease, 
Comb = combined exposures, ^ = % increase greater in single exposure compared to 
persistent exposures, Diff = difference of increase found with persistent exposures 
compared to single exposure, NH = no hybridization, ER+/- = ER positive/negative, 
Her2+/- = Her2 positive and negative. 
 
Inferential Statistics & Hypothesis Testing 
Hypothesis 1 
Research question #1) Do increasing concentrations of synthetic xenoestrogens 
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significantly increase the Her2 copy numbers? 
Null (H01): There will be no significant increase in Her2 copy numbers with 
application with increasing concentrations of xenoestrogens. 
Alternate (H11): There will be a significant increase in Her2 copy observed with 
the application of xenoestrogens with increasing concentration 
The first hypothesis predicted that increasing concentrations of the four commonly used 
xenoestrogens (BPA, DDT, EE and NPH) would increase Her2 copy numbers 
significantly with the log10 increase of concentration (.001, .01 and.1nM), and when 
each concentration is compared to the control (No Treatment) group. Kruskal Wallis test 
was performed for control (No Treatment) and all concentrations (.001nM, .01nM, and 
.1nM) of xenoestrogens applied to examine the relationship between the various 
concentrations of xenoestrogens as the predictor/independent variable and Her2 copy 
number as the outcome/dependent variable. The result of the Kruskal Wallis omnibus 
model was significant (p = 0.000). Table 13 displays the results of the Kruskal Wallis.  
Table 13   
Kruskal Wallis Results Comparing Her2 Copy Numbers Between Different 
Concentrations and Controls 
Concentrations N Mean Rank Chi-square df P 
Control (No exposure) 








2461         
Note: N = number of nuclei scored, df = degrees of freedom, P = 
asymptotic and 2-tailed, * and boldface numbers denote significant 




Post-hoc pairwise analysis performed showed that the Her2 copy numbers 
increased significantly (one-sided p < .000 or p = <.05) for all three concentrations (.001, 
.01 and .1nM) of xenoestrogens applied when compared to the control (No Treatment) 
group. Pairwise comparisons between the different groups of concentration showed that 
the Her2 copy numbers significantly increased between .001nM and .01nM 
concentrations of xenoestrogens (one-sided p = .008 or p = <.05), and the null hypothesis 
(H01) was rejected. However, the Her2 copy number increase was not significant 
between .01nM and .1nM concentration (one-sided p = .101, or p = >.05) concentrations 
of xenoestrogens applied, and the null (H01) was accepted in this case. Table 14 
represents the results of the post-hoc pairwise tests respectively.  
Table 14 
Pairwise Comparisons for Increasing Concentrations (Control, .001nM, .01nM and .1nM) 








.001nM -379.106 62.161 -6.099 0 0* 
Control, 0.00nM-.01nM -495.672 61.696 -8.034 0 0* 
Control, 0.00nM-.1nM -501.868 61.189 -8.202 0 0* 
.001nM -.1nM -116.564 37.15 -3.138 0 0* 
.001nM-.01nM -122.76 36.303 -3.381 0 0* 
.01nM-.1nM 6.196 35.501 0.175 0.861 1 
Note. Control = Unexposed, nM = nanomolar, Sig. = P value, asymptotic, 2-tailed, Adj. 
Sig. = Adjusted P-values, 2-tailed, * and boldface numbers denotes significance (p = 
<.01), Comparisons of samples with increasing concentrations are marked in bold. 
Each row tests the null hypothesis that the distribution of Her2 absolute values for 
Samples 1 & 2 is similar. 
 
 The box plot (Figure 6) below further displays the differences in Her2 







Figure 6. Box plots of Her2 copy numbers with different concentrations. The 
concentrations used are .001, .01 and .1nM. The control group remained unexposed. 
Differences between each concentration when compared to the control is significant (p = 
<.01). There is also a significant increase in the Her2 copy number between .001nM and 
.01nM (nanomolar) concentrations, however, this increase becomes non-significant (p = 
>.01) with the further increase in concentration from .01nM to .1nM. 
 
To further explore if the above noted concentration gradient existed in every cell 
line, Mann Whitney tests were performed on each line using a similar gradient (i.e., 
Control to .001nM, .001nM to .01nM and .01nM to .1nM). It was noted that although for 
lines BT474 and MCF7 significant increase in Her2 copy numbers does cap off at .01nM 
(p = >.01, single-tailed), this was not so for lines MDA-MB-231 and SKBR3. In both, 
MDA-MB-231 and SKBR3 lines the Her2 copy numbers increase significantly (p = <.01, 
single-tailed) even from .01nM to .1nM concentrations of the xenoestrogenic application. 
Another variation noted in cell line MDA-MB-231 was that the Her2 copy numbers do 
not significantly increase (p = >.01, single-tailed) between the Control and .001nM 




Mann Whitney Results for Increasing Concentrations of Xenoestrogen Application for 
Individual Line 
Cell Line & 








ER+/Her2+ 40 59.39 2375.5 1555.5 2375.5 -6.1 0.000* 
BT474 .001nM 
  200 132.72 26544.5         
Total 
  240 
    
        
BT474 .001nM 
  200 172.47 34493.5 14393.5 34493.5 -4.85 .000* 
BT474 .01nM   
200 228.53 45706.5 
Total   
400     
BT474 .01nM 
  200 181.19 36238.5 16138.5 36238.5 -1.741 0.082 
BT474 .1nM 
180 200.84 36151.5 
Total             380   
MCF7, Control 
ER+/Her2- 40 82.75 3310 2490 3310 -3.927 .000* 
MCF7 .001nM 
  200 128.05 25610       
Total 
  240 
    
  
    
MCF7 .001nM 
  200 185.92 37184 17084 37184 -2.602 .009* 
MCF7 .01nM 
  200 215.08 43016 
Total 
  400     
MCF7 .01nM 
  200 191.67 38333 18233 38333 -1.56 0.119 
MCF7 .1nM 
  200 209.34 41867 
Total 
  400             
MDA-MB-231, Control 
ER-/Her2- 40 102.24 4089.5 3269.5 4089.5 -1.91 0.056 
MDA-MB-231 .001nM 
  200 124.15 24830.5 
Total 
  240 
    
MDA-MB-231 .001nM 
  200 185.04 37007.5 16907.5 37007.5 -2.768 .006* 
MDA-MB-231 .01nM 
  200 215.96 43192.5   
Total 
  400       
MDA-MB-231 .01nM 
  200 177.17 35433.5 15333.5 35433.5 -4.092 .000* 
MDA-MB-231 .1nM 
  200 223.83 44766.5   
Total   400             






Cell Line & 








/Her2+ 40 88.11 3524.5 2704.5 3524.5 -3.232 0.001* 
SKBR3 .001nM 
  200 126.98 25395.5   
Total 
  240 
    
  
SKBR3 .001nM 
200 159.4 31879.5 11779.5 31879.5 -5.819 .000* 
SKBR3 .01nM 
  180 225.06 40510.5   
Total 
  380       
SKBR3 .01nM 
  180 155.61 28010 11720 28010 -4.538 .000* 
SKBR3 .1nM 
  180 205.39 36970 
Total 
  360             
 
Note. Control = No exposure, nM = nanomolar, N = number of nuclei scored, MWU = 
Mann Whitney U statistic, ER+/ER- = ER positive or negative respectively, Her2+/ 
Her2- = Her2 positive and negative respectively, P = asymptotic and 2- tailed, * and 
boldface numbers denote significant values (p = ≤.01, 1-tailed). 
 
Additionally, the incidence rate ratios (IRR) were analyzed using the negative 
binomial on the Her2 count data, since the variances were larger than the mean 
(Ngatchou-Wandji and Paris, 2011). The control (No treatment) group was used as the 
reference (1.00). The results of IRR performed showed that the incidence of Her2 copy 
number increase was 25% (IRR: 1.25, 95% CI = 1.13 to 1.38, p = .000), 58% (IRR: 1.58, 
95% CI = 1.43 to 1.75, p = .000), and 96% (IRR: 1.96, 95% CI = 1.77 to 2.17, p = .000) 
more between the control and .001nM, .01nM, and .1nM concentrations of 
xenoestrogenic exposures respectively. These results showed that there was a steady 
increase in the Her2 copy numbers from the lowest concentration of .001nM to .01nM 
and the highest concentration of .1nM of exposure concentrations when compared to the 











value IRR 95% CI 
            LCI UCI 
No Treatment 
(Reference) 1.00 
(Dose)-0.001nM 0.22 0.05 4.29 0.000* 1.25 1.13 1.38 
(Dose)-0.01nM 0.46 0.05 8.80 0.000* 1.58 1.43 1.75 
(Dose)-0.1nM 0.67 0.05 13.01 0.000* 1.96 1.77 2.17 
 
Note. CI = confidence interval, % = percent, Z = z value, nM = nanomolar, Est. = 
estimated, LCI = lower confidence interval, UCI = upper confidence interval, Std. Err = 
standard error, * and boldface represent significant values (p = <.01), Control 
(unexposed) group was used as the reference. Scaled at 1.00 
 
Hypothesis 2 
Research question #2) Do the concentration at which the increments in Her2 copy 
numbers become significant vary between the four xenoestrogens? 
Null (H02): A significant increase in Her2 copy numbers occurred at similar 
concentration levels for all four xenoestrogens (BPA, NPH, DDT, and Estrogen). 
Alternate (H12): A significant increase in Her2 copy numbers occurred at 
different concentration levels for all xenoestrogens. 
The second hypothesis predicted that Her2 copy numbers will increase 
significantly with similar concentrations of the four xenoestrogens applied. To examine 
this, I performed the Mann Whitney U (MWU) test to individually assess each 
xenoestrogen (BPA, DDT, EE, and NPH) applied at various concentrations applied (.001, 
.01 and .1nM) and compared to the control group for significance. The dependent 
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variable was Her2 copies and the predictor variables were xenoestrogens at the different 
concentrations. The results of this test showed that for each category of xenoestrogen 
(BPA, DDT, EE, and NPH) there was a significant increase (p = <.01, single-tailed) in 
Her2 copy numbers at the lowest concentration (.001nM) for all of the 4 xenoestrogens, 
applied individually or in combination. Because significant increases in Her2 copy 
numbers were found to be at the same concentration (.001nM) for all categories of 
xenoestrogens applied, the null hypothesis (H02) was accepted. 
Although, significant increase (p = <.01, single-tailed) was observed for all 4 of 
the commonly used xenoestrogens at the lowest concentration (.001nM) of application, 
but interestingly in the case of BPA, the increase of Her2 copy numbers for exposures at 
.01nM concentrations were not significant (p = .018, single-tailed or p = >.01). However, 
with the further increase in concentration (.1nM) the increase in Her2 copy numbers did 
become significant once again (p = <.01, single-tailed). Table 17 represents the results 
















MWU Wilcoxon  Z 
   P (2-
tailed) 
BPA 0.001 160 174.43 27909.5 10570.5 23450.5 -2.708 0.007* 
Control No exposure 160 146.57 23450.5 




      
BPA 0.01 140 161.64 22629 9641 22521 -2.09 0.037 
Control No exposure 160 140.76 22521 
Total   300 
BPA 0.1 140 164.58 23041.5 9228.5 22108.5 -2.645 0.008* 
Control No exposure 160 138.18 22108.5 
Total   300             
DDT 0.001 160 175.39 28062 10418 23298 -2.891 0.004* 
Control No exposure 160 145.61 23298 





DDT 0.01 160 180.8 28928.5 9551.5 22431.5 -3.942 0.000* 
Control No exposure 160 140.2 22431.5 
Total   320 
DDT 0.1 160 188.24 30118 8362 21242 -5.374 0.000* 
Control No exposure 160 132.76 21242 
Total   320             
EE 0.001 160 172.94 27670.5 10809.5 23689.5 -2.424 0.015* 





EE 0.01 160 181.17 28986.5 9493.5 22373.5 -4.016 0.000* 
Control No exposure 160 139.83 22373.5 
Total   320 
EE 0.1 160 186.2 29792 8688 21568 -4.983 0.000* 
Control No exposure 160 134.8 21568 










N Mean Rank 
Sum of 
Ranks 
MWU Wilcoxon  Z 
   P (2-
tailed) 
NPH 0.001 160 172.39 27582 10898 23778 -2314 0.021* 





NPH 0.01 160 180.11 28817.5 9662.5 22542.5 -3.816 0.000* 
Control No exposure 160 140.89 22542.5 
Total   320 
NPH 0.1 160 185.86 29737.5 8742.5 21622.5 -4.922 0.000* 
Control No exposure 160 135.14 21622.5 
Total   320             
Combined 0.001 160 176.05 28168.5 10311.5 23191.5 -3.02 0.003*  





   
Combined 0.01 160 185.1 29616.5 8863.5 21743.5 -4.77 0.000* 
Control No exposure 160 135.9 21743.5 
 
Total   320 
 
Combined 0.1 140 170.51 23871.5 8398.5 21278.5 -3.75 0.000* 
Control No exposure 160 132.99 21278.5 
Total   300             
 
Note. N = total nuclei scored, MWU = Mann Whitney U statistic, P = asymptotic and 2-
tailed, Total = sum of nuclei scored for the xenoestrogen (applied individually or in 




Research question #3) Overall, is there a significant increase in the Her2 gene 
copies between short-term (5 days) and persistent/long-term (50 days) exposures to the 
xenoestrogens? 
Null (H03): No significant increase will be found in Her2 copy numbers between 
the short and long term applications of xenoestrogens. 
Alternate (H13): A significant difference in Her2 copy numbers will be found 
between short and long term xenoestrogenic exposures. 
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The third hypothesis predicted that there would be a significant increase in Her2 
copy numbers between xenoestrogens applied for a single, short-term (5 days) exposure 
when compared to persistent, and long-term (50 days) applications. To test this 
hypothesis, I conducted the Mann Whitney U analysis for both durations of 
xenoestrogenic application (single, short-term and persistent, long-term) as the 
predictor/independent variables and Her2 copy number as the dependent variable. The 
results of the analysis indicated that a significant increase of Her2 copy numbers had 
occurred with the increasing durations of xenoestrogenic exposures (p = .000). Also, 
since the Mann Whitney U test results are two-tailed, thus the significance values for a 
single-tailed experiment can be divided by two. This would make the p-value even lower 
than .000 (p = <.000). Thus, the alternate hypothesis (H13) was accepted. The results are 
presented in Table 18, and Figure 7 shows the representative box plot.  
Table 18 
 
Mann Whitney U Results of Her2 Copies for Short & Long-term Xenoestrogenic 
Exposures 
Exposure Type & Duration N Mean Rank Sum of Ranks MWU Wilcoxon  Z 
P (2-
tailed) 
Single, short-term (5 days) 1240 1083.25 1343235.5 573815.5 1343235.5 -11.528 .000* 
Persistent, long-term (50 days) 1260 1415.09 1783014.5 
Total 2500             
 
Note. N = number of nuclei scored, MWU = Mann Whitney U statistic, P = asymptotic 






Figure 7. Box plot of Her2 copies with short-term and long-term exposures. Significant 
(p = <.000) in Her2 copies were observed with persistent, long-term (exposed daily for 
50 days) when compared to single, short-term exposures (cultured for 5 days) with BPA, 
DDT, EE and NPH. 
 
Incident rate ratios (IRR) of Her2 copy numbers between single, short-term and 
persistent, long-term exposures were also calculated using negative binomial (Ngatchou-
Wandji & Paris, 2011). Single, short-term exposure was used as the reference. These 
results found an 86% increase (IRR: 1.86, LCI = 1.78 and UCI = 1.94, p = .000*) in the 
incidence of Her2 copy numbers with persistent, long-term exposures compared to 
single, short-term exposure durations. 
To further explore whether the increase in Her2 copy numbers occurs in some or 
all of the four xenoestrogens with their application duration, I conducted the Mann 
Whitney U test for each individual xenoestrogen that compared the Her2 copy numbers 
between single, short-term exposure duration and persistent, long-term exposure duration. 
The results of the Mann Whitney U tests for each of the 4 commonly used xenoestrogens 
further showed a significant increase in the Her2 copy numbers with increasing duration 
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of their use (p = .000). Thus, the alternate hypothesis (H13) was accepted for each 
individual xenoestrogen. The results of this research inquiry are presented in Table 19. 
Table 19 
 
Mann Whitney U Results of Her2 Copy Numbers for Single vs. Persistent Exposures of 











Z P (2-tailed) 
BPA, single exposure 200 165.71 33142.5 13042.5 33142.5 -8.284 0.000* 
BPA, persistent 
exposures 
240 266.16 63877.5 
Total 440 
    
DDT, single exposure 240 206.47 49552.5 20632.5 49552.5 -5.384 0.000* 
DDT, persistent 
exposures 
240 274.53 65887.5 
Total 480 
      
EE, single exposure 240 218.16 52358 23438 52358 -3.542 0.000* 
EE, persistent exposures 240 262.84 63082 
Total 480 
  
NPH, single exposure 240 217.02 52084 23164 52084 -3.727 0.000* 
NPH, persistent 
exposures 





240 207.11 49706.5 
20786.5 49706.5 -3.948 0.000* 
Combinatorial, persistent 
exposures 
220 256.02 56323.5 
Total 460             
 
Note. N = number of nuclei scored, Single exposure = cells were exposed to 
xeneoestrogen/s once and harvested on 5th day, Persistent exposure = cells were exposed 
daily with xenoestrogen/s and harvested on the 50th day, MWU = Mann Whitney U 
statistic, P = asymptotic and 2-tailed, * and boldface numbers denotes significant values 
(p = ≤.01). 
 
Hypothesis 4 
Research question # 4) Overall, does Her2 gene expression vary significantly 
with each specific receptor type (i.e., cell line) upon exposure to xenoestrogens? 
Outcome/Dependent Variable: Her2 gene copy numbers 
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Predictor/Independent Variable: Receptor types/Cell lines (ER+/Her2+, ER-
/Her2-, ER+/Her2-, and ER-/Her2+) and Exposure durations (single, short-term vs. 
multiple, long-term). 
Null (H04): Her2 copy numbers will not vary significantly between the different 
receptor types/cell lines upon exposure to xenoestrogens. 
Alternate (H14): A significant difference will be found in the Her2 copy numbers 
between the different receptor types/cell lines upon exposure to xenoestrogens. 
The fourth hypothesis predicted that the magnitude or amount increase of the 
Her2 copy numbers noted between the different receptor types found in the 4 lines when 
they are exposed to xenoestrogens would vary significantly. To test this hypothesis, I 
performed the Kruskal Wallis test using the 4 cell lines as the predictor/independent 
variables and Her2 copy number as the outcome/dependent variable. These results were 
found to be significant for the receptor types found in the four cell lines (p = .000). The 
results from the Kruskal Wallis omnibus are represented below in Table 20. 
Table 20  
Kruskal Wallis Test for Her2 Signals and Different Receptors 
Cell Line Receptors N      Mean Rank Chi-Square df P (2-tailed) 
BT474 (ER+/Her2+) 620 1894.38 1888.416 3 0.000* 
MCF7 (ER+/Her2-) 640 578.08 
MDA-MB-231 (ER-/Her2-) 640 705.03 
SKBR3 (ER-/Her2+) 600 1884.23 
Total   2500         
Note: N = number of nuclei scored, df = degrees of freedom, P = asymptotic and 2-




Because the results of the Kruskal-Wallis omnibus were significant, post-hoc 
pairwise comparisons were conducted to check for similarities in Her2 copy numbers 
between the different receptor types. The pairwise analyses found significant differences 
(adjusted p = ≤.005 for one-sided test, or p = <.01) for Her2 copy numbers increments 
observed between all of the different pairs of receptor types found in the various lines, 
except for ER-/Her2+ (SKBR3) and ER+/Her2+ (BT474) lines where the distribution of 
Her2 copies were similar (adjusted p = .5 for one-sided test, or p = >.01). The results 
from the post-hoc pairwise analysis for this hypothesis are represented below in Table 21. 
Table 21 
Post-hoc Pairwise Comparison of the Different Receptor Types and Her2 Signals 
Sample 1 - Sample 2 Test Statistic Std. Error Std. Test  Statistic Sig. Adj. Sig. 
ER+/Her2- and ER-/Her2- -126.95 40.226 -3.156 0.002     0.010* 
(MCF7 – MDA-MB-231)           
ER+/Her2- and ER-/Her2+ -1,306.15 40.891 -31.943 0 0.000* 
(MCF7 – SKBR3)           
ER+/Her2- and 
ER+/Her2+ 1,316.30 40.549 32.462 0 0.000* 
(MCF7 – BT474)           
ER-/Her2- and ER-/Her2+ -1,179.20 40.891 -28.838 0 0.000* 
(MDA-MB-231 – SKBR3)           
ER-/Her2- and ER+/Her2+ 1,189.35 40.549 29.331 0 0.000* 
(MDA-MB-231 – BT474)           
ER-/Her2+ and 
ER+/Her2+ 10.152 41.208 0.246 0.805 1 
(SKBR3 – BT474)           
 
Note: Sig = P-value, asymptotic significance (2-tailed), Std. Error = standard error, Adj. 
Sig = Adjusted P-values (2-tailed), * and boldface numbers denotes significant values (p 
= ≤.01 of adjusted significance).  





To further elucidate the magnitude of increase found in the different receptor 
types, the IRRs were examined using the negative binomial model. Since ER+/Her2- 
(MCF7) line showed the lowest increase in its Her2 copy number changes with exposures 
(single and persistent) to the various xenoestrogens; it was used as the reference line 
(1.00). The IRR results indicated that the incident rates of Her2 copy number increase for 
both of the Her2 positive lines regardless of their ER receptor status (BT474: ER+/Her2+ 
and SKBR3: ER-/Her2+) is 30 times greater than the reference which was Her2 negative 
(95% CI, BT474: 28.81 to 32.59, and SKBR3: 27.88 to 31.58, p = .000). Additionally, 
the incidence rates of Her2 for the line negative (or normal) for both ER and Her2 
receptors (MDA-MB-231: ER-/Her2-), showed a 44% increase (IRR: 1.44, 95% CI = 
1.35 to 1.54, p = .000) in its Her2 copy numbers when compared to the reference line. 
Because significant differences found were significant for all receptor types, the null 
(H04) was rejected. The IRR results are represented in Table 22. 
Table 22 
 
Incidence Rate Ratios (IRR) of Her2 Copy Numbers between the Receptor Types 








ER-/Her2+ (SKBR3) 3.39 0.03 107.42 0.00000* 29.67 27.88 31.58 
ER+/Her2+ (BT474) 3.42 0.03 108.99 0.00000* 30.64 28.81 32.59 
ER-/Her2- (MDA-MB-231) 0.37 0.03 10.68 0.00000* 1.44 1.35 1.54 
 
Note. CI = confidence interval, LCI = lower confidence interval, UCI = upper confidence 
interval, * and boldface denotes significant values (p = <.01). 
MCF7 line was used as the reference line (1.00), because the lowest levels of Her2 





To check whether the Her2 gene copy numbers increased significantly for each 
line with increasing exposures durations to the 4 commonly used xenoestrogens, 
comparisons between the single vs. persistent exposures were made for individual lines 
using the Mann Whitney U test. Highly significant results (p = <.01) were observed 
between the single vs. persistent exposures for all 4 lines, hence the alternate (H14) was 
accepted for all of the lines in this case. The results of the Mann Whitney U tests 
conducted for this hypothesis are displayed in Table 23 below. 
Table 23 
 
Comparison of Her2 Absolute Values for Single vs. Persistent Exposures in Individual 
Line 

















BT474, Single ER+/Her2+ 300 174.59 52377.5 7227.5 52377.5 -17.244 0.000* 
BT474, Persistent   280 414.69 116112.5 
Total   580             
MCF7, Single ER+/Her2- 300 205.25 61574 16424 61574 -13.812 0.000* 
MCF7, Persistent    300 395.75 118726 
Total   600             
MDA-MB-231, 
Single 
ER-/Her2- 300 256.35 76904 31754 76904 -6.37 0.000* 
MDA-MB-231, 
Persistent 
  300 344.65 103396 
Total   600             
SKBR3, Single ER-/Her2+ 260 235.79 61304.5 27374.5 61304.5 -6.088 0.000* 
SKBR3, Persistent   300 319.25 95775.5 
Total   560             
 
Note. N = total nuclei scored, Single = cells exposed to xeneoestrogen/s once and 
harvested on 5th day, Persistent = cells exposed daily with xenoestrogen/s and harvested 
on the 50th day, ER+ = Estrogen receptor positive, ER- = Estrogen receptor negative, 
Her2+ = Her2 receptor positive, Her2- = Her2 receptor negative, P = asymptotic and 2-





Sample characteristics and data distribution using histograms, Q-Q plots and 
Shapiro-Wilk’s tests of normality all showed non-normal distribution of the dependent 
variable (i.e., Her2 signals) for all four cell lines. The data were also found to be highly 
dispersed, leading to a greater standard deviation (SD) than the mean values in two of the 
cell lines (MCF7 and MDA-MB-231). A Levene’s test was conducted that further 
evaluated the similarity in the variances of the four lines which was non-significant. This 
meant that the differences in the variances between the four lines were similar. Since the 
assumptions for Kruskal Wallis analysis were cleared with the non-significant result of 
Levene’s test, inferential statistics using this test were then performed. 
The inferential analysis of this research study data supports hypothesis 3 and 4. 
Significant increase in the Her2 copies were incurred with multiple, persistent exposures 
consisting of daily exposures of the xenoestrogens for 7 weeks compared to the single, 
short-term exposure cultured for five days. This held true for each categorical 
xenoestrogen (BPA, DDT, EE and NPH) applied individually or in combination, and for 
each receptor type (ER and Her2 positive and negative). The various receptor types were 
found to be significantly different in their responses to the xenoestrogens and they were 
all found to incur significant increases in their Her2 values compared to the reference line 
(MCF7, ER+/Her2-) that had the least amount of Her2 copy number gain. 
For hypothesis 1, a similar patterns of Her2 copy number gains were noted (i.e., 
from control (unexposed) to .001nM to .01nM) with both the cell lines with ER positive 
status (BT474, ER+/Her2+; and MCF7, ER+/Her2-) as was found with the overall 
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exposures for all 4 lines. However, the patterns were dissimilar with respect to the other 
two lines. Here, one line (SKBR3, ER-/Her2+), the alternate was accepted, as in this line 
the Her2 copy numbers did increase significantly (p = .000) with the control and each 
log10 increase in concentration (i.e., control to .001nM to .01nM to .1nM); whereas the 
other line (MDA-MB-231, ER-/Her2-) did show a significant increase in Her2 copies (p 
= .000) between each categorical exposure concentration (i.e., .001nM to .01nM to 
.1nM), but a significant gain in Her2 copy numbers did not occur between the control 
(unexposed) and .001nM exposure concentration. The alternate was accepted for line 
SKBR3 (ER-/Her2+) for all concentration gradients. For lines BT474 and MCF7, the 
alternate was accepted for concentration increase from control (unexposed) to .001nM to 
.01nM of exposures. Lastly, for MDA-MB-231 (ER-/Her2-) line, the alternate was 
accepted for concentration increase from .001nM to .01nM to .1nM of exposures.  
With regards to hypothesis 2, although the alternate hypothesis supported a 
significant increase in the Her2 copy numbers with dissimilar concentrations of the 
various xenoestrogens due to their disparate nature, but interestingly all four of the 
xenoestrogens studied (BPA, DDT, EE and NPH) were observed to significantly increase 
in their Her2 values at the lowest nanomolar concentration of .001nM. This also held true 
for individual as well as combinatorial exposures. Thus, the null hypothesis was accepted 
in this case. 
The following chapter has summarized the study, discussed social change 
implications of the study findings; presented the limitations of the study, pointed out 
future perspectives, and presented concluding remarks. 
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Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
Xenoestrogens are substances with estrogenic properties, and repeated exposures 
with synthetic xenoestyrogens could chemically modulate the promotion and progression 
of breast cancer (Aube, Larochelle, & Ayotte, 2013; Brody & Rudel, 2003; Valeron, 
Pestano, Luzardo, Zumbado, & Boada, 2009). Her2, a proto-oncogene, is found in two 
copies in a normal mammary cell and is required for its normal development and 
function. However, it can mutate by amplification and become oncogenic (i.e., cancer-
causing gene). Also for the normal functioning of the mammary cell, cross-
communications occur between the ER and Her2 receptors at the cell’s surface, which 
further activates the Her2 gene within the cell’s nucleus (Her2 gene expression) (Stoica 
et al., 2003; Yang, Barnes, & Kumar, 2004), and the nuclear ER (Jung et al., 2010; 
Montemurro, Di Cosimo, & Arpino, 2013). Hence, the perturbations of the ER with 
repeated extrinsic xenoestrogenic exposures could perturb the Her2 proto-oncogene, 
thereby converting it to an oncogene. Animal models have demonstrated a connection 
between xenoestrogenic exposures and Her2 gene activity; however, the carcinogenic 
potential influencing the expression of the Her2 gene upon exposures to commonly used 
xenoestrogens has not been systematically examined. 
Using molecular genetics techniques (FISH) with a case-control study design, this 
study assessed Her2 gene expression with differential exposures to 4 commonly used 
household xenoestrogens (BPA, DDT, EE, and NPH) using 4 human breast cancer lines 
that were ER- and Her2-positive or -negative providing mechanistic insights to the 
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carcinogenicity of these xenoestrogens and evaluated their carcinogenic potential. 
Additionally, the study discerned cellular phenotypes more susceptible to aggressive 
disease with exposures to these xenoestrogens. 
Summary and Interpretation of Findings 
In a study conducted by Calfat et al. (2005) on 1,000 participants, the authors 
observed that 95% and 51% had more than 0.1microgram/Liter (µg /L) urine 
concentrations of BPA and NPH respectively, indicating that people are being exposed to 
at least 0.1 µg/L concentrations of BPA and NPH. In another study by Calafat et al. 
(2008) consisting of over 2,500 Americans, BPA concentrations ranging from 0.4 to 149 
μg/L (mean=2.6 μg/L) were found in 92.6% of the study participants. The average levels 
of total BPA in male and female urine was 1.63 and 1.12 ng/ml (nanograms/milliliter) 
respectively. Additionally, Vandenburg, Maffini, Sonnenschein, & Soto (2009) estimated 
that adult human exposures to BPA ranged from <1 µg/Kg/day to 5 µg/Kg/day. 
Collectively, these data showed that human exposures to BPA ranged anywhere from 
1.12 ng/ml to 5 µg /Kg/day. 
In the current study, I applied xeneoestrogens in increasing log10 ratios of 
nanomolar concentrations (i.e., .001nM, .01nM, and .1nM), and observed that even the 
lowest concentrations (.001nM) of xenestrogenic applications significantly increased the 
Her2 copy numbers when compared to the control (p = .000). Ad hoc pairwise 
comparisons found significant increase (p = .000) in every concentration category applied 
(.001nM, .01nM, and .1nM), when compared to the control group. 
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The incidence rate ratio (IRR) values further showed that the Her2 copy number 
increase was almost twice as much (1.96, or 96% greater) with the applications of .1nM 
(highest) concentrations of xenoestrogen when compared to the control. The incidence of 
Her2 increase was also found to have increased with increasing concentrations applied 
compared to the control. An increase of 25% (IRR: 1.25, p = .000) of Her2 copy numbers 
was found in the lowest concentration of xenoestrogenic application, which steadily 
increased to 58% (IRR: 1.58, p = .000) at .01nM concentration of xenoestrogenic 
exposures, and capped off at 96% (1.96, p = .000) with the highest concentration (.1nM) 
of xenoestrogenic applications compared to the control. Comparing the three 
concentrations to the control group, there was a 33% increase (from 25% to 58%) in Her2 
copy numbers between .001 and .01nM concentrations, and a 38% increase (from 58% to 
96%) observed in the Her2 copies between .01 and .1nM concentrations of 
xenoestrogenic exposures. Thus, it can be inferred from Hypothesis 1 that Her2 oncogene 
expression had increased even with nanomolar (nM) concentrations of xenoestrogenic 
applications compared to the control.  
Interestingly, when comparing within the three different concentration groups, the 
pairwise comparisons found that that there was a significant increase (p = .008) in the 
Her2 copy numbers ascending from .001nM to .01nM concentrations; however, a 
significant increase in the Her2 copy numbers was not observed (p > .05) moving from 
.01nM to .1nM concentration. This further implied that the lowest concentrations could 
be more lethal in the case of Her2 gene copy number gains and mutations of this gene.  
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Each line used in the study constituted of different types of receptors (ER and 
Her2 positive or negative) and I further wanted to assess whether each line reacts 
differently to xenoestrogenic exposures. Thus, Hypothesis 1 also examined whether the 
increments in Her2 copy numbers were similar or not for each receptor type with 
increasing concentrations of exposures to the 4 commonly used xenoestrogens. 
Interestingly, different patterns emerged for these lines. Both lines that were ER+ (i.e., 
BT474 and MCF7) showed a similar pattern as was observed with the overall 
concentrations; that is, Her2 copies increased significantly until .01nM exposure 
concentrations to the 4 commonly used xenoestrogens and then they became non-
significant (control to .001nM, and .001nM to .01nM, p = .000). However, for the lines 
that were ER- (i.e., MDA-MB-231 and SKBR3), the values in Her2 copy numbers had 
increased significantly (p = .000) even from .01nM to .1nM concentrations of exposures 
to the 4 xenoestrogens. Also, for line MDA-MB-231, there was no significant increase in 
the Her2 copy numbers found between the control and .001nM concentrations of 
exposures to the xenoestrogens. 
Previous research has indicated that some xenoestrogens are slow-activators while 
others react quickly and are fast-activators of the cellular membrane (Bulaveya & 
Watson, 2004; Payne, Rajapakse, Wilkins, & Kortenkamp, 2000). Nuclear transcriptional 
assays performed that assessed their potency showed that some xenoestrogens were very 
weak (e.g., DDE), while others were somewhat weak (e.g., BPA), yet others were quite 
strong (e.g., DES) in their estrogenic activity (Silva, Scholze, & Kortenkamp, 2007). 
Together, these studies provided that even though xenoestrogens are categorically 
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grouped under one umbrella, they interacted differentially within biological systems. 
Also, because the biochemical nature of xenoestrogens is disparate, it follows that the 
carcinogenicity of xenoestrogens used individually as well as in combination may be 
quite different. 
In this study, one way carcinogenicity of these four (i.e., BPA, DDT, EE, and 
NPH) commonly used household xenoestrogens was assessed was by examining the 
concentrations at which significant increase in Her2 copy numbers initiated and when it 
plateaus off for each xenoestrogen. Keeping in mind lessons from the past research 
regarding the disparity of their biochemical nature, because some (e.g., DDT) are fast 
activators, whereas others (e.g., BPA and NPH) are moderate and slow activators 
respectively, it was proposed in Hypothesis 2 that the four xenoestrogens would 
significantly increase Her2 copies at different concentrations of exposures when 
compared to the control. Further, there would be differences in concentrations at which 
individual vs. combinatorial exposures significantly increased in their Her2 copy 
numbers. 
Surprisingly, the Mann Whitney test statistics showed that not only did all four 
(BPA, DDT, EE, NPH) commonly used household xenoestrogens incurred significant (p 
= .000) increases in Her2 copies at similar concentration, but this held true for individual 
as well as combinatorial xenoestrogenic exposures. Additionally, the significant increase 
in Her2 copies was found at the lowest concentration (.001nM, p = .000) of application 
for each xenoestrogen, whether applied individually or in combination.  
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Studies conducted on xenoestrogens that assessed their carcinogenicity have been 
performed using cellular proliferation, reporter gene assays (estrogen and androgen 
receptor genes) and transcription arrays after short-term exposures (up to a week) with 
OCs and their derivatives (Aube, Larochelle, & Ayotte, 2011; Valeron Pestano, Luzardo, 
Zumbado, & Boada, 2009). However, breast cancer is observed to have a long latency 
period (Nadler & Zurbenko, 2013; Olsson, Baldetorp, Ferno, & Perfekt, 2003; Paez et al., 
2012), but the aforementioned studies only studied short-term exposures ranging from 1 
to 9 days. 
In an effort to learn regarding the long-term effects of persistent applications of 
the 4 common household xenoestrogens on Her2, I subjected the 4 lines to 50 days of 
exposure with these xenoestrogens. Although the breast carcinogenesis latency period is 
anywhere from 20 to 30 years (Marsden, Wright, Carrier, Moroz, & Rowan, 2012; Nadler 
& Zurbenko, 2013), the breast cancer cell lines could only be treated for up to 50 days, 
because as per the ATCC culturing instructions, these cells may start to die after 8 weeks 
(56 days) of long-term culturing. Another caveat to long-term culturing of cells was the 
threat of losing all of the cells to contamination with various microbes (e.g., bacteria, 
mycoplasma, mold, yeasts, and viruses) (Life Technologies, n.d.). Due to these two 
reasons, for persistent, long-term exposures the four breast cancer cell lines were treated 
up to 50 days with the xenoestrogens. The results of the Mann Whitney test found that a 
significant increase did occur in the Her2 copy numbers with persistent, long-term 
exposures (50 daily exposures) to the 4 xenoestrogens compared to the single, short-term 
(5 days) exposures (p = <.000). 
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Because highly significant values (p = <.000) were observed between the single, 
short-term exposures and persistent, long-term exposures, I next examined how much 
difference in the Her2 copy number gains had occurred between these two exposure 
durations. Incidence rate ratios (IRR) were performed to compare differences in the 
magnitude of increase occurs between the single, short-term and persistent, long-term 
exposure durations. Almost twice as much (86% increase, IRR: 1.86, p = 0.000) Her2 
copy numbers were found with the persistent, long-term exposures with the 4 commonly 
used xenoestrogens compared to their single, short-term exposures. It can be inferred 
from this data that persistent low-level exposures occurring for even 7 weeks caused 
significant (p = .000) amounts of amplifications to the Her2 oncogene. This finding is 
important since most women worldwide are being exposed on a daily basis to these 
common household xenoestrogens (Cohn, 2011; Darbre & Charles, 2010; Inifo-Nunez, 
Herreros, Eucinas, and Gonzalez-Bulnes, 2010; Kuch, Metzer, & von der Trenck, 2010; 
Qui, Suri, Bi, Sheng, & Fu, 2010). 
Individual xenoestrogens have disparate characteristics even though they all have 
estrogenic properties (Payne, Rajapakse, Wilkins, & Kortenkamp, 2000; Silva, Scholze, 
& Kortenkamp, 2007; Aube, Larochelle, & Ayotte, 2008), therefore Hypothesis 3 of this 
study further classified whether the differences in single vs. persistent exposures 
significantly increased Her2 copies in some or all of the 4 commonly used xenoestrogens. 
Mann Whitney tests were conducted with each xenoestrogen applied individually or in 
combinatorial exposures compared the Her2 copy numbers between single, short-term 
(single exposure cultured for 5 days) and multiple, persistent exposures (daily exposures 
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cultured for 50 days). The results revealed that multiple, persistent exposures to all 4 
commonly used xenoestrogens (BPA, DDT, EE and NPH) regardless of whether they 
were applied individually or in combination had significantly (p = .000) increased the 
Her2 copy numbers when compared to single, short-term exposures. 
A sentinel population study by Gammon et al. (1999) has indicated that exposures 
to contraceptive pills lead to aggressive breast cancer and that these women had an 
increased Her2 receptor status. Additionally, patient data also demonstrated that when 
there is amplification of the Her2 oncogene, then the patient prognosis related to a more 
aggressive type of breast cancer with disease progression, tumor invasion, fewer disease-
free days, and worse survival outcomes lending to its poor prognostic value (Baselga & 
Swain, 2009; Gutierrez & Schiff, 2011; Johnson et al., 2012; Lindemann et al., 2007; 
Slamon et al., 2011). 
The 4 cell lines used in this study were ER and Her2 positive or negative. 
Pairwise analysis conducted on all of the different receptor types showed that the 
distribution of Her2 copy numbers were significantly different for all of the lines except 
those that already had a Her2 positive status (BT474 with ER+/Her2+ status, and 
SKBR3 with ER-/Her2+ status). Comparing the 4 lines, it was noted that MCF7 line with 
ER+/Her2- receptors had the least amount of Her2 copy number increase, and was used 
as the reference. Both of the Her2+ lines regardless of the status of the ER receptor 
(BT474 and SKBR3) showed a 30 times greater Her2 copy number increment compared 
to the reference, implying that women with a Her2 positive status are highly susceptible 
to cancer progression with exposures to even nanomolar concentrations of these four 
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commonly used xenoestrogens. Importantly, even for the MDA-MB-231 line with ER-
/Her2- status, it was observed that a significant increase of 44% in the Her2 copy 
numbers (IRR: 1.44, p = 0.000) occurred when compared to the MCF7 line with 
ER+/Her2- status. Because the ER-/Her2- status is typically found on a normal mammary 
cell, this statistic can have important mechanistic implications, since it can be inferred 
from these results that the Her2 negative expression had mutated via amplification and 
became Her2 positive with exposures to nanomolar concentrations of the 4 commonly 
used xenoestrogens (BPA, DDT, EE, and NPH). Additionally, these results indicated that 
the increase in Her2 oncogenic expression is multiplicative between the various receptors 
found in these 4 cell lines. 
I also performed Mann Whitney analysis on each line (ER and Her2 positive or 
negative), that compared the Her2 copy numbers between single, short-term exposures 
(cultured for 5 days) with the multiple, persistent exposures (daily exposures for 50 days) 
for individual line. The increase in the Her2 copy numbers was found to highly 
significant (p = .000) in each of the 4 lines regardless of their receptor status (i.e., ER and 
Her2 positive or negative). 
Breast carcinogenesis occurs with the activation of oncogenes or the inactivation 
of TSGs (Lee & Muller, 2010; Pitot & Dragon, 1993). Exposures to chemicals and 
hormones including xenoestrogens can trigger the activation of oncogenes (Brody, 
Tickner, & Rudel, 2005; Davis et al., 1993; Montemurro, Cosimo & Arpino, 2013) 
provided the theoretical construct of this study. All of the results of this study validated 
that exposing human mammary cells to the 4 commonly used xenoestrogens (BPA, DDT, 
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EE and NPH) leads to the mutation (i.e., copy number increase/amplification) of the Her2 
gene located on the long-arm of chromosome 17 in the human genome.  
A pathway to breast carcinogenesis (Davis et al., 1993; Soto & Sonnenschein, 
2010) hypothesized that xenoestrogens increased the estrogenicity in a mammary cell 
above normal levels and this led to mutation of genes located in 17q loci. Although, this 
study did not check for increases in the estrogen in mammary cells after exposing them to 
xenoestrogens used in the study, however, the results confirmed that xenoestrogenic 
exposures mutated the Her2 gene located in 17q (17q11.2-17q12) via copy number 
gains/amplification. 
Implications for Social Change 
Breast cancer is the main cause of death for women worldwide with mortality 
rates reaching 522,000 women in 2012 (Ferlay et al., 2014; IARC, 2013). It is the second 
leading cause of cancer-related deaths for women in the U.S. (ACS, 2015; SEER, n.d.). 
Currently, an estimated 2.9 million women are living with a history of breast cancer in 
the United States alone (ACS, 2014; SEER, n.d.). Breast cancer care ranks the highest 
amongst all cancer care expenditures, accounting for $18.1 billion of annual healthcare 
cost in the United States alone (NCI, 2015a).  
Synthetic xenoestrogens are partially being blamed for increase in breast cancer 
incidence (Aube, Larochelle, & Ayotte, 2011; Buteau-Lozano, Velasco, Cristofari, 
Balaguer, & Perrot-Applanat, 2008; Davis et al., 1997). In the case of breast cancer, 
synthetic xenoestrogenic exposures are now being researched as potential risk factors, 
and are considered as a modifiable lifestyle factors (Aube, Larochelle, & Ayotte, 2011; 
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Rudel, Attfield, Schifano, & Brody, 2007). Synthetic xenoestrogens are found in 
commercial products, and are easily available (e.g., herbicides, plastics, pesticides, 
contraceptives) to women in all societies worldwide (Cohn, 2011; Darbre and Charles, 
2010; Inifo-Nunez, Herreros, Eucinas, & Gonzalez-Bulnes, 2010; Kuch, Metzer, & von 
der Trenck, 2010; Qui, Suri, Bi, Sheng, & Fu, 2010; Vogel, 2009). 
This research has provided a GEI model that predicts the carcinogenic potential of 
4 commonly used synthetic xenoestrogens (BPA, DDT, EE, and NPH) and how 
exposures to these xenoestrogens affected the Her2 oncogenic expression, a biomarker of 
breast carcinogenesis. Using précis dosage analysis, this study clearly demonstrated that 
exposures to all 4 xenoestrogens even at .001 nanomolar (nM) concentrations resulted in 
significantly increasing the Her2 oncogenic expression, regardless of whether these 4 
xenoestrogens were applied individually or in combination. Also, this study found that 
with the increase in the concentrations from .001 to .1nM, the incidence of Her2 copy 
number increase is almost twice as much (96% increase), indicating that even low-level 
increase in concentrations of these 4 synthetic xenoestrogens greatly impacted the Her2 
oncogenic expression levels. 
The study further indicated that highly significant increase in Her2 copies 
occurred not only with daily, persistent (chronic exposures) to all 4 xenoestrogens (BPA, 
DDT, EE, NPH), but also with all 4 receptor types (ER and Her2 positive or negative). 
Highly significant increments in Her2 oncogenic expression was found to occur (86% 
more) with persistent exposures to the 4 synthetic xenoestrogens within 7 weeks 
compared to a single exposure for five days. Although, these values are a little less than 
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two fold, but these persistent exposures accounted for only 7 weeks; whereas due to their 
ease of availability most women worldwide are constantly being exposed to these 
commonly used xenoestrogens for all or most of their lives (Cohn, 2011; Darbre and 
Charles, 2010; Inifo-Nunez, Herreros, Eucinas, & Gonzalez-Bulnes, 2010; Kuch, Metzer, 
& von der Trenck, 2010; Qui, Suri, Bi, Sheng, & Fu, 2010; Vogel, 2009). 
Additionally, this study provided direct biological evidence to the altercations of 
the Her2 oncogene upon exposures with synthetic xenoestrogens. The study 
demonstrated that the Her2 mutated by the amplification of its copy numbers with 
exposures to the 4 commonly used synthetic xenoestrogens. Taken together, these results 
established the 4 commonly used xenoestrogens as a risk factor for breast carcinogenesis, 
and this information should be useful in making policy level decisions to curtail the sale 
of these synthetic xenoestrogens and encourage the use of alternate chemicals. These 
results have provided valuable information for advocacy groups to educate and empower 
women regarding the ill health effects even with low-level exposures to these 
xenoestrogens.  
Because most women around the world are constantly exposed to these synthetic 
xenoestrogens due to their omnipresence, modifying these risk factors should have a 
great public health impact even though they only account for low levels (less than twice) 
of risk (Aube, Larochelle, & Ayotte, 2011; Brody, Tickner, & Rudel, 2005; Johnson et 
al., 2012). Reducing these risk factors of breast cancer would not only affect women 
worldwide by reducing its incidence and mortality, but doing so would also translate in 
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reducing the indirect costs that the disease incurs on family and extended family 
members, such as lost work days and wages.  
The cell line data showed that women with a Her2 positive (Her2+) status are at a 
very high risk (~30 times greater than Her2- status) of cancer progression with 
nanomolar levels of exposures to these synthetic xenoestrogens. If these results are 
corroborated in human mammary tissue samples, these findings may have implications 
for women with breast cancer with a greater risk for disease progression, especially since 
added Her2 amplifications does lead to a more aggressive disease type, with disease 
progression, poor prognosis, and lower survival rates (Baselga & Swain, 2009; Gutierrez 
& Schiff, 2011; Johnson et al., 2012; Lindemann et al., 2007; Slamon et al., 2011).  
For women with breast cancer under the age of 40 (young women), the Her2 
expression (Her2+) has been found to be significantly higher compared to those that are 
65 years or older (11.1 vs. 9.4 respectively; p = .0001) (Assi, Khoury, Dbouk, Khalil, 
Mouhieddine, & ElSaghir, 2013). An increased proportion of ER-/HER2+ with high 
tumor grade occur in younger women (Anders et al., Collins et al., 2012). Younger 
women with breast cancer also had higher mortality rates compared those older than 40 
years (18.3% vs. 12.1% respectively, p = .001). Although women with breast cancer 
under the age of 40 years constituted a small proportion (worldwide 146,660 incident 
cases in 2008) of the total, this was a significant burden not only on women but society as 
well since they presented with a more aggressive disease (Assi et al., 2013). Azim et al. 
(2012) demonstrated that there is an age-related differential in the gene expression 
associated with MAPK and PI3K growth factor signaling found especially in younger 
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women, thus heightening their risk for aggressive breast cancer. Xenoestrogens and Her2 
are known to use these specific signaling pathways (Jung et al., 2010; Lemmon & 
Schlesinger, 2010; Serra et al., 2011). This research study has also demonstrated that the 
Her2 oncogenic expression increased even with nanomolar exposures to commonly used 
xenoestrogens. Taken together, these results indicated that the risk associated for 
aggressive breast cancer with low-level exposures to xenoestrogens would be far greater 
for younger women compared to those that are over the age of 40 years. These findings 
have implications for targeted advocacy, monitoring and early intervention/s for women 
under the age of 40 years. 
Importantly, this study demonstrated that even with ER and Her2 negative status 
(MDA-MB-231 line) a significant increase (44% more) had occurred in their Her2 copy 
numbers, marking a shift in their Her2 status from Her2 negative to Her2 positive 
(Her2+) at nanomolar levels of exposures and with increasing concentrations (i.e., 
.001nM to .01nM to .1nM ) to commonly used synthetic xenoestrogens. Because, ER and 
Her2 negative status is found in a normal mammary cell, these results indicate that even 
in a cell that has normal Her2 gene expression, the expression can change or mutate via 
Her2 gene amplification upon low-levels of exposures to these xenoestrogens and 
become Her2 positive and oncogenic; which ultimately would lead to breast 
carcinogenesis. These findings can be generalized to all women worldwide since normal 
levels of Her2 or Her2 negative (Her2-) gene status is found in a normal mammary cell. 
These findings further reiterate that even at nanomolar levels of exposures of these 4 
commonly used synthetic xenoestrogens are risk factors for breast carcinogenesis. These 
189 
 
findings further reiterated that even at nanomolar levels of exposures of these four 
commonly used synthetic xenoestrogens they are indeed risk factors for breast 
carcinogenesis, and that its population-attributable risk for breast cancer is significant.  
This information can be used by public health and policy-makers to impose policies that 
will curtail the ease of availability and use of these xenoestrogens. Additionally, breast 
cancer advocacy groups, cancer agencies, public health nurses, cancer forums and 
foundations should use this information to advocate, educate and inform women against 
the use of these commonly found xenoestrogens due to their imposed risks even when 
used in low concentration levels. Health educators should use this information to teach 
the general public; especially young girls and women about the health risks with 
exposures to these commonly used xenoestrogens, thereby making the consumers privy 
to this information so they can make healthier choices when buying substances that 
contain these xenoestrogens. 
Limitations 
Although this study provided précis measurements of each categorical 
xenoestrogen and the durations of their exposures, however, due to ethical reasons this 
study was conducted using breast cancer cell lines from ATCC, bioresource center. 
Therefore, this study did not have any data on other risk factors (e.g., genetic 
predisposition of BRCA1 and 2, parity, age at menarche, lactation, reproductive history, 
smoking, breast-feeding, diet, and alcohol) involved in breast carcinogenesis (Aube, 
Larochelle, & Ayotte, 2011; Buteau-Lozano, Velasco, Cristofari, Balaguer, & Perrot-
Applanat, Davis & Sieber, 1997). Including all of these risk factors and studying how 
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they interacted with exposures to some of the commonly used xenoestrogens would 
further enhance our knowledge regarding risk factor assessment and interventions against 
this disease.  
Only ER and Her2 positive and negative cell lines were selected for studying the 
effects of these xenoestrogens, mainly because xenoestrogens are thought to exert their 
effects via the ER (Mercado-Feliciano & Bigsby, 2008; Stoica et al., 2003), then the ER 
cross-communicate with Her2, and these two receptors are known to be the main drivers 
of breast carcinogenesis (Gutierrez & Stoica, 2011). But, other receptors, such as the 
insulin growth factor receptors, progesterone receptors, and androgenic receptors are also 
found in the mammary cell. Thus, the generalizability of this study is limited to the 
interactions of ER and Her2 receptors only with exposures to the 4 commonly used 
xenoestrogens. 
Lastly, because of the threat of losing the cell lines to either contamination or cell 
death due to viability of cells in long-term culturing (ATCC; Gibco, Life Technologies), 
this study was only be conducted for 7 weeks in order to study the long-term effects of 
the 4 commonly used synthetic xenoestrogens. Because breast cancer has a long latency 
period that could last up to 28 years (Marsden, Wright, Carrier, Moroz, & Rowan, 2012; 
Nadler & Zurbenko, 2013; Paez et al., 2011), this study mimicked persistent long-term 
exposures by daily exposing the cell lines to the four commonly used xenoestrogens for 




Based on the findings of this study, and due to the high reproducibility of FISH, it 
would be beneficial to use FISH technology in the future to study direct gene expression 
on fresh tissue samples using a hospital-based case-control design to study the effects of 
commonly used xenoestrogens and incorporating other breast cancer risk factors (e.g., 
genetic predisposition, smoking, alcohol, diet, lactation, age at menarche). Here, the 
patient exposures to the xenoestrogens can be assessed using gas chromatography or 
mass spectrometry (Boada et al., 2012; Charlier et al., 2003; Cohn, Wolff, Cirillo, & 
Scholtz, 2007; Hoyer, Jorgensen, Grandjean, & Hartvig, 2000, Hoyer et al; 2000; Hoyer, 
Jorgensen, Rank, & Grandjean, 2001; Warner et al., 2002). Although Her2 is an 
important biomarker of breast carcinogenesis, using FISH technology for future studies 
would allow the incorporation of other genes in conjunction with Her2, such as p53, a 
TSG also known to be involved in breast carcinogenesis and could be affected with 
exposures to xenoestrogens (Davis et al., 1993; Soto and Sonnenschein, 2010)).  
Because breast cancer is the main cause of death for women worldwide (IARC, 
2013), and it is the second leading cause of death in women in the United States (CDC, 
2014), using the aforementioned study design to perform survival analysis will also aid in 
providing important data and insights regarding breast carcinogenesis and mortality due 
to exposures to these xenoestrogens.  
Conclusion 
Breast cancer is still a public health concern (Aube, Larochelle, & Ayotte, 2011; 
Valeron, Pestano, Luzardo, Zumbado, & Boada, 2009). This study has biological 
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underpinnings and provides mechanistic insights that exposures to the 4 commonly used 
xenoestrogens (BPA, DDT, EE and NPH) incur changes in the Her2 oncogene, a 
biomarker of breast carcinogenesis and aggressive disease via its copy number 
increase/gene amplification.  
All the results of this study provide direct evidence of changes incurred to the 
Her2 oncogene even with low-levels (nanomolar concentrations) of exposures to all 4 
xenoestrogens, and that Her2 copies increase significantly with daily exposures within 
short time span of 7 weeks (persistent, long-term exposures). A normal mammary cell 
expresses only two copies of the Her2 gene and is Her2- (Grusko et al., 2002). 
Importantly, this data also indicates that Her2 negative mammary cells can become Her2 
positive with exposures to synthetic xenoestrogens. This phenomena was observed in the 
lines that were Her2 negative (MDA-MB-231 and MCF7), but with xenoestrogenic 
exposures their Her2 copy numbers increase significantly (p = <.000), thereby shifting 
their Her2 status from Her2-negative to Her2-positive. As Her2 negative (Her2-) status 
can be generalized to all women worldwide, this data should help regulatory agencies to 
recognize the potential risk posed by even the low-levels of exposures to these 
xenoestrogens and apply the precautionary principle, either by substituting these 
chemicals with others that are not harmful to health or banning their sale to curtail their 
usage.  
The epidemiology of Her2 suggests that an increased proportion of ER-/Her2+ 
breast cancer with high tumor grade is found in younger women (<40 years) compared to 
those that are older (Anders et al., Collins et al., 2012). This study also discerned that the 
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women with a Her2 positive status are at the highest risk of disease progression to a more 
aggressive disease type with exposures to these xenoestrogens. Cancer advocacy groups, 
and public health nurses should inform and educate these women with the potential risks 
with exposures to these 4 commonly used xenoestrogens and breast cancer progression. 
Furthermore, because women with a Her2 positive status are at the greatest risk of 
disease progression with exposures to these commonly used xenoestrogens, they should 
regularly be monitored for their Her2 levels even if their Her2status changes with 
therapy. 
In all, this research improved our understanding of the molecular mechanisms 
underlying breast cancer pathogenesis and progression with exposures to the 4 commonly 
used xenoestrogens. Future breast cancer prevention efforts should benefit from this 
study in the following ways; first, this study will bring about awareness of the importance 
of avoiding or reducing exposures to the 4 commonly used xenoestrogens, and; second, 
by increasing our understanding that some women due to their greater genetic based 
sensitivity would need increased medical surveillance in order to intervene before the 
occurrence of a more serious disease condition. Because these xenoestrogens are found 
all over the world and the two receptor types incorporated in the study design are 
common to all women around the globe, these findings would help not only our 
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